2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Developed in Collaboration With the American Academy of Family Physicians, American College of Chest Physicians, and International Society for Heart and Lung Transplantation

WRITING GROUP MEMBERS*

Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFS, Chair
Mariell Jessup, MD, FACC, FAHA, Vice Chair

Biykem Bozkurt, MD, PhD, FACC, FAHA‡
Javed Butler, MD, MBA, MPH, FACC, FAHA**‡
Donald E. Casey, Jr, MD, MPH, MBA, FACC§
Monica M. Colvin, MD, FAHA¶
Mark H. Drazner, MD, MSc, FACC, FAHA, FHFS‡
Gerasimos S. Filippatos, MD*
Gregg C. Fonarow, MD, FACC, FAHA, FHFS‡†
Michael G. Givertz, MD, FACC, FHFS§¶

Steven M. Hollenberg, MD, FACC#
JoAnn Lindenfeld, MD, FACC, FAHA, FHFS**¶
Frederick A. Masoudi, MD, MSPH, FACC**
Patrick E. McBride, MD, MPH, FACC††
Pamela N. Peterson, MD, FACC, FAHA‡‡
Lynne Warner Stevenson, MD, FACC*‡‡
Cheryl Westlake, PhD, RN, ACNS-BC, FAHA, FHFS¶¶

ACC/AHA TASK FORCE MEMBERS

Glenn N. Levine, MD, FACC, FAHA, Chair
Patrick T. O’Gara, MD, FACC, FAHA, Chair-Elect
Jonathan L. Halperin, MD, FACC, FAHA, Immediate Past Chair††

Sana M. Al-Khatib, MD, MHS, FACC, FAHA
Kim K. Birtcher, PharmD, MS, AACC
Biykem Bozkurt, MD, PhD, FACC, FAHA
Ralph G. Brindis, MD, MPH, MACC‡‡
Joaquin E. Cigarroa, MD, FACC
Lesley H. Curtis, PhD, FAHA
Lee A. Fleisher, MD, FACC, FAHA
Federico Gentile, MD, FACC
Samuel Gidding, MD, FAHA
Mark A. Hlatky, MD, FACC
John Ikonomidis, MD, PhD, FAHA
José Joglar, MD, FACC, FAHA
Susan J. Pressler, PhD, RN, FAHA
Duminda N. Wijeysundera, MD, PhD

*Writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. ‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison. †‡ACC/AHA Representative. §ACP Representative. ¶¶ISHL Representative. ¶¶¶FHSA Representative. #CHEST Representative. **ACC/AHA Task Force on Performance Measures Representative. ††AAP Representative. ‡‡‡Former Task Force member; current member during the writing effort.

This document was approved by the American College of Cardiology Clinical Policy Approval Committee, the American Heart Association Science Advisory and Coordinating Committee, the American Heart Association Executive Committee, and the Heart Failure Society of America Executive Committee in April 2017.
# Table of Contents

Preamble ....................................................................................................................................................... 4

1. Introduction ............................................................................................................................................... 7
   1.1. Methodology and Evidence Review ................................................................................................. 7
   1.2. Organization of the Writing Group .................................................................................................. 8
   1.3. Document Review and Approval ....................................................................................................... 8

6. Initial and Serial Evaluation of the HF Patient ....................................................................................... 10
   6.3. Biomarkers ....................................................................................................................................... 10
      6.3.1. Biomarkers for Prevention: Recommendation .......................................................................... 11
      6.3.2. Biomarkers for Diagnosis: Recommendation ........................................................................... 12
      6.3.3. Biomarkers for Prognosis or Added Risk Stratification: Recommendations ............................ 12

7. Treatment of Stages A to D ..................................................................................................................... 14
   7.3. Stage C ............................................................................................................................................. 14
      7.3.2. Pharmacological Treatment for Stage C HF With Reduced Ejection Fraction: Recommendations ............................................................................................................................... 14
         7.3.2.10. Renin-Angiotensin System Inhibition With Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker or ARNI: Recommendations ............................................................................................... 15
         7.3.2.11. Ivabradine: Recommendation .......................................................................................... 18
      7.3.3. Pharmacological Treatment for Stage C HFpEF: Recommendations ........................................ 22

9. Important Comorbidities in HF ............................................................................................................... 23
   9.2. Anemia: Recommendations ............................................................................................................. 23
   9.5. Hypertension (New Section) ............................................................................................................. 24
      9.5.1. Treating Hypertension to Reduce the Incidence of HF: Recommendation ..................................... 24
      9.5.2. Treating Hypertension in Stage C HFrEF: Recommendation ..................................................... 25
      9.5.3. Treating Hypertension in Stage C HFpEF: Recommendation .................................................... 25
   9.6. Sleep Disordered Breathing: Recommendations ............................................................................. 26

References ................................................................................................................................................... 28

Appendix 1. Author Relationships With Industry and Other Entities (Relevant) ....................................... 37
Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) ....................... 40
Appendix 3. Abbreviations ......................................................................................................................... 45
Preamble

Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines (guidelines) with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a cornerstone for quality cardiovascular care. The ACC and AHA sponsor the development and publication of guidelines without commercial support, and members of each organization volunteer their time to the writing and review efforts. Guidelines are official policy of the ACC and AHA.

Intended Use

Practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in collaboration with other organizations may have a global impact. Although guidelines may be used to inform regulatory or payer decisions, their intent is to improve patients’ quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances and should not replace clinical judgment.

Clinical Implementation

Guideline recommended management is effective only when followed by healthcare providers and patients. Adherence to recommendations can be enhanced by shared decision making between healthcare providers and patients, with patient engagement in selecting interventions based on individual values, preferences, and associated conditions and comorbidities.

Methodology and Modernization

The ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) continuously reviews, updates, and modifies guideline methodology on the basis of published standards from organizations including the Institute of Medicine (1, 2) and on the basis of internal reevaluation. Similarly, the presentation and delivery of guidelines are reevaluated and modified on the basis of evolving technologies and other factors to facilitate optimal dissemination of information at the point of care to healthcare professionals. Given time constraints of busy healthcare providers and the need to limit text, the current guideline format delineates that each recommendation be supported by limited text (ideally, <250 words) and hyperlinks to supportive evidence summary tables. Ongoing efforts to further limit text are underway. Recognizing the importance of cost-value considerations in certain guidelines, when appropriate and feasible, an analysis of the value of a drug, device, or intervention may be performed in accordance with the ACC/AHA methodology (3).

To ensure that guideline recommendations remain current, new data are reviewed on an ongoing basis, with full guideline revisions commissioned in approximately 6-year cycles. Publication of new, potentially practice-changing study results that are relevant to an existing or new drug, device, or management strategy will prompt evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned. For additional information and policies regarding guideline development, we encourage readers to consult the ACC/AHA guideline methodology manual (4) and other methodology articles (5-8).
Selection of Writing Committee Members
The Task Force strives to avoid bias by selecting experts from a broad array of backgrounds. Writing committee members represent different geographic regions, sexes, ethnicities, races, intellectual perspectives/biases, and scopes of clinical practice. The Task Force may also invite organizations and professional societies with related interests and expertise to participate as partners, collaborators, or endorsers.

Relationships With Industry and Other Entities
The ACC and AHA have rigorous policies and methods to ensure that guidelines are developed without bias or improper influence. The complete relationships with industry and other entities (RWI) policy can be found at http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy. Appendix 1 of the current document lists writing committee members’ relevant RWI. For the purposes of full transparency, writing committee members’ comprehensive disclosure information is available online at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000509/-/DC1. Comprehensive disclosure information for the Task Force is available at http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces.

Evidence Review and Evidence Review Committees
When developing recommendations, the writing committee uses evidence-based methodologies that are based on all available data (4-7). Literature searches focus on randomized controlled trials (RCTs) but also include registries, nonrandomized comparative and descriptive studies, case series, cohort studies, systematic reviews, and expert opinion. Only key references are cited.

An independent evidence review committee (ERC) is commissioned when there are 1 or more questions deemed of utmost clinical importance that merit formal systematic review. This systematic review will strive to determine which patients are most likely to benefit from a drug, device, or treatment strategy and to what degree. Criteria for commissioning an ERC and formal systematic review include: a) the absence of a current authoritative systematic review, b) the feasibility of defining the benefit and risk in a time frame consistent with the writing of a guideline, c) the relevance to a substantial number of patients, and d) the likelihood that the findings can be translated into actionable recommendations. ERC members may include methodologists, epidemiologists, healthcare providers, and biostatisticians. When a formal systematic review has been commissioned, the recommendations developed by the writing committee on the basis of the systematic review are marked with “SR”.

Guideline-Directed Management and Therapy
The term guideline-directed management and therapy (GDMT) encompasses clinical evaluation, diagnostic testing, and pharmacological and procedural treatments. For these and all recommended drug treatment regimens, the reader should confirm the dosage by reviewing product insert material and evaluate the treatment regimen for contraindications and interactions. The recommendations are limited to drugs, devices, and treatments approved for clinical use in the United States.

Class of Recommendation and Level of Evidence
The Class of Recommendation (COR) indicates the strength of the recommendation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the
quality of scientific evidence that supports the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 1) (4-6).

Glenn N. Levine, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Clinical Practice Guidelines
1. Introduction

The purpose of this focused update is to update the “2013 ACCF/AHA Guideline for the Management of Heart Failure” (9) (2013 HF guideline) in areas in which new evidence has emerged since its publication. For this update and future heart failure (HF) guidelines, the Heart Failure Society of America (HFSA) has partnered with the ACC and AHA to provide coordinated guidance on the management of HF.

The scope of the focused update includes revision to the sections on biomarkers; new therapies indicated for stage C HF with reduced ejection fraction (HFrEF); updates on HF with preserved ejection fraction (HFpEF); new data on important comorbidities, including sleep apnea, anemia, and hypertension; and new insights into the prevention of HF.

This focused update represents the second part of a 2-stage publication; with the first part having been published as the “2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure” (10), which introduced guidance on new therapies, specifically for the use of an angiotensin receptor–neprilysin inhibitor (ARNI) (valsartan/sacubitril) and a sinoatrial node modulator (ivabradine). That focused update was published concurrently with the European Society of Cardiology’s complete guideline, “2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure” (11).

1.1. Methodology and Evidence Review

To identify key data that influence guideline recommendations, the Task Force and members of the 2013 HF guideline writing committee reviewed clinical trials that were presented at the annual scientific meetings of the ACC, AHA, and European Society of Cardiology and other scientific meetings and that were published in peer-reviewed format from April 2013 through November 2016. The evidence is summarized in tables in the Online Data Supplement (http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000509/-/DC2). All recommendations (new, modified, and unchanged) for each clinical section are included to provide a comprehensive assessment. The text explains new and modified recommendations, whereas recommendations from the previous guideline that have been deleted or superseded no longer appear. Please consult the full-text version of the 2013 HF guideline (9) for text and evidence tables supporting the unchanged recommendations and for clinical areas not addressed in this focused update. Individual recommendations in this focused update will be incorporated into the full-text guideline in the future. Recommendations from the prior guideline that remain current have been included for completeness, but the LOE reflects the COR/LOE system used when the recommendations were initially developed. New and modified recommendations in this focused update reflect the latest COR/LOE system, in which LOE
B and C are subcategorized for greater specificity (4-6). The section numbers correspond to the full-text guideline sections.

### 1.2. Organization of the Writing Group

For this focused update, representative members of the 2013 HF guideline writing committee were invited to participate. They were joined by additional invited members to form a new writing group, which is referred to as the 2017 HF focused update writing group. Members were required to disclose all RWI relevant to the data under consideration. The group was composed of experts representing general cardiologists, HF and transplantation specialists, electrophysiologists, pharmacists, and general internists. The 2017 HF focused update writing group included representatives from the ACC, AHA, and HFSA, as well as the American Academy of Family Physicians, American College of Chest Physicians, American College of Physicians, and International Society for Heart and Lung Transplantation.

### 1.3. Document Review and Approval

The focused update was reviewed by 2 official reviewers each nominated by the ACC, AHA, and HFSA; 1 reviewer each from the American Academy of Family Physicians, American College of Chest Physicians, and International Society for Heart and Lung Transplantation; and 19 individual content reviewers. Reviewers’ RWI information is published in this document (Appendix 2).

This document was approved for publication by the governing bodies of the ACC, AHA, and HFSA.
Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015)

**CLASS (STRENGTH) OF RECOMMENDATION**

**CLASS I (STRONG)**
- Benefit >>> Risk
  - Suggested phrases for writing recommendations:
    - Is recommended
    - Is indicated/useful/effective/beneficial
    - Should be performed/administered/other
    - Comparative-Effectiveness Phrases†:
      - Treatment/strategy A is recommended/indicated in preference to treatment B
      - Treatment A should be chosen over treatment B

**CLASS IIa (MODERATE)**
- Benefit >> Risk
  - Suggested phrases for writing recommendations:
    - Is reasonable
    - Can be useful/effective/beneficial
    - Comparative-Effectiveness Phrases†:
      - Treatment/strategy A is probably recommended/indicated in preference to treatment B
      - It is reasonable to choose treatment A over treatment B

**CLASS IIb (WEAK)**
- Benefit ≥ Risk
  - Suggested phrases for writing recommendations:
    - May/might be reasonable
    - May/might be considered
    - Usefulness/effectiveness is unknown/unclear/uncertain or not well established

**CLASS III: No Benefit (MODERATE)**
- Benefit = Risk
  - (Generally, LOE A or B use only)
  - Suggested phrases for writing recommendations:
    - Is not recommended
    - Is not indicated/useful/effective/beneficial
    - Should not be performed/administered/other

**CLASS III: Harm (STRONG)**
- Risk > Benefit
  - Suggested phrases for writing recommendations:
    - Potentially harmful
    - Causes harm
    - Associated with excess morbidity/mortality
    - Should not be performed/administered/other

**LEVEL (QUALITY) OF EVIDENCE‡**

**LEVEL A**
- High-quality evidence† from more than 1 RCT
- Meta-analyses of high-quality RCTs
- One or more RCTs corroborated by high-quality registry studies

**LEVEL B-R**
- Moderate-quality evidence† from 1 or more RCTs
- Meta-analyses of moderate-quality RCTs

**LEVEL B-NR**
- Moderate-quality evidence† from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies
- Meta-analyses of such studies

**LEVEL C-LD**
- (Limited Data)
  - Randomized or nonrandomized observational or registry studies with limitations of design or execution
  - Meta-analyses of such studies
  - Physiological or mechanistic studies in human subjects

**LEVEL C-EO**
- (Expert Opinion)
  - Consensus of expert opinion based on clinical experience

COR and LOE are determined independently (any COR may be paired with any LOE).
A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).
† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
‡ The method of assessing quality is evolving, including the application of standardized, widely used, and preferably validated evidence grading tools; and for systematic reviews, the incorporation of an Evidence Review Committee.

COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Level of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.
6. Initial and Serial Evaluation of the HF Patient

6.3. Biomarkers

Assays for BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pro-B-type natriuretic peptide), which are both natriuretic peptide biomarkers, have been used increasingly to establish the presence and severity of HF. In general, both natriuretic peptide biomarker values track similarly, and either can be used in patient care settings as long as their respective absolute values and cutpoints are not used interchangeably. Notably, BNP, but not NT-proBNP, is a substrate for neprilysin. Therefore, ARNI increases BNP levels (12) but not NT-proBNP levels (13). Note that the type of natriuretic peptide assay that has been performed must be considered during interpretation of natriuretic peptide biomarker levels in patients on ARNI. In 2 studies with ARNI, NT-proBNP levels were reduced (12, 14), with the reduction in 1 study being associated with improved clinical outcomes (12).

A substantial evidence base exists that supports the use of natriuretic peptide biomarkers to assist in the diagnosis or exclusion of HF as a cause of symptoms (e.g., dyspnea, weight gain) in the setting of chronic ambulatory HF (15-21) or in the setting of acute care with decompensated HF (22-30), especially when the cause of dyspnea is unclear. The role of natriuretic peptide biomarkers in population screening to detect incident HF is emerging (31-37). Elevated plasma levels of natriuretic peptide biomarkers are associated with a wide variety of cardiac and noncardiac causes (Table 2) (38-42). Obesity may be associated with lower natriuretic peptide concentrations, and this may modestly reduce diagnostic sensitivity in morbidly obese patients (42).

Because of the absence of clear and consistent evidence for improvement in mortality and cardiovascular outcomes (43-62), there are insufficient data to inform specific guideline recommendations related to natriuretic peptide–guided therapy or serial measurements of BNP or NT-proBNP levels for the purpose of reducing hospitalization or deaths in the present document.

Like natriuretic peptides, cardiac troponin levels may be elevated in the setting of chronic or acute decompensated HF, suggesting myocyte injury or necrosis (63). Troponins I and T respond similarly for acute coronary syndromes and acute decompensated HF. Elevations in either troponin I or T levels in the setting of acute HF are of prognostic significance and must be interpreted in the clinical context (64).

In addition to natriuretic peptides and troponins (65-67), multiple other biomarkers, including those of inflammation, oxidative stress, vascular dysfunction, and myocardial and matrix remodeling, have been implicated in HF (68-71). Biomarkers of myocardial fibrosis, soluble ST2 receptor, and galectin-3 are predictive of hospitalization and death and may provide incremental prognostic value over natriuretic peptide levels in patients with HF (72-74). Strategies that combine multiple biomarkers may
ultimately prove beneficial in guiding HF therapy in the future, but multicenter studies with larger derivation and validation cohorts are needed (75, 76). Several emerging biomarkers await validation with well-defined outcome measures and prognostic accuracy before they can reach the clinical arena (77-84).

This section categorizes the role of biomarkers into prevention, diagnosis, prognosis, and added risk stratification to clarify evidence-based objectives of their use in clinical practice.

**Table 2. Selected Potential Causes of Elevated Natriuretic Peptide Levels (38-41)**

<table>
<thead>
<tr>
<th>Cardiac</th>
<th>Noncardiac</th>
</tr>
</thead>
<tbody>
<tr>
<td>HF, including RV syndromes</td>
<td>Advancing age</td>
</tr>
<tr>
<td>Acute coronary syndromes</td>
<td>Anemia</td>
</tr>
<tr>
<td>Heart muscle disease, including LVH</td>
<td>Renal failure</td>
</tr>
<tr>
<td>Valvular heart disease</td>
<td>Pulmonary: obstructive sleep apnea, severe pneumonia</td>
</tr>
<tr>
<td>Pericardial disease</td>
<td>Pulmonary hypertension</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>Critical illness</td>
</tr>
<tr>
<td>Myocarditis</td>
<td>Bacterial sepsis</td>
</tr>
<tr>
<td>Cardiac surgery</td>
<td>Severe burns</td>
</tr>
<tr>
<td>Toxic-metabolic myocardial insults, including cancer chemotherapy</td>
<td></td>
</tr>
</tbody>
</table>

HF indicates heart failure; LVH, left ventricular hypertrophy; and RV, right ventricular.

Modified from Table 8 of the 2013 HF guideline (9).

**6.3.1. Biomarkers for Prevention: Recommendation**

<table>
<thead>
<tr>
<th>Biomarkers: Recommendation for Prevention of HF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COR</strong></td>
</tr>
<tr>
<td>IIa</td>
</tr>
</tbody>
</table>

In a large-scale unblinded single-center study (STOP-HF [The St Vincent’s Screening to Prevent Heart Failure]) (85), patients at risk of HF (identified by the presence of hypertension, diabetes mellitus, or known vascular disease [e.g., stage A HF]), but without established left ventricular systolic dysfunction or symptomatic HF at baseline, were randomly assigned to receive screening with BNP testing or usual primary care. Intervention-group participants with BNP levels of ≥50 pg/mL underwent echocardiography and were referred to a cardiovascular specialist who decided on further investigation and management. All patients received further coaching by a specialist nurse who emphasized individual risk and the importance of adherence to medication.
and healthy lifestyle behaviors. BNP-based screening reduced the composite endpoint of asymptomatic left ventricular dysfunction (systolic or diastolic) with or without newly diagnosed HF (85). Similarly, in another small, single-center RCT, accelerated up-titration of renin-angiotensin-aldosterone system antagonists and beta blockers reduced cardiac events in patients with diabetes mellitus and elevated NT-proBNP levels but without cardiac disease at baseline (86). Developing a standardized strategy to screen and intervene in patients at risk of HF can be difficult because of different definitions of HF risk, heterogeneity of prevalence in different populations, variable duration until clinical HF or left ventricular dysfunction develops, and variable interventions for risk factor modification or treatment. Further studies are needed to determine cost-effectiveness and risk of such screening, as well as its impact on quality of life (QoL) and mortality rate.

### 6.3.2. Biomarkers for Diagnosis: Recommendation

<table>
<thead>
<tr>
<th>Biomarkers: Recommendation for Diagnosis</th>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I</td>
<td>A</td>
<td>In patients presenting with dyspnea, measurement of natriuretic peptide biomarkers is useful to support a diagnosis or exclusion of HF (15-24, 28-30).</td>
<td>MODIFIED: 2013 acute and chronic recommendations have been combined into a diagnosis section.</td>
</tr>
<tr>
<td>See Online Data Supplements A and B.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Natriuretic peptide biomarker testing in the setting of chronic ambulatory HF provides incremental diagnostic value to clinical judgment, especially when the etiology of dyspnea is unclear (15-21). In emergency settings, natriuretic peptide biomarker levels usually have higher sensitivity than specificity and may be more useful for ruling out than ruling in HF (20). Although lower values of natriuretic peptide biomarkers exclude the presence of HF, and higher values have reasonably high positive predictive value to diagnose HF, clinicians should be aware that elevated plasma levels for both natriuretic peptides have been associated with a wide variety of cardiac and noncardiac causes (Table 2) (38-41).

### 6.3.3. Biomarkers for Prognosis or Added Risk Stratification: Recommendations

<table>
<thead>
<tr>
<th>Biomarkers: Recommendations for Prognosis</th>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I</td>
<td>A</td>
<td>Measurement of BNP or NT-proBNP is useful for establishing prognosis or disease severity in chronic HF (16, 87-92).</td>
<td>2013 recommendation remains current.</td>
</tr>
<tr>
<td>See Online Data Supplements A and B.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Measurement of baseline levels of natriuretic peptide biomarkers and/or cardiac troponin on admission to the hospital is useful to establish a prognosis in acutely decompensated HF (27, 93-100). MODIFIED: Current recommendation emphasizes that it is admission levels of natriuretic peptide biomarkers that are useful.

Higher levels of natriuretic peptide biomarkers on admission are usually associated with greater risk for clinical outcomes, including all-cause and cardiovascular mortality, morbidity, and composite outcomes, across different time intervals in patients with decompensated HF (20, 27, 29, 93-101). Similarly, abnormal levels of circulating cardiac troponin are commonly found in patients with acute decompensated HF, often without obvious
myocardial ischemia or underlying coronary artery disease (CAD), and this is associated with worse clinical outcomes and higher risk of death (95, 99, 102, 103).

Studies have demonstrated incremental prognostic value of these biomarkers to standard approaches of cardiovascular disease risk assessment (29, 95). However, there were differences in the risk prediction models, assay cutoffs, and lengths of follow-up (29). Furthermore, not all patients may need biomarker measurement for prognostication, especially if they already have advanced HF with established poor prognosis or persistently elevated levels of biomarkers in former settings. Therefore, assays of natriuretic peptide biomarkers for incremental prognostication should not preclude good clinical judgment; an individualized approach to each patient is paramount.

<table>
<thead>
<tr>
<th>IIa</th>
<th>B-NR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>During a HF hospitalization, a predischarge natriuretic peptide level can be useful to establish a postdischarge prognosis (93, 96, 104-113).</strong></td>
<td><strong>NEW:</strong> Current recommendation reflects new observational studies.</td>
</tr>
</tbody>
</table>

Predischarge natriuretic peptide biomarker levels and the relative change in levels during hospital treatment are strong predictors of the risk of death or hospital readmission for HF (93, 96, 104-113). Several studies have suggested that predischarge natriuretic peptide biomarker levels had higher reclassification and discrimination value than clinical variables in predicting outcomes (96, 106, 108-111). Patients with higher predischarge levels and patients who do not have a decrease in natriuretic peptide biomarker levels during hospitalization have worse outcomes (96, 106, 108-111). Although observational or retrospective studies have suggested that patients with natriuretic peptide biomarker reduction had better outcomes than those without any changes or with a biomarker rise (93, 107, 112, 113), targeting a certain threshold, value, or relative change in these biomarker levels during hospitalization may not be practical or safe for every patient and has not been tested in a prospective large-scale trial. Clinical assessment and adherence to GDMT should be the emphasis, and the prognostic value of a predischarge value or relative changes does not imply the necessity for serial and repeated biomarker measurements during hospitalization.

<table>
<thead>
<tr>
<th>IIb</th>
<th>B-NR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In patients with chronic HF, measurement of other clinically available tests, such as biomarkers of myocardial injury or fibrosis, may be considered for additive risk stratification (27, 95, 98, 99, 103, 114-119).</strong></td>
<td><strong>MODIFIED:</strong> 2013 recommendations have been combined into prognosis section, resulting in LOE change from A to B-NR.</td>
</tr>
</tbody>
</table>

Biomarkers of myocardial fibrosis (e.g., soluble ST2 receptor, galectin-3, high-sensitivity cardiac troponin, and others) are predictive of hospitalization and death in patients with HF and also are additive to natriuretic peptide biomarker levels in their prognostic value (117, 119-126). A combination of biomarkers may ultimately prove to be more informative than single biomarkers (127).
**Figure 1. Biomarkers Indications for Use**

Colors correspond to COR in Table 1.
*Other biomarkers of injury or fibrosis include soluble ST2 receptor, galectin-3, and high-sensitivity troponin.

ACC indicates American College of Cardiology; AHA, American Heart Association; ADHF, acute decompensated heart failure; BNP, B-type natriuretic peptide; COR, Class of Recommendation; ED, emergency department; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; and pts, patients.

7. Treatment of Stages A to D

7.3. Stage C

7.3.2. **Pharmacological Treatment for Stage C HF With Reduced Ejection Fraction:**

**Recommendations**

(See Figure 2 and Table 3).
7.3.2.10. Renin-Angiotensin System Inhibition With Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker or ARNI: Recommendations

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>ACE-I: A</td>
<td>The clinical strategy of inhibition of the renin-angiotensin system with ACE inhibitors (Level of Evidence: A) (128-133), OR ARBs (Level of Evidence: A) (134-137), OR ARNI (Level of Evidence: B-R) (138) in conjunction with evidence-based beta blockers (9, 139, 140), and aldosterone antagonists in selected patients (141, 142), is recommended for patients with chronic HFrEF to reduce morbidity and mortality.</td>
<td>NEW: New clinical trial data prompted clarification and important updates.</td>
</tr>
</tbody>
</table>
|     | ARB: A |                                                                                                                                                                                                                 | - Angiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Randomized controlled trials (RCTs) clearly establish the benefits of ACE inhibition in patients with mild, moderate, or severe symptoms of HF and in patients with or without coronary artery disease (128-133). ACE inhibitors can produce angioedema and should be given with caution to patients with low systemic blood pressures, renal insufficiency, or elevated serum potassium. ACE inhibitors also inhibit kininase and increase levels of bradykinin, which can induce cough but also may contribute to their beneficial effect through vasodilation.  
- Angiotensin receptor blockers (ARBs) were developed with the rationale that angiotensin II production continues in the presence of ACE inhibition, driven through alternative enzyme pathways. ARBs do not inhibit kininase and are associated with a much lower incidence of cough and angioedema than ACE inhibitors; but like ACE inhibitors, ARBs should be given with caution to patients with low systemic blood pressure, renal insufficiency, or elevated serum potassium. Long-term therapy with ARBs produces hemodynamic, neurohormonal, and clinical effects consistent with those expected after interference with the renin-angiotensin system and have been shown in RCTs (134-137) to reduce morbidity and mortality, especially in ACE inhibitor–intolerant patients.  
- In ARNI, an ARB is combined with an inhibitor of neprilysin, an enzyme that degrades natriuretic peptides, bradykinin, adrenomedullin, and other vasoactive peptides. In an RCT that compared the first approved ARNI, valsartan/sacubitril, with enalapril in symptomatic patients with HFrEF tolerating an adequate dose of either ACE inhibitor or ARB, the ARNI reduced the composite endpoint of cardiovascular death or HF hospitalization significantly, by 20% (138). The benefit was seen to a similar extent for both death and HF hospitalization and was consistent across subgroups. The use of ARNI is associated with the risk of hypotension and renal insufficiency and may lead to angioedema, as well. |

See Online Data Supplements 1, 2, 18-20.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th>The use of ACE inhibitors is beneficial for patients with prior or current symptoms of chronic HFrEF to reduce morbidity and mortality (128-133, 143).</th>
<th>2013 recommendation repeated for clarity in this section.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ACE-I: A</td>
<td>ACE inhibitors have been shown in large RCTs to reduce morbidity and mortality in patients with HFrEF with mild, moderate, or severe symptoms of HF, with or without coronary artery disease (128-133). Data suggest that there are no differences among available ACE inhibitors in their effects on symptoms or survival (143). ACE inhibitors should be started at low doses and titrated upward to doses shown to reduce the risk of cardiovascular events in clinical trials. ACE inhibitors can produce angioedema and should be given with caution to patients with low systemic blood pressures, renal insufficiency, or elevated serum potassium (&gt;5.0 mEq/L). Angioedema occurs in &lt;1% of patients who take an ACE inhibitor, but it occurs more frequently in blacks and women (144). Patients should not be given ACE inhibitors if they are pregnant or plan to become pregnant. ACE inhibitors also inhibit kininase and increase levels of bradykinin, which can induce cough in up to 20% of patients but also may contribute to beneficial vasodilation. If maximal doses are not tolerated, intermediate doses should be tried; abrupt withdrawal of ACE inhibition can lead to clinical deterioration and should be avoided. Although the use of an ARNI in lieu of an ACE inhibitor for HFrEF has been found to be superior, for those patients for whom ARNI is not appropriate, continued use of an ACE inhibitor for all classes of HFrEF remains strongly advised.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>See Online Data Supplement 18.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>see Online Data Supplements 2 and 19.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ARB: A</td>
<td>The use of ARBs to reduce morbidity and mortality is recommended in patients with prior or current symptoms of chronic HFrEF who are intolerant to ACE inhibitors because of cough or angioedema (134-137, 145, 146).</td>
<td>2013 recommendation repeated for clarity in this section.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ARBs have been shown to reduce mortality and HF hospitalizations in patients with HFrEF in large RCTs (134-137). Long-term therapy with ARBs in patients with HFrEF produces hemodynamic, neurohormonal, and clinical effects consistent with those expected after interference with the renin-angiotensin system (145, 146). Unlike ACE inhibitors, ARBs do not inhibit kininase and are associated with a much lower incidence of cough and angioedema, although kininase inhibition by ACE inhibitors may produce beneficial vasodilatory effects. Patients intolerant to ACE inhibitors because of cough or angioedema should be started on ARBs; patients already tolerating ARBs for other indications may be continued on ARBs if they subsequently develop HF. ARBs should be started at low doses and titrated upward, with an attempt to use doses shown to reduce the risk of cardiovascular events in clinical trials. ARBs should be given with caution to patients with low systemic blood pressure, renal insufficiency, or elevated serum potassium (&gt;5.0 mEq/L). Although ARBs are</td>
<td></td>
</tr>
</tbody>
</table>
alternatives for patients with ACE inhibitor–induced angioedema, caution is advised because some patients have also developed angioedema with ARBs.

Head-to-head comparisons of an ARB versus ARNI for HF do not exist.

For those patients for whom an ACE inhibitor or ARNI is inappropriate, use of an ARB remains advised.

**In patients with chronic symptomatic HFrEF NYHA class II or III who tolerate an ACE inhibitor or ARB, replacement by an ARNI is recommended to further reduce morbidity and mortality (138).**

Benefits of ACE inhibitors with regard to decreasing HF progression, hospitalizations, and mortality rate have been shown consistently for patients across the clinical spectrum, from asymptomatic to severely symptomatic HF. Similar benefits have been shown for ARBs in populations with mild-to-moderate HF who are unable to tolerate ACE inhibitors. In patients with mild-to-moderate HF (characterized by either 1) mildly elevated natriuretic peptide levels, BNP [B-type natriuretic peptide] >150 pg/mL or NT-proBNP [N-terminal pro-B-type natriuretic peptide] ≥600 pg/mL; or 2) BNP ≥100 pg/mL or NT-proBNP ≥400 pg/mL with a prior hospitalization in the preceding 12 months) who were able to tolerate both a target dose of enalapril (10 mg twice daily) and then subsequently an ARNI (valsartan/sacubitril; 200 mg twice daily, with the ARB component equivalent to valsartan 160 mg), hospitalizations and mortality were significantly decreased with the valsartan/sacubitril compound compared with enalapril. The target dose of the ACE inhibitor was consistent with that known to improve outcomes in previous landmark clinical trials (129). This ARNI has been approved for patients with symptomatic HFrEF and is intended to be substituted for ACE inhibitors or ARBs. HF effects and potential off-target effects may be complex with inhibition of the neprilysin enzyme, which has multiple biological targets. Use of an ARNI is associated with hypotension and a low-frequency incidence of angioedema. To facilitate initiation and titration, the approved ARNI is available in 3 doses that include a dose that was not tested in the HF trial; the target dose used in the trial was 97/103 mg twice daily (147). Clinical experience will provide further information about the optimal titration and tolerability of ARNI, particularly with regard to blood pressure, adjustment of concomitant HF medications, and the rare complication of angioedema (14).

**ARNI should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor (148, 149).**

**NEW:** Available evidence demonstrates a potential signal of harm for a concomitant use of ACE inhibitors and ARNI.
Oral neprilysin inhibitors, used in combination with ACE inhibitors can lead to angioedema and concomitant use is contraindicated and should be avoided. A medication that represented both a neprilysin inhibitor and an ACE inhibitor, omapatrilat, was studied in both hypertension and HF, but its development was terminated because of an unacceptable incidence of angioedema (148, 149) and associated significant morbidity. This adverse effect was thought to occur because both ACE and neprilysin break down bradykinin, which directly or indirectly can cause angioedema (149, 150). An ARNI should not be administered within 36 hours of switching from or to an ACE inhibitor.

### Harm

**ARNI should not be administered to patients with a history of angioedema.**

Omapatrilat, a neprilysin inhibitor (as well as an ACE inhibitor and aminopeptidase P inhibitor), was associated with a higher frequency of angioedema than that seen with enalapril in an RCT of patients with HFrEF (148). In a very large RCT of hypertensive patients, omapatrilat was associated with a 3-fold increased risk of angioedema as compared with enalapril (149). Blacks and smokers were particularly at risk. The high incidence of angioedema ultimately led to cessation of the clinical development of omapatrilat (151, 152). In light of these observations, angioedema was an exclusion criterion in the first large trial assessing ARNI therapy in patients with hypertension (153) and then in the large trial that demonstrated clinical benefit of ARNI therapy in HFrEF (138). ARNI therapy should not be administered in patients with a history of angioedema because of the concern that it will increase the risk of a recurrence of angioedema.

### 7.3.2.11. Ivabradine: Recommendation

#### Recommendation for Ivabradine

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendation</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>B-R</td>
<td>Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II-III) stable chronic HFrEF (LVEF ≤35%) who are receiving GDEM*, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest (154-157).</td>
<td>NEW: New clinical trial data.</td>
</tr>
</tbody>
</table>

Ivabradine is a new therapeutic agent that selectively inhibits the I_f current in the sinoatrial node, providing heart rate reduction. One RCT demonstrated the efficacy of ivabradine in reducing the composite endpoint of cardiovascular death or HF hospitalization (155). The benefit of ivabradine was driven by a reduction in HF hospitalization. The study included patients with HFrEF (NYHA class II-IV, albeit with only a modest representation of NYHA class IV HF) and left ventricular ejection fraction (LVEF) ≤35%, in sinus rhythm with a resting heart rate of ≥70 beats per minute. Patients enrolled included a small number with paroxysmal atrial fibrillation (<40% of the time) but otherwise in...
sinus rhythm and a small number experiencing ventricular pacing but with a predominant sinus rhythm. Those with a myocardial infarction within the preceding 2 months were excluded. Patients enrolled had been hospitalized for HF in the preceding 12 months and were on stable GDEM* for 4 weeks before initiation of ivabradine therapy. The target of ivabradine is heart rate slowing (the presumed benefit of action), but only 25% of patients studied were on optimal doses of beta-blocker therapy (9, 139, 140, 155). Given the well-proven mortality benefits of beta-blocker therapy, it is important to initiate and up titrate these agents to target doses, as tolerated, before assessing the resting heart rate for consideration of ivabradine initiation (155).

*In other parts of the document, the term “GDMT” has been used to denote guideline-directed management and therapy. In this recommendation, however, the term “GDEM” has been used to denote this same concept in order to reflect the original wording of the recommendation that initially appeared in the “2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure” (10).
Figure 2. Treatment of HFrEF Stage C and D

**Step 1** Establish Dx of HFrEF; assess volume; initiate GDMT

**Step 2** Consider the following patient scenarios

- NYHA class II–IV, provided est. CrCl > 30 mL/min & K+ < 5.0 mEq/L
  - NYHA class II–III HF
  - Adequate BP on ACEI or ARB; No C/I to ARB or sacubitril
  - NYHA class III–IV, in black patients
  - NYHA class II–IV, LVEF ≤ 35%, (caveat: >1 y survival, >40 d post MI)
  - NYHA class II–III, LVEF ≤ 35%; (caveat: >1 y survival, >40 d post MI)
  - NYHA class II–III, NSR, heart rate ≥70 bpm on maximally tolerated dose beta blocker

**Step 3** Implement indicated GDMT. Choices are not mutually exclusive, and no order is inferred

- Aldosterone antagonist (COR I)
- Hydral-Nitrates†‡ (COR I)
- ICD‡ (COR I)
- CRT or CRT-D‡ (COR I)
- Ivabradine (COR Ila)

**Step 4** Reassess symptoms

- Refractory NYHA class III–IV (Stage D)
- Symptoms improved

**Step 5** Consider additional therapy

- Palliative care† (COR I)
- Transplant‡ (COR I)
- LVAD‡ (COR Ila)
- Investigational studies§

Continue GDMT with serial reassessment & optimized dosing/adherence

Colors correspond to COR in Table 1. For all medical therapies, dosing should be optimized and serial assessment exercised.

*See text for important treatment directions.
†Hydral-Nitrates green box: The combination of ISDN/HYD with ARNI has not been robustly tested. BP response should be carefully monitored.
‡See 2013 HF guideline (9).
§Participation in investigational studies is also appropriate for stage C, NYHA class II and III HF.

ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor-blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BP, blood pressure; bpm, beats per minute; C/I, contraindication; COR, Class of Recommendation; CrCl, creatinine clearance; CRT-D, cardiac resynchronization therapy–device; Dx, diagnosis; GDMT, guideline-directed management and therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; ISDN/HYD, isosorbide dinitrate-hydral-nitrates; K+, potassium; LBBB, left bundle-branch block; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSR, normal sinus rhythm; and NYHA, New York Heart Association.
Table 3. Drugs Commonly Used for HF rEF (Stage C HF)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Daily Dose(s)</th>
<th>Maximum Doses(s)</th>
<th>Mean Doses Achieved in Clinical Trials</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACE inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Captopril</td>
<td>6.25 mg TID</td>
<td>50 mg TID</td>
<td>122.7 mg QD</td>
<td>(158)</td>
</tr>
<tr>
<td>Enalapril</td>
<td>2.5 mg BID</td>
<td>10–20 mg BID</td>
<td>16.6 mg QD</td>
<td>(129)</td>
</tr>
<tr>
<td>Fosinopril</td>
<td>5–10 mg QD</td>
<td>40 mg QD</td>
<td>N/A</td>
<td>---</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>2.5–5 mg QD</td>
<td>20–40 mg QD</td>
<td>32.5–35.0 mg QD</td>
<td>(130)</td>
</tr>
<tr>
<td>Perindopril</td>
<td>2 mg QD</td>
<td>8–16 mg QD</td>
<td>N/A</td>
<td>---</td>
</tr>
<tr>
<td>Quinapril</td>
<td>5 mg BID</td>
<td>20 mg BID</td>
<td>N/A</td>
<td>---</td>
</tr>
<tr>
<td>Ramipril</td>
<td>1.25–2.5 mg QD</td>
<td>10 mg QD</td>
<td>N/A</td>
<td>---</td>
</tr>
<tr>
<td>Trandolapril</td>
<td>1 mg QD</td>
<td>4 mg QD</td>
<td>N/A</td>
<td>---</td>
</tr>
<tr>
<td><strong>ARBs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candesartan</td>
<td>4–8 mg QD</td>
<td>32 mg QD</td>
<td>24 mg QD</td>
<td>(137)</td>
</tr>
<tr>
<td>Losartan</td>
<td>25–50 mg QD</td>
<td>50–150 mg QD</td>
<td>129 mg QD</td>
<td>(136)</td>
</tr>
<tr>
<td>Valsartan</td>
<td>20–40 mg BID</td>
<td>160 mg BID</td>
<td>254 mg QD</td>
<td>(134)</td>
</tr>
<tr>
<td><strong>ARNI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacubitril/valsartan</td>
<td>49/51 mg BID</td>
<td>97/103 mg BID</td>
<td>375 mg QD; target dose: 24/26 mg, 49/51 mg OR 97/103 mg QD</td>
<td>(138)</td>
</tr>
<tr>
<td></td>
<td>(therapy may be initiated at 24/26 mg BID)</td>
<td>(sacubitril/valsartan)</td>
<td>(sacubitril/valsartan)</td>
<td></td>
</tr>
<tr>
<td><strong>I1 channel inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ivabradine</td>
<td>5 mg BID</td>
<td>7.5 mg BID</td>
<td>6.4 mg BID (at 28 d) 6.5 mg BID (at 1 y)</td>
<td>(155-157)</td>
</tr>
<tr>
<td><strong>Aldosterone antagonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spironolactone</td>
<td>12.5–25 mg QD</td>
<td>25 mg QD or BID</td>
<td>26 mg QD</td>
<td>(142)</td>
</tr>
<tr>
<td>Eplerenone</td>
<td>25 mg QD</td>
<td>50 mg QD</td>
<td>42.6 mg QD</td>
<td>(159)</td>
</tr>
<tr>
<td><strong>Beta blockers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bisoprolol</td>
<td>1.25 mg QD</td>
<td>10 mg QD</td>
<td>8.6 mg QD</td>
<td>(160)</td>
</tr>
<tr>
<td>Carvedilol</td>
<td>3.125 mg BID</td>
<td>50 mg QD</td>
<td>37 mg QD</td>
<td>(161)</td>
</tr>
<tr>
<td>Carvedilol CR</td>
<td>10 mg QD</td>
<td>80 mg QD</td>
<td>N/A</td>
<td>---</td>
</tr>
<tr>
<td>Metoprolol succinate extended release (metoprolol CR/XL)</td>
<td>12.5–25 mg QD</td>
<td>200 mg QD</td>
<td>159 mg QD</td>
<td>(139)</td>
</tr>
<tr>
<td><strong>Isosorbide dinitrate and hydralazine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed-dose combination</td>
<td>20 mg isosorbide dinitrate / 37.5 mg hydralazine TID</td>
<td>40 mg isosorbide dinitrate / 75 mg hydralazine TID</td>
<td>90 mg isosorbide dinitrate / ~175 mg hydralazine QD</td>
<td>(162)</td>
</tr>
<tr>
<td>Isosorbide dinitrate and hydralazine</td>
<td>20–30 mg isosorbide dinitrate / 25–50 mg hydralazine TID or QD</td>
<td>40 mg isosorbide dinitrate TID with 100 mg hydralazine TID</td>
<td>N/A</td>
<td>(163)</td>
</tr>
</tbody>
</table>

Modified (Table 15) from the 2013 HF guideline (9).
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BID, twice daily; CR, controlled release; CR/XL, controlled release/extended release; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; N/A, not applicable; QD, once daily; and TID, 3 times daily.

### 7.3.3. Pharmacological Treatment for Stage C HFpEF: Recommendations

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B</td>
<td>Systolic and diastolic blood pressure should be controlled in patients with HFpEF in accordance with published clinical practice guidelines to prevent morbidity (164, 165).</td>
<td>2013 recommendation remains current.</td>
</tr>
<tr>
<td>I</td>
<td>C</td>
<td>Diuretics should be used for relief of symptoms due to volume overload in patients with HFpEF.</td>
<td>2013 recommendation remains current.</td>
</tr>
<tr>
<td>IIa</td>
<td>C</td>
<td>Coronary revascularization is reasonable in patients with CAD in whom symptoms (angina) or demonstrable myocardial ischemia is judged to be having an adverse effect on symptomatic HFpEF despite GDMT.</td>
<td>2013 recommendation remains current.</td>
</tr>
<tr>
<td>IIa</td>
<td>C</td>
<td>Management of AF according to published clinical practice guidelines in patients with HFpEF is reasonable to improve symptomatic HF.</td>
<td>2013 recommendation remains current (Section 9.1 in the 2013 HF guideline).</td>
</tr>
<tr>
<td>IIa</td>
<td>C</td>
<td>The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF.</td>
<td>2013 recommendation remains current.</td>
</tr>
<tr>
<td>IIb</td>
<td>B-R</td>
<td>In appropriately selected patients with HFpEF (with EF ≥45%, elevated BNP levels or HF admission within 1 year, estimated glomerular filtration rate &gt;30 mL/min, creatinine &lt;2.5 mg/dL, potassium &lt;5.0 mEq/L), aldosterone receptor antagonists might be considered to decrease hospitalizations (83, 166, 167).</td>
<td>NEW: Current recommendation reflects new RCT data.</td>
</tr>
</tbody>
</table>

Mechanistic studies have suggested that mineralocorticoid receptor antagonists can improve measures of diastolic function in patients with HFpEF, possibly by a similar effect on remodeling (83, 168).

The TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial (166) investigated the effects of spironolactone on a combined endpoint of death, aborted cardiac death, and HF hospitalization in patients with HFpEF. A small reduction (HR=0.89) in this composite endpoint did not reach statistical significance, although HF hospitalization was reduced (HR=0.83); known side effects of hyperkalemia and rising creatinine were seen more commonly in the treatment group (166). An unusual amount of regional variation was seen in this trial, prompting a post-hoc analysis (167) that showed that rates of the primary endpoint were 4-fold lower in Russia/Georgia than in North America and South America (the Americas). Rates in the Americas were comparable to those in other HFpEF trials (169, 170). The post-hoc analysis showed efficacy in the Americas (HR=0.83) but not in Russia/Georgia (HR=1.10). Moreover, a sample of the Russia/Georgia population, despite having been in the active treatment arm, had nondetectable levels of
the metabolite of spironolactone. These post-hoc analyses have significant limitations, but they suggest that in appropriately selected patients with symptomatic HFpEF (with ejection fraction \( [EF] \geq 45\% \), elevated BNP level or HF admission within 1 year, estimated glomerular filtration rate \( >30 \text{ mL/min creatinine} < 2.5 \text{ mg/dL} \), and potassium \( < 5.0 \text{ mEq/L} \)), particularly in those with elevated BNP levels, use of spironolactone might be considered with close monitoring of potassium and renal function. Confirmatory studies are required.

With regard to the use of mineralocorticoid receptor antagonists, creatinine should be \( < 2.5 \text{ mg/dL} \) in men or \( < 2.0 \text{ mg/dL} \) in women (or estimated glomerular filtration rate \( >30 \text{ mL/min} \)) and potassium should be \( < 5.0 \text{ mEq/L} \). Careful monitoring of potassium, renal function, and diuretic dosing represents best practices at initiation and during follow-up thereafter to minimize risk of hyperkalemia and worsening renal function.

<table>
<thead>
<tr>
<th>IIb</th>
<th>B</th>
<th>The use of ARBs might be considered to decrease hospitalizations for patients with HFpEF (169).</th>
<th>2013 recommendation remains current.</th>
</tr>
</thead>
<tbody>
<tr>
<td>III: No Benefit</td>
<td>B-R</td>
<td>Routine use of nitrates or phosphodiesterase-5 inhibitors to increase activity or QoL in patients with HFpEF is ineffective (171, 172).</td>
<td>NEW: Current recommendation reflects new data from RCTs.</td>
</tr>
<tr>
<td></td>
<td>See Online Data Supplement C.</td>
<td>Routine use of nutritional supplements is not recommended for patients with HFpEF.</td>
<td>2013 recommendation remains current.</td>
</tr>
</tbody>
</table>

Nitrate therapy can reduce pulmonary congestion and improve exercise tolerance in patients with HFpEF. However, the NEAT-HFpEF (Nitrate’s Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction) trial (171) randomized 110 patients with EF \( \geq 50\% \) on stable HF therapy, not including nitrates, and with activity limited by dyspnea, fatigue, or chest pain, to either isosorbide mononitrate or placebo and found no beneficial effects on activity levels, QoL, exercise tolerance, or NT-proBNP levels. On the basis of this trial, routine use of nitrates in patients with HFpEF is not recommended. This recommendation does not apply to patients with HFpEF and symptomatic CAD for whom nitrates may provide symptomatic relief.

Phosphodiesterase-5 inhibition augments the nitric oxide system by upregulating cGMP activity. The RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction) trial (172) randomized 216 patients with EF \( \geq 50\% \) on stable HF therapy and with reduced exercise tolerance (peak observed VO\(_2\) \( <60\% \) of predicted) to phosphodiesterase-5 inhibition with sildenafil or placebo. This study did not show improvement in oxygen consumption or exercise tolerance.

### 9. Important Comorbidities in HF

#### 9.2. Anemia: Recommendations

<table>
<thead>
<tr>
<th>Recommendations for Anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>COR</td>
</tr>
<tr>
<td>IIb</td>
</tr>
</tbody>
</table>

Routine baseline assessment of all patients with HF includes an evaluation for anemia in addition to other baseline laboratory measurements. Anemia is independently associated with HF disease severity, and iron
deficiency appears to be uniquely associated with reduced exercise capacity. When iron deficiency is diagnosed and after full evaluation for cause, intravenous repletion of iron, especially in the setting of concomitant hepcidin deficiency in HF, may improve exercise capacity and QoL. Studies examining correction of iron deficiency in HF have demonstrated improvement in surrogate endpoints, such as QoL, NT-proBNP, and LVEF; however, controlled trials have been underpowered to detect reductions in hard clinical endpoints. The FAIR-HF (Ferric Carboxymaltose Assessment in Patients With Iron Deficiency and Chronic Heart Failure) trial (173) demonstrated improvements in NYHA class and functional capacity over a short-term exposure. The CONFIRM-HF (Ferric Carboxymaltose Evaluation on Performance in Patients With Iron Deficiency in Combination with Chronic Heart Failure) trial (174) included a larger cohort of patients (n=304) and demonstrated improvements in 6-minute walk test. A meta-analysis of 5 prospective controlled studies (631 patients) evaluated the effect of intravenous iron on deaths, hospitalizations, and other events in patients with HF and iron deficiency (175). Patients receiving intravenous iron experienced limited but statistically significant improvements in functional capacity and LVEF but no reduction in mortality rate. The FAIR-HF 2 trial is underway to further address the potential benefit of intravenous iron in HF associated with iron deficiency. Therefore, a strong recommendation for intravenous iron repletion must await the results of an appropriately powered trial on morbidity and mortality. There is an uncertain evidence base for oral iron repletion in the setting of anemia associated with HF.

III: No Benefit

In patients with HF and anemia, erythropoietin-stimulating agents should not be used to improve morbidity and mortality (176).

NEW: Current recommendation reflects new evidence demonstrating absence of therapeutic benefit.

Small studies evaluating the treatment of anemia in patients with HF have suggested a trend toward improvement in functional capacity and reduction in hospitalization with the use of erythropoietin-stimulating agents (177-182), but results have varied (183) and have been limited because of sample size. Although a meta-analysis of 11 RCTs (n=794) comparing erythropoietin-stimulating agents to control in patients with HF demonstrated significant improvements in 6-minute walk, exercise duration, peak VO₂, NYHA functional status, EF, BNP, HF-related hospitalizations, and QoL (184), in the STAMINA-HeFT (Study of Anemia in Heart Failure) trial (183), darbepoetin alfa was not associated with significant clinical benefits. In the largest RCT to date (n=2,278), correction of anemia with darbepoetin alfa did not result in benefit and resulted in a significant increase in the risk of thromboembolic events and a nonsignificant increase in fatal and nonfatal strokes, supporting findings from other trials (176, 185-188). In summary, the strongest evidence on erythropoietin-stimulating agent therapy in HF suggests lack of benefit and increased adverse events. Therefore, erythropoietin-stimulating agent therapy cannot be recommended in patients with HF and anemia.

9.5. Hypertension (New Section)

9.5.1. Treating Hypertension to Reduce the Incidence of HF: Recommendation

<table>
<thead>
<tr>
<th>Recommendation for Prevention</th>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>B-R</td>
<td></td>
<td>In patients at increased risk, stage A HF, the optimal blood pressure in those with hypertension should be</td>
<td>NEW: Recommendation reflects new RCT data.</td>
</tr>
</tbody>
</table>
A large RCT demonstrated that in those with increased cardiovascular risk (defined as age >75 years, established vascular disease, chronic renal disease, or a Framingham Risk Score >15%), control of blood pressure to a goal systolic pressure of <120 mm Hg, as determined by blood pressure assessment as per research protocol, was associated with a significant reduction in the incidence of HF (191) and an overall decrease in cardiovascular death. Blood pressure measurements as generally taken in the office setting are typically 5 to 10 mm Hg higher than research measurements; thus, the goal of <130/80 mm Hg is an approximation of the target blood pressure in conventional practice. **Targeting a significant reduction in systolic blood pressure in those at increased risk for cardiovascular disease is a novel strategy to prevent HF.**

### 9.5.2. Treating Hypertension in Stage C HFrEF: Recommendation

<table>
<thead>
<tr>
<th>Recommendation for Hypertension in Stage C HFrEF</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COR</strong></td>
<td><strong>LOE</strong></td>
</tr>
<tr>
<td>I</td>
<td>C-EO</td>
</tr>
<tr>
<td>See Online Data Supplements E and F.</td>
<td></td>
</tr>
</tbody>
</table>

Clinical trials evaluating goal blood pressure reduction and optimal blood pressure–lowering agents in the setting of HFrEF and concomitant hypertension have not been done. However, it is apparent that in those patients at higher risk, blood pressure lowering is associated with fewer adverse cardiovascular events. GDMT for HFrEF with agents known to lower blood pressure should consider a goal blood pressure reduction consistent with a threshold now associated with improved clinical outcomes but not yet proven by RCTs in a population with HF.

### 9.5.3. Treating Hypertension in Stage C HFpEF: Recommendation

<table>
<thead>
<tr>
<th>Recommendation for Hypertension in Stage C HFpEF</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COR</strong></td>
<td><strong>LOE</strong></td>
</tr>
<tr>
<td>I</td>
<td>C-LD</td>
</tr>
<tr>
<td>See Online Data Supplements E and F.</td>
<td></td>
</tr>
</tbody>
</table>

The use of nitrates in the setting of HFpEF is associated with a signal of harm and, in most situations, should be avoided. For many common antihypertensive agents, including alpha blockers, beta blockers, and calcium channel blockers, there are limited data to guide the choice of antihypertensive therapy in the setting of HFpEF (172). Nevertheless, RAAS inhibition with ACE inhibitor, ARB (especially mineralocorticoid receptor antagonists), and possibly ARNI would represent the preferred choice. A shared decision-making discussion with the patient influenced by physician judgment should drive the ultimate choice of antihypertensive agents.
9.6. Sleep Disordered Breathing: Recommendations

(Moved from Section 7.3.1.4, Treatment of Sleep Disorders in the 2013 HF guideline.)

<table>
<thead>
<tr>
<th>COR</th>
<th>LOE</th>
<th>Recommendations</th>
<th>Comment/Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>IIa</td>
<td>C-LD</td>
<td>In patients with NYHA class II–IV HF and suspicion of sleep disordered breathing or excessive daytime sleepiness, a formal sleep assessment is reasonable (200, 201).</td>
<td>NEW: Recommendation reflects clinical necessity to distinguish obstructive versus central sleep apnea.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>See Online Data Supplement G.</td>
<td></td>
</tr>
</tbody>
</table>

Sleep disorders are common in patients with HF. A study of adults with chronic HF treated with evidence-based therapies found that 61% had either central or obstructive sleep apnea (202). It is clinically important to distinguish obstructive sleep apnea from central sleep apnea, given the different responses to treatment. Adaptive servo-ventilation for central sleep apnea is associated with harm (203). Continuous positive airway pressure (CPAP) for obstructive sleep apnea improves sleep quality, reduces the apnea-hypopnea index, and improves nocturnal oxygenation (200, 201).

| IIb  | B-R  | In patients with cardiovascular disease and obstructive sleep apnea, CPAP may be reasonable to improve sleep quality and daytime sleepiness (204). | NEW: New data demonstrate the limited scope of benefit expected from CPAP for obstructive sleep apnea. |
|      |      | See Online Data Supplement G.                                                   |                                                                                  |

In patients with sleep apnea, a trial evaluated the impact of CPAP with usual therapy versus usual therapy alone on subsequent cardiovascular events, including HF (204). In this RCT of >2,700 patients, there was no evidence of benefit on cardiovascular events at a mean follow-up of 3.7 years for CPAP plus usual care compared with usual care alone. Improvements in sleep quality were noteworthy and represented the primary indication for initiating CPAP treatment (204). However, in patients with atrial fibrillation (AF) (a frequent comorbidity noted with HF), the use of CPAP for obstructive sleep apnea was helpful. In a trial of 10,132 patients with AF and obstructive sleep apnea, patients on CPAP treatment were less likely to progress to more permanent forms of AF than were patients without CPAP (205).

| III: Harm | B-R | In patients with NYHA class II–IV HFrEF and central sleep apnea, adaptive servo-ventilation causes harm (203). | NEW: New data demonstrate a signal of harm when adaptive servo-ventilation is used for central sleep apnea. |
|           |     | See Online Data Supplement G.                                                   |                                                                                  |

Mortality rate (all cause and cardiovascular) was higher with adaptive servo-ventilation plus GDMT than with GDMT alone in a single RCT to test the addition of adaptive servo-ventilation (≥5 hours/night, 7 days/week) to GDMT in patients with HFrEF and central sleep apnea (203). A similar risk has been seen in another trial, and a third trial of adaptive servo-ventilation in central sleep apnea and HF was aborted because of ethical concerns. The weight of evidence does not support the use of adaptive servo-ventilation for central sleep apnea in HFrEF.
Presidents and Staff

American College of Cardiology
Mary Norine Walsh, MD, FACC, President
Shalom Jacobovitz, Chief Executive Officer
William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, Quality, and Publishing
Amelia Scholtz, PhD, Publications Manager, Science, Education, Quality, and Publishing

American College of Cardiology/American Heart Association
Katherine Sheehan, PhD, Director of Guideline Strategy and Operations
Lisa Bradfield, CAE, Director, Guideline Methodology and Policy
Abdul R. Abdullah, MD, Science and Medicine Advisor
Morgane Cibotti-Sun, MPH, Project Manager, Clinical Practice Guidelines
Sam Shahid, MBBS, MPH, Associate Science and Medicine Advisor

American Heart Association
Steven R. Houser, PhD, FAHA, President
Nancy Brown, Chief Executive Officer
Rose Marie Robertson, MD, FAHA, Chief Science and Medicine Officer
Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations
Jody Hundley, Production Manager, Scientific Publications, Office of Science Operations

Key Words: AHA Scientific Statements ■ heart failure ■ focused update ■ angiotensin receptor-neprilysin inhibitor ■ ivabradine ■ angiotensin receptor blockers ■ angiotensin-converting enzyme inhibitors ■ beta blockers ■ angioedema ■ natriuretic peptides ■ ferric carboxymaltose ■ iron deficiency ■ hypertension ■ sleep apnea ■ natriuretic peptide biomarker
References

62. Stienen S, PRIMA II: can NT-pro-brain-natriuretic peptide (NT-proBNP) guided therapy during admission for acute heart failure reduce mortality and readmissions?


### Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (December 2015)

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Voting Recusals By Section*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clyde W. Yancy</td>
<td>Northwestern University Feinberg School of Medicine, Division of Cardiology—Professor of Medicine and Chief; Diversity and Inclusion—Vice Dean</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mariell Jessup</td>
<td>Fondation Leducq—Chief Scientific Officer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Biykem Bozkurt</td>
<td>Baylor College of Medicine, Department of Medicine — Professor of Medicine; Cardiology Section, DeBakey VA Medical Center — Chief; The Mary and Gordon Cain Chair &amp; W.A. “Tex” and Deborah Moncrief, Jr. — Chair; Winters Center for Heart Failure Research — Director; Cardiovascular Research Institute — Associate Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Novartis</td>
<td>None</td>
<td>None</td>
<td>7.3.2.10, 7.3.2.11, 7.3.3, and 9.5.</td>
</tr>
<tr>
<td>Javed Butler</td>
<td>Stony Brook University—Division Chief of Cardiology</td>
<td>Bayer†</td>
<td>None</td>
<td>Novartis†</td>
<td>None</td>
<td>Amgen (DSMB)†</td>
<td>None</td>
<td>7.3.2.10, 7.3.2.11, 7.3.3, and 9.5.</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Donald E. Casey, Jr</td>
<td>Thomas Jefferson College of Population Health—Faculty; Alvarez &amp; Marsal IPO4Health—Principal and Founder</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Monica M. Colvin</td>
<td>University of Michigan—Associate Professor of Medicine, Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mark H. Drazner</td>
<td>University of Texas Southwestern Medical Center—Professor, Internal Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gerasimos S. Filippatos</td>
<td>National and Kapodistrian University of Athens; Attikon University Hospital, Department of Cardiology, Heart Failure Unit—Professor of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gregg C. Fonarow</td>
<td>Ahmanson-UCLA Cardiomyopathy Center—Director; UCLA Division of Cardiology—Co-Chief</td>
<td>Amgen</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Novartis †</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael M. Givertz</td>
<td>Brigham and Women’s Hospital—Professor of Medicine</td>
<td>Merck</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Steven M. Hollenberg</td>
<td>Cooper University Hospital—Director, Coronary Care Unit, Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>JoAnn Lindenfeld</td>
<td>Vanderbilt Heart and Vascular Institute—Director, Advanced Heart Failure and Transplant Section—Professor of Medicine</td>
<td>Abbott</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Frederick A. Masoudi</td>
<td>University of Colorado, Anschutz Medical Campus—Professor of Medicine, Division of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Patrick E. McBride</td>
<td>University of Wisconsin School of Medicine and Public Health—Professor of Medicine and Family</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of \( \geq 5\% \) of the voting stock or share of the business entity, or ownership of \( \geq \$5,000 \) of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a relevant relationship IF:  
- a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or  
- b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or  
- c) the person or a member of the person’s household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.
†Significant relationship.

ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; DCRI, Duke Clinical Research Institute; DSMB, data safety monitoring board; HFSA, Heart Failure Society of America; NHLBI, National Heart, Lung, and Blood Institute; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; PARENT, Pulmonary artery pressure reduction with entresto; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.
### Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (October 2016)

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Representation</th>
<th>Employment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim K. Birther</td>
<td>Official Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>University of Houston College of Pharmacy—Clinical Professor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Jones &amp; Bartlett Learning</td>
</tr>
<tr>
<td></td>
<td></td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>None</td>
</tr>
</tbody>
</table>

| Akshay S. Desai           | Official Reviewer—HFSA                | Brigham and Women’s Hospital—Director, Heart Failure Disease Management, Advanced Heart Disease Section, Cardiovascular Division; Associate Professor of Medicine, Harvard Medical School |
|                           |                                        | • Medscape Cardiology*                                                     |
|                           |                                        | • Merck                                                                   |
|                           |                                        | • Novartis*                                                               |
|                           |                                        | • Relypsa*                                                                |
|                           |                                        | • St. Jude Medical*                                                       |
|                           |                                        | None                                                                      |
|                           |                                        | None                                                                      |
|                           |                                        | None                                                                      |

| Anita Deswal              | Official Reviewer—AHA                 | Michael E. DeBakey VA Medical Center—Chief of Cardiology; Director, Heart Failure Program; Baylor College of Medicine—Professor of Medicine |
|                           |                                        | None                                                                      |
|                           |                                        | None                                                                      |
|                           |                                        | None                                                                      |

| Dipti Itchhaporia         | Official Reviewer—ACC Board of Trustees | Newport Coast Cardiology—Robert and Georgia Roth Endowed Chair for Excellence in Cardiac Care; Director of Disease Management |
|                           |                                        | None                                                                      |
|                           |                                        | None                                                                      |
|                           |                                        | None                                                                      |

| Ileana L. Piña            | Official Reviewer—AHA                 | Montefiore Medical Center—Associate Chief for Academic Affairs, Cardiology; Professor of Medicine & Epidemiology and Population Health—Albert Einstein College of Medicine |
|                           |                                        | • Relypsa                                                                 |
|                           |                                        | None                                                                      |
|                           |                                        | None                                                                      |

| Geetha                    | Official                                | University of Missouri-Kansas                                           |
|                           |                                        | None                                                                      |
|                           |                                        | None                                                                      |
|                           |                                        | None                                                                      |

<table>
<thead>
<tr>
<th>Institutional, Organizational, or Other Financial Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
</tr>
</tbody>
</table>

* indicates financial relationship with the company (e.g., speaker, consulting, ownership).
<table>
<thead>
<tr>
<th>Yancy et al</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017 ACC/AHA/HFSA Heart Failure Focused Update</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Institution/Position</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuveer</td>
<td>Reviewer—ACC Board of Governors</td>
<td>City School of Medicine—Professor of Pediatrics; Children's Mercy Hospital—Pediatric Cardiology</td>
<td>Lantheus Medical Imaging; Gilead (DSMB); GlaxoSmithKline (DSMB); NHLBI; Otsuka</td>
</tr>
<tr>
<td>James E. Udelson</td>
<td>Official Reviewer—HFSA</td>
<td>Tufts Medical Center—Chief, Division of Cardiology</td>
<td>Abbott Laboratories; AHA*; Circulation / Circulation: Heart Failure†; HFSA (Executive Council)†; Pfizer/ GlaxoSmithKline; Sunshine Heart</td>
</tr>
<tr>
<td>Mary Norine Walsh</td>
<td>Official Reviewer—ACC Board of Trustees</td>
<td>St Vincent Heart Center of Indiana—Medical Director, Heart Failure and Cardiac Transplantation</td>
<td>Corvia Medical; Otsuka; PCORI; Thoratec</td>
</tr>
<tr>
<td>David A. Baran</td>
<td>Organizational Reviewer—ISHLT</td>
<td>Newark Beth Israel Medical Center—Director of Heart Failure and Transplant Research</td>
<td>Maquet; Otsuka*; Novartis; XDx*; NIH*</td>
</tr>
<tr>
<td>Kenneth Casey</td>
<td>Organizational Reviewer—CHEST</td>
<td>Wm. S. Middleton Memorial Veterans Hospital—Director, Sleep Medicine</td>
<td>CHEST</td>
</tr>
<tr>
<td>M. Fuad Jan</td>
<td>Organizational Reviewer—CHEST</td>
<td>Aurora Advanced Healthcare—Cardiologist</td>
<td>None</td>
</tr>
<tr>
<td>Kenneth W. Lin</td>
<td>Organizational Reviewer—AAFP</td>
<td>Georgetown University School of Medicine—Clinician Educator Track, Associate Professor</td>
<td>None</td>
</tr>
<tr>
<td>Joaquin E. Cigarroa</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Oregon Health &amp; Science University—Clinical Professor of Medicine</td>
<td>ACC/AHA†; AHA†; ASA†; Catheterization and Cardiovascular</td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Institution/Role</td>
<td>Conflicts of Interest</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Lee A. Fleisher</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>University of Pennsylvania Health System—Robert Dunning Dripps Professor of Anesthesiology and Critical Care; Chair, Department of Anesthesiology &amp; Critical Care</td>
<td>• Blue Cross/Blue Shield* • NQF† • Yale University • Johns Hopkins (DSMB) • Association of University Anesthesiologists† • NIH*</td>
</tr>
<tr>
<td>Samuel S. Gidding</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>Nemours/Alfred I. duPont Hospital for Children—Chief, Division of Pediatric Cardiology</td>
<td>• FH Foundation† • International FH Foundation† • FH Foundation† • NIH*</td>
</tr>
<tr>
<td>James L. Januzzi</td>
<td>Content Reviewer</td>
<td>Massachusetts General Hospital—Hutter Family Professor of Medicine in the Field of Cardiology</td>
<td>• Critical Diagnostics* • Novartis* • Phillips • Roche Diagnostics* • Sphingotec* • Amgen (DSMB) • Boeringer Ingelheim (DSMB)* • Janssen Pharmaceuticals (DSMB) • Prevencio*</td>
</tr>
<tr>
<td>José A. Joglar</td>
<td>Content Reviewer—ACC/AHA Task Force on Clinical Practice Guidelines</td>
<td>UT Southwestern Medical Center—Professor of Internal Medicine; Clinical Cardiac Electrophysiology—Program Director</td>
<td>None✈️</td>
</tr>
<tr>
<td>Edward K. Kasper</td>
<td>Content Reviewer</td>
<td>Johns Hopkins Cardiology—E. Cowles Andrus Professor in Cardiology</td>
<td>None✈️</td>
</tr>
<tr>
<td>Wayne C.</td>
<td>Content Reviewer</td>
<td>University of Washington</td>
<td>• Abbott • NIH • Amgen*</td>
</tr>
</tbody>
</table>

Intervention† • NIH • Portland Metro Area AHA (President)† • SCAI Quality Interventional Council†
Yancy et al  
2017 ACC/AHA/HFSA Heart Failure Focused Update

<table>
<thead>
<tr>
<th>Levy</th>
<th>Professor of Medicine</th>
<th>Laboratories</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>• Biotronik</td>
<td>• GE Healthcare</td>
<td>• HeartWare</td>
<td>• PharminIN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Novartis*</td>
<td>• St. Jude Medical*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• AHA*</td>
<td>• HeartWare*</td>
<td>• Novartis*</td>
<td>• Resmed*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Thoratec</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Judith E. Mitchell     | Content Reviewer      | SUNY Downstate Medical Center—Director/Heart Failure Center; SUNY Downstate College of Medicine—Associate Professor of Medicine | None | None | None |
|                        |                       |   |   |   |   |
|                        |                       | • Association of Black Cardiologists† | None | None |   |

| Sean P. Pinney         | Content Reviewer—ACC Heart Failure and Transplant Council | Mount Sinai School of Medicine—Associate Professor of Medicine, Cardiology | None | None | None |
|                        |                       |   |   |   |   |
|                        |                       | • Acorda Therapeutics | • Thoratec | • Xdx |   |
|                        |                       | • Medtronic | • Novartis | • St. Jude Medical† |   |
|                        |                       | • AHA* | • HeartWare* | • Novartis* | • Resmed* |
|                        |                       | • Thoratec† | • NIH† |   |   |

| Randall C. Starling    | Content Reviewer—ACC Heart Failure and Transplant Council | Cleveland Clinic Department of Cardiovascular Medicine—Vice Chairman, Department of Cardiovascular Medicine; Section Head, Heart Failure & Cardiac Transplant | None | None | None |
|                        |                       |   |   |   |   |
|                        |                       | • BioControl | • Medtronic | • Novartis | • St. Jude Medical† |
|                        |                       | • NIH* |   |   |   |
|                        |                       | • Alnylam Pharmaceuticals | • NIH | • NHLBI | • Roche |
|                        |                       | • Novartis | • Thoratec |   |   |

| W. H. Wilson Tang      | Content Reviewer      | Cleveland Clinic Foundation—Assistant Professor of Medicine | None | None | None |
|                        |                       |   |   |   |   |
|                        |                       | • NIH* |   |   |   |
|                        |                       | • Alnylam Pharmaceuticals | • NIH | • NHLBI | • Roche |
|                        |                       | • Novartis | • Thoratec |   |   |

| Emily J. Tsai          | Content Reviewer      | Columbia University College of Physicians & Surgeons—Assistant Professor of Medicine, Division of Cardiology | None | None | None |
|                        |                       |   |   |   |   |
|                        |                       | • Bayer† | • Bristol-Myers Squib† | • NHLBI* |   |
|                        |                       | • CIHR (DSMB)† | • CIHR* | • Heart and Stroke Foundation of Canada* | None |
|                        |                       |   |   |   |   |

| Duminda N. Wijeysundera | Content Reviewer—ACC/AHA Task Force on Clinical Practice | Li Ka Shing Knowledge Institute of St. Michael’s Hospital—Scientist; University of Toronto—Assistant Professor, | None | None | None |
|                         |                       |   |   |   |   |
|                         |                       | • CIHR (DSMB)† | • CIHR* | • Heart and Stroke Foundation of Canada* | None |
|                         |                       |   |   |   |   |
This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq$5,000 of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

American College of Physicians did not provide a peer reviewer for this document.

<table>
<thead>
<tr>
<th>Guidelines</th>
<th>Department of Anesthesia and Institute of Health Policy Management and Evaluation</th>
<th></th>
</tr>
</thead>
</table>

*Significant relationship.
†No financial benefit.

AAFP indicates American Academy of Family Physicians; ACC, American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; ASA, American Stroke Association; CHEST, American College of Chest Physicians; CIHR, Canadian Institutes of Health Research; DSMB, data safety monitoring board; FH, familial hypercholesterolemia; GWTG, Get With The Guidelines; HFSA, Heart Failure Society of America; ISHLT, International Society for Heart and Lung Transplantation; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; NQF, National Quality Forum; PCORI, Patient-Centered Outcomes Research Institute; SCAI, Society for Cardiac Angiography and Interventions; SUNY, State University of New York; UT, University of Texas; and VA, Veterans Affairs.
Appendix 3. Abbreviations

ACE = angiotensin-converting enzyme
ARB = angiotensin-receptor blocker
ARNI = angiotensin receptor–neprilysin inhibitor
BNP = B-type natriuretic peptide
BP = blood pressure
COR = Class of Recommendation
CPAP = continuous positive airway pressure
EF = ejection fraction
GDMT = guideline-directed management and therapy
HFpEF = heart failure with preserved ejection fraction
HFrEF = heart failure with reduced ejection fraction
LOE = Level of Evidence
LVEF = left ventricular ejection fraction
NT-proBNP = N-terminal pro-B-type natriuretic peptide
QoL = quality of life
RCT = randomized controlled trial

Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E. Casey, Jr, Monica M. Colvin, Mark H. Drazner, Gerasimos S. Filippatos, Gregg C. Fonarow, Michael M. Givertz, Steven M. Hollenberg, JoAnn Lindenfeld, Frederick A. Masoudi, Patrick E. McBride, Pamela N. Peterson, Lynne Warner Stevenson and Cheryl Westlake

*Circulation*. published online April 28, 2017;

*Circulation* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2017 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circ.ahajournals.org/content/early/2017/04/26/CIR.0000000000000509.citation

Data Supplement (unedited) at:

http://circ.ahajournals.org/content/suppl/2017/04/26/CIR.0000000000000509.DC1
http://circ.ahajournals.org/content/suppl/2017/04/26/CIR.0000000000000509.DC2

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:

http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Circulation* is online at:

http://circ.ahajournals.org/subscriptions/
## Author Relationships With Industry and Other Entities (Comprehensive)—2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
</table>
| Clyde W. Yancy  
(*Chair*) | Northwestern University Feinberg School of Medicine, Division of Cardiology—Professor of Medicine and Chief; Diversity and Inclusion—Vice Dean | None | None | None | • PCORI† | • JAMA Cardiology (Deputy Editor)* | None |
| Mariell Jessup  
(*Vice Chair*) | Fondation Leducq—Chief Scientific Officer | None | None | None | None | • ABIM†  
• AHA†  
• Up to Date | None |
| Biykem Bozkurt | Baylor College of Medicine, Department of Medicine — Professor of Medicine; Cardiology Section, DeBakey VA Medical Center — Chief; The Mary and Gordon Cain Chair & W.A. “Tex” and Deborah Moncrief, Jr. — Chair; Winters Center for Heart Failure Research — Director; Cardiovascular Research Institute — Associate Director | None | None | None | • Novartis† | • ABIM  
• ACC Heart Failure Council Chair  
• Circulation Heart Failure Associate Editor  
• Circulation Editorial Board Membership | None |
| Javed Butler | Stony Brook University—Division Chief of Cardiology | • Bayer*  
• Boehringer Ingelheim*  
• CardioCell*  
• CVRx  
• Gilead Sciences  
• Janssen Pharmaceuticals | • Novartis* | None | • Amgen (DSMB)*  
• Bristol-Myers Squibb (DSMB)  
• Corvia Medical (DSMB)  
• European Union*  
• NIH* | • AHA (Deputy Chief Science Officer)*  
• American Heart Journal (Editorial Board)†  
• European Journal of Heart Failure (Associate Editor)†  
• HFSA (Executive) | None |
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Committee Members</th>
<th>Acknowledgments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donald E. Casey, Jr.</td>
<td>Thomas Jefferson College of Population Health—Adjunct Faculty; Alvarez &amp; Marsal IPO4Health—Principal and Founder</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Monica M. Colvin</td>
<td>University of Michigan—Associate Professor of Medicine, Cardiology</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mark H. Drazner</td>
<td>University of Texas Southwestern Medical Center—Professor, Internal Medicine</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gerasimos S. Filippatos</td>
<td>National and Kapodistrian University of Athens; Attikon University Hospital, Department of Cardiology, Heart Failure Unit—Professor of Cardiology</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Position</th>
<th>Affiliations</th>
<th>None</th>
<th>None</th>
<th>Affiliations</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregg C. Fonarow</td>
<td>Ahmanson-UCLA Cardiomyopathy Center—Director; UCLA Division of Cardiology—Co-Chief</td>
<td>• Amgen&lt;br&gt;• Janssen Pharmaceuticals&lt;br&gt;• Medtronic&lt;br&gt;• Novartis*</td>
<td>None</td>
<td>None</td>
<td>• Medtronic—IMPROVE-HF (Steering Committee)<em>&lt;br&gt;• NHLBI</em>&lt;br&gt;• NIH/NIAID*&lt;br&gt;• Novartis*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ACC/AHA Task Force on Data Standards†&lt;br&gt;• ACC/AHA Task Force on Performance Measures (Chair-Elect)†&lt;br&gt;• ACTION Registry GWTG Steering Committee (Chair)†&lt;br&gt;• AHA Consumer Health Quality Coordinating Committee†&lt;br&gt;• AHA Manuscript Oversight Committee†&lt;br&gt;• GWTG Steering Committee (PRT)†&lt;br&gt;• JAMA Cardiology (Associate Editor)†</td>
<td></td>
</tr>
<tr>
<td>Michael M. Givertz</td>
<td>Brigham and Women's Hospital—Professor of Medicine</td>
<td>• Cardioxyl&lt;br&gt;• Merck&lt;br&gt;• Novartis</td>
<td>None</td>
<td>None</td>
<td>• BioControl (CEC)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steven M. Hollenberg</td>
<td>Cooper University Hospital—Director, Coronary Care Unit, Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JoAnn Lindenfeld</td>
<td>Vanderbilt Heart and Vascular Institute—Director, Advanced Heart Failure and Transplant</td>
<td>• Abbott&lt;br&gt;• Boston Scientific&lt;br&gt;• Cardiomems*&lt;br&gt;• CVRx</td>
<td>None</td>
<td>None</td>
<td>• AstraZeneca†&lt;br&gt;• Novartis*&lt;br&gt;• St. Jude Medical*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• JACC HF (Deputy Editor)</td>
<td></td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution and Department</th>
<th>Significant Interests</th>
<th>Other Interests</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frederick A. Masoudi</td>
<td>University of Colorado, Denver—Associate Professor of Medicine, Division of Cardiology</td>
<td>• Janssen Pharmaceuticals • Novartis • Relypsa* • RESMED*</td>
<td>• ABIM</td>
<td>• ACC* • ACC-NCDR* • AHRQ* • ABIM (Associate Editor) • Journal Watch Cardiology</td>
</tr>
<tr>
<td>Patrick E. McBride</td>
<td>University of Wisconsin School of Medicine and Public Health—Professor of Medicine and Family Medicine; Associate Director, Preventive Cardiology</td>
<td>None</td>
<td>None</td>
<td>• NIH-NIDDK (DSMB) • ABIM (Associate Editor)*</td>
</tr>
<tr>
<td>Pamela N. Peterson</td>
<td>University of Colorado, Denver Health Medical Center—Associate Professor of Medicine, Division of Cardiology</td>
<td>• ACC*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lynne W. Stevenson</td>
<td>Brigham and Women’s Hospital Cardiovascular Division—Director, Cardiomyopathy and Heart Failure Program</td>
<td>• St. Jude Medical • NHLBI</td>
<td>None</td>
<td>• JAHA (Associate Editor)* • Novartis (PI for Parent Trial) • NHLBI (Co–PI) • NHLBI—INTERMACS (Co–PI) • St. Jude Medical • Circulation Heart Failure (Senior Associate Editor) • Medtronic†</td>
</tr>
<tr>
<td>Cheryl Westlake</td>
<td>Azusa Pacific University—Professor and Associate Dean, International and Community Programs</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no
Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (December 2015)

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speakers Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
<th>Voting Recusals By Section*</th>
</tr>
</thead>
</table>
| Clyde W. Yancy  
*(Chair)* | Northwestern University Feinberg School of Medicine, Division of Cardiology—Professor of Medicine and Chief; Diversity and Inclusion—Vice Dean | None | None | None | None | None | None | None |
| Mariell Jessup  
*(Vice Chair)* | Fondation Leducq—Chief Scientific Officer | None | None | None | None | None | None | None |
| Biykem Bozkurt | Michael E. DeBakey VA Medical Center—The Mary and Gordon Cain Chair and Professor of Medicine | None | None | None | None | • Novartis | None | None |
| Javed Butler | Stony Brook University—Division Chief of Cardiology | • Bayer†  
• Boehringer Ingelheim  
• CardioCell† | None | • Novartis† | None | • Amgen (DSMB)† | None | None |

*Significant relationship.
†No financial benefit.

ACC indicates American College of Cardiology; AHA, American Heart Association; ABIM, American Board of Internal Medicine; AHRQ, Agency for Healthcare Research and Quality; DCRI, Duke Clinical Research Institute; DSMB, data safety monitoring board; GWTG, Get With The Guidelines; HF, heart failure; HFSA, Heart Failure Society of America; HRSA, Heath Resources and Services Administration; HSAG, Health Services Advisory Group; IMPROVE-HF, Registry to Improve the use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; JAHA, Journal of the American Heart Association; PCORI, Patient Centered Outcomes Research Institute; PI, principal investigator; PRT, pharmaceutical round table; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; NIH, National Institutes of Health; NHLBI, National Heart, Lung, and Blood Institute; NIAID, National Institute of Allergy and Infectious Diseases; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Confl x</th>
<th>Cmtns</th>
<th>Notes</th>
<th>Confl x</th>
<th>Cmtns</th>
<th>Notes</th>
<th>Confl x</th>
<th>Cmtns</th>
<th>Notes</th>
<th>Confl x</th>
<th>Cmtns</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donald E. Casey, Jr</td>
<td>Thomas Jefferson College of Population Health</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Faculty; Alvarez &amp; Marsal IPO4Health—Principal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>and Founder</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monica M. Colvin</td>
<td>University of Michigan—Associate Professor of</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Medicine, Cardiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark H. Drazner</td>
<td>University of Texas Southwestern Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Professor, Internal Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gerasimos S. Filippatos</td>
<td>National and Kapodistrian University of Athens;</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Attikon University Hospital, Department of</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiology, Heart Failure Unit—Professor of</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gregg C. Fonarow</td>
<td>Ahmanson-UCLA Cardiomyopathy Center—Director;</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>UCLA Division of Cardiology—Co-Chief</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amaxgen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Janssen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michael M. Givertz</td>
<td>Brigham and Women's Hospital—Professor of</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steven M.</td>
<td>Cooper University Hospital—</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Relationships</th>
<th>Conflict of Interest</th>
<th>AstraZeneca</th>
<th>Abbott</th>
<th>Janssen Pharmaceuticals</th>
<th>Novartis</th>
<th>ResMed</th>
<th>Relypsa†</th>
<th>Novartis†</th>
<th>NHLBI—INTERMACS (Co–PI)</th>
<th>PARENT trial (PI)</th>
<th>NHLBI—INTERMACS (Co–PI)</th>
<th>PARENT trial (PI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hollenberg</td>
<td>Director, Coronary Care Unit, Professor of Medicine</td>
<td>• Abbott</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• AstraZeneca</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>JoAnn Lindenfeld</td>
<td>Vanderbilt Heart and Vascular Institute—Director, Advanced Heart Failure and Transplant Section—Professor of Medicine</td>
<td>• Janssen Pharmaceuticals • Novartis • Relypsa† • ResMed†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Frederick A. Masoudi</td>
<td>University of Colorado, Denver—Associate Professor of Medicine, Division of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Patrick E. McBride</td>
<td>University of Wisconsin School of Medicine and Public Health—Professor of Medicine and Family Medicine; Associate Director, Preventive Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Pamela N. Peterson</td>
<td>University of Colorado, Denver Health Medical Center—Associate Professor of Medicine, Division of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lynne W. Stevenson</td>
<td>Brigham and Women’s Hospital Cardiovascular Division—Director, Cardiomyopathy and Heart Failure Program</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Novartis—PARENT trial (PI)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Cheryl Westlake</td>
<td>Azusa Pacific University—Professor and Associate Dean, International and Community Programs</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the
person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.
†Significant relationship.

ACC indicates American College of Cardiology; AHA, American Heart Association; DCRI, Duke Clinical Research Institute; DSMB, data safety monitoring board; HFSA, Heart Failure Society of America; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; PARENT, Pulmonary Artery Pressure Reduction With Entresto; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.
Table of Contents

Data Supplement A. RCTs and Meta-analyses With Biomarkers (Section 6.3) ............................................................................................................ 3
Data Supplement B. Nonrandomized Trials/Observational Studies/Registries for Changes in or Discharge NP Levels in ADHF – Biomarkers (Section 6.3) ................................................................................................................. 15
Data Supplement 1. RCTs Comparing ARNI (Section 7.3.2.10) ................................................................................................................................ 27
Data Supplement 2. RCTs Comparing RAAS Inhibition (Section 7.3.2.3) ................................................................................................................. 29
Data Supplement 3. RCTs Comparing Pharmacological Treatment for of ARNI With ACE (Section 7.3.2.10) ............................................................. 31
Data Supplement 4. RCTs Comparing Pharmacological Treatment for Stage C HFrEF (Section 7.3.2.11) ................................................................................................................. 33
Data Supplement C. RCTs Comparing Pharmacologic Treatment for HFpEF: Recommendations (Section 7.3.3) ............................................................. 36
Data Supplement D. RCTs Comparing Anemia (Section 9.2) ................................................................................................................................ 41
Data Supplement E. RCTs Comparing HTN (Section 9.5) ............................................................................................................................... 44
Data Supplement F. Nonrandomized Trials for Hypertension (Section 9.5) ................................................................................................................. 50
Data Supplement G. RCTs Comparing Treatment of Sleep Disorders (CPAP makers) (Section 9.6) ................................................................................................................................ 51
2013 HF Guideline Data Supplement 18. ACE Inhibitors (Section 7.3.2.2) ............................................................................................................... 62
2013 HF Guideline Data Supplement 19. ARBs (Section 7.3.2.3) .............................................................................................................................. 65
2013 HF Guideline Data Supplement 20. Beta Blockers (Section 7.3.2.4) ................................................................................................................. 66


Master Abbreviation List:

1° indicates primary; 2°, secondary; ~, approximately; 6MWT, 6 min walk test; ACE, angiotensin-converting enzyme; ACEI indicates angiotensin-converting-enzyme inhibitor; ACS, acute coronary syndrome; ADHF, acute decompensated heart failure; ADHERE, Acute Decompensated Heart Failure National Registry; AF, atrial fibrillation; AHI, apnea-hypopnea index; AHRQ, Agency for Healthcare Research and Quality; AIRE, Acute Infarction Ramipril Efficacy; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ALT, alanine aminotransaminase; AMI, acute myocardial infarction; APE, acute pulmonary embolism; ARB, angiotensin-receptor blocker; AKI/ARF, acute kidney injury/acute renal failure; ARNI, angiotensin receptor-neprilysin inhibitor; ASA, aspirin; AST, aspartate transaminase; ATLAS, Assessment of Treatment with Lisinopril and Survival; AUC, area under the curve; AV, atrioventricular; ; BEAUTIFUL, Morbidity-Mortality Evaluation of the If Inhibitor Ivabradine in Patients With Coronary Disease and
2017 Heart Failure Focused Update Data Supplement

Left-Ventricular Dysfunction; BID, twice a day; BL, baseline; BNP, plasma B-type natriuretic peptide; BP, blood pressure; bpm, beats per minute; BSA, body surface area; CABG, coronary artery bypass graft; CAD, coronary artery disease; CANPAP, Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Study; CCB, calcium channel blockers; CKD, chronic kidney disease; cGMP, cyclic guanosine monophosphate; CHaRM, Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity; CHF, chronic heart failure; CI, confidence interval; CM, contrast media; CONFIRM-HF, Ferric carboxymaltose evaluation on performance in patients with iron deficiency in combination with chronic heart failure; CONSENSUS Cooperative North Scandinavian Enalapril Survival Study; COPD, chronic obstructive pulmonary disease; CPAP, Continuous positive airway pressure; Ctr, creatinine; CRT, cardiac resynchronization therapy; CSA, central sleep apnea; cTnl, cardiac troponin I; CTR, cardiothoracic ratio; CV, cardiovascular; CVA, cerebrovascular accident; CVD, cardiovascular disease; C/W, compared with; DBP, diastolic blood pressure; DM, diabetes mellitus; DOSE-AHF, Diuretic Optimization Evaluation in Acute HF; DPB, diastolic blood pressure; ECG, electrocardiography; ED, emergency department; EF, ejection fraction; eGFR, estimated glomerular filtration rate; ELAN-HF, European Collaboration on Acute Decompensated Heart Failure; ESRD, end-stage renal disease; EMPHASIS, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EQ-5D, EuroQoL five dimensions questionnaire; ET, ; FAIR-HF, Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure; FCM, ferric carboxymaltose; FU, follow-up; GDEM, guideline-directed evaluation and management; GDMT, guideline-directed management and therapy; GP, ; HCM, ; HDL, high density lipoprotein; HEAAL study, effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure; HF, heart failure; HFpEF, Heart failure with preserved ejection fraction; h/o, history of; HFrEF, Heart failure with reduced ejection fraction; HR, hazard ratio; hs-CRP, high sensitivity C-reactive protein; HTN, hypertension; HYVET, Hypertension in the Very Elderly Trial; Hx, history; ICD, implantable cardioverter defibrillator; ID, iron deficiency; IDI, integrated discrimination improvement; IHD, ischemic heart disease; IMPRESS, Comparison of Vasopeptidase Inhibitor, Omapatrilat, and Lisinopril on Exercise Tolerance and Morbidity; IMPRESERVE, Irbesartan in Heart Failure with Preserved Ejection Fraction Study; IQR, interquartile range; ITT, intent to treat; IV, intravenous; KCCQ, Kansas City Cardiomyopathy Questionnaire; LCZ, ; LV, left ventricular; LVD, Left ventricular dysfunction; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVH, left ventricular hypertrophy; MACE, major adverse cardiac event; MI, myocardial infarction; MR-proANP, ; MR-proADM, ; MRA, mineralocorticoid receptor antagonists; MTD, maximal tolerated dose; MV, mitral valve; MWT, minute walk test; N/A, not available; NEAT-HFpEF, Nitrate’s Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction; NEP, neutral endopeptidase; NNH, number needed to harm; NNT, number needed to treat; NP, natriuretic peptide; NRI, net reclassification improvement; NS, nonsignificant; NSTEMI, non-ST-elevation myocardial infarction; NT-proBNP, ; NT-proADMA, ; NYHA, New York Heart Association; OCTAVE, The Omapatrilat Cardiovascular Treatment vs. Enalapril; ONTARGET, The Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure; OR, odds ratio; OSA, obstructive sleep apnea; OVERTURE, Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events; PAD, peripheral artery disease; PARADIGM-HF, Prospective Comparison of ARNI With ACE to Determine Impact on Global Mortality and Morbidity in Heart Failure; PARAMOUNT, Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction; PAP, positive airway pressure; PCI, percutaneous coronary intervention; PCP, Primary Care Physician; PDE, phosphodiesterase; PEP-CHF, Perindopril in Elderly People With Chronic Heart Failure; PGA, patient global assessment; PPM, permanent pacemaker; PSG, polysomnography; PTCA, percutaneous transluminal coronary angioplasty; PONTIAC, NT-proBNP Guided Primary Prevention of CV Events in Diabetic Patients; PRIMA, Can Pro-Brain-Natriuretic Peptide Guided Ejection Fraction Guided Therapy Improve Chronic Heart Failure Morbidity and Mortality?; PROTECT, Pro-Enalapril NP outpatient Tailored Chronic Heart Failure Therapy; pts, patients; PVD, peripheral vascular disease; QoL, quality of life; RAAS, renin-angiotensin-aldosterone system; RAS, renin-angiotensin system; RCT, randomized controlled trial; RED-HF, Reduction of events by darbepoetin alfa in heart failure; RELAX, Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure With Preserved Ejection Fraction; ROC, receiver-operating characteristic; RR, relative risk; SBP, systolic blood pressure; SCR, serum creatinine; SERVE-HF, Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure; SHEP, Systolic Hypertension in the Elderly Program; SHIFT, Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial; SIGNIFY, Study Assessing the Morbidity–Mortality Benefits of the If Inhibitor Ivabradine in Patients with Coronary Artery Disease; SOB, shortness of breath; SPRINT, Systolic Blood Pressure Intervention Trial; SR, systematic review; SSS, sick sinus syndrome; STARBRUTE, the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting; STARS-BNP, Systolic Heart Failure Treatment Supported by BNP; STEMI, ST-elevation myocardial infarction; STOP-HF, St. Vincent’s Screening to Prevent Heart Failure; SUPPORT, Supplemental Benefit of ARB in Hypertensive Patients With Stable Heart Failure Using Olmesartan; SURVIVE, Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support; TIA, transient ischemic attack; TIME-CHF, ; TOPCAT, Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist; TRANSCEND, the Telmisartan Randomised Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease; TSAT, transferrin saturation; UA, unstable angina; UL, ; UPSTEP, Use of Peptides in Tailoring Heart Failure Project; VF, ventricular fibrillation; VHD, valvular heart disease VT, ventricular tachycardia; and w/o, without.

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>PONTIAC Huelsmann et al. 2013 (1) 23810874</td>
<td>Aim: To assess the effectiveness of neurohumoral therapy for the prevention of cardiac events in pts with type 2 DM with increased biomarker NT-proBNP</td>
<td>Inclusion criteria: Pts with type 2 DM, age ≥18 y, elevated NT-proBNP (≥125 pg/mL)</td>
<td>Intervention: Individualized up-titration of RAS antagonists and beta blockers in addition to diabetes treatment (150), treated at cardiology clinic</td>
<td>1° endpoint: • Hospitalization or death due to cardiac disease following 24 mo • Results: Significant reduction of 1° endpoint in intervention group (HR: 0.351; 95% CI: 0.127–0.975; p=0.044)</td>
<td>All-cause hospitalizations, HF hospitalizations and unplanned CV hospitalizations or death (p&lt;0.05 reduction) • Study limitations: Absence of pt randomization for treatment, pt population mainly Caucasian, statistical analysis done without adjustment of co-variates • Pts treated with a RAS antagonist/beta-blocker and the dosage reached higher in intensified group (p&lt;0.0001) • No difference in NT-proBNP levels</td>
</tr>
<tr>
<td>STOP-HF Ledwidge et al. 2013 (2) 23821090</td>
<td>Aim: To establish efficacy of BNP screening and collaborative care in at-risk population in reducing newly</td>
<td>Inclusion criteria: Pts ≥40 y, and history of HTN (on meds ≥1 mo), hypercholesterolemia, obesity, vascular disease including</td>
<td>Intervention: BNP screening at BL and annually and protocol referral for BNP ≥50 pg/mL for echocardiography and collaborative care. (697)</td>
<td>1° endpoint: • LV dysfunction (systolic: LVEF &lt;50% or diastolic: E/E’ ratio &gt;15) with or without newly diagnosed HF(with symptoms of HF requiring admission to</td>
<td>Emergency hospitalizations for major MACE [40 vs. 22 (0.60 OR; 95% CI: .45-0.81; p=.002)] • CV investigations more likely to be done in the intervention group with BNP levels ≥50 pg/mL • Increase in RAAS agents in the</td>
</tr>
<tr>
<td>Study Title</td>
<td>Study Type</td>
<td>Inclusion Criteria</td>
<td>Exclusion Criteria</td>
<td>Comparator</td>
<td>Intervention</td>
</tr>
<tr>
<td>-------------</td>
<td>------------</td>
<td>--------------------</td>
<td>-------------------</td>
<td>------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Brunner-La Rocca et al. 2015</td>
<td>Meta-Analysis</td>
<td>Studies that included individual pt data HFpEF and HFrEF. EF ≤45%</td>
<td>Pts with unknown LVEF, STARBRiTE study, 1st meta-analyses that aggregated data</td>
<td>(NT-pro)BNP-guided therapy and HFrEF (1,731)</td>
<td>(NT-pro)BNP-guided therapy and HFpEF (301)</td>
</tr>
<tr>
<td>Don-Wauchope et al. 2015</td>
<td>Review of SRs</td>
<td>SRs that authors were aware of through their participation in an AHRQ comparative effectiveness review.</td>
<td>• In the subgroup with BNP levels ≥50 pg/mL, increase in BNP levels in the intervention group was ~1/2 of that in the control group&lt;br&gt;• The results might not be applicable to general population (single center), non-blinding introduces bias. Event rate was lower than expected. Cost-effectiveness unclear. Incremental value of and cut-off of BNP may change in population studied.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Aim: To assess which HF pts benefit from NT-pro BNP therapy

Inclusion criteria: Studies that included individual pt data HFpEF and HFrEF. EF ≤45%

Exclusion criteria: Pts with unknown LVEF, STARBRiTE study, 1st meta-analyses that aggregated data

Comparator: (NT-pro)BNP-guided therapy and HFrEF (1,731)

Intervention: (NT-pro)BNP-guided therapy and HFpEF (301)

1st endpoint: • All-cause mortality and admission for HF

Results: • Lower mortality in HFrEF with guided treatment (HR: 0.78; 95% CI: 0.62–0.97; p=0.03). • Lesser HF admissions in HFrEF (HR: 0.80; 95% CI: 0.67–0.97; p=0.02)

Limitations: Bias due to exclusion of aggregate data, Lack of specific testing for diagnosis of comorbidities, absence of morbidity index, insufficient sample size for pts with HFpEF, treatment management aspects unaddressed and statistical tests are not powerful

Meta-Analyses or SRs of RCTs of NP Guided Therapy in Stage C HF
### Xin W. et al. 2015

**Aim:** To assess the effects of NP-guided treatment of chronic HF on outcomes

**Study type:** Meta-analysis

**Size:** 14 studies, 3,004 pts

**Inclusion criteria:** Prospective RCTs with adult HF pts comparing the effects of BNP or NT-proBNP-guided therapy with clinically guided therapy

**Intervention:** BNP or NT-proBNP-guided therapy (1,503)

**Comparator:** Clinically guided therapy (1,501)

**1st endpoints:**
- All-cause mortality, HF hospitalization, all-cause hospitalization, safety (adverse events)

**Results:**
- Compared with clinical group, BNP-guided treatment significantly decreased the risk of HF-related hospitalization (RR: 0.79; 95% CI: 0.63–0.98; p=0.03), although did not significantly affect the risk of all-cause mortality (RR: 0.94, 95% CI: 0.81–1.08, p=0.39) or all-cause hospitalization (RR: 0.97, 95% CI: 0.89–1.07; p=0.56).

**1st Safety endpoint:**
- NP-guided therapy was not associated with increased risk for serious adverse events.

### Troughton RW et al. 2014

**Aim:** To assess the effects of NP-guided treatment of chronic HF on outcomes

**Study type:** Meta-analysis

**Size:** 14 reviews

**Exclusion criteria:** N/A

**Inclusion criteria:** RCTs reporting all-cause mortality and comparing BNP-guided treatment of HF with clinically guided treatment and 1 study (PROTECT trial) that did not

**Intervention:** BNP-guided therapy (1,006)

**Comparator:** Clinically guided therapy (994)

**1st endpoint:**
- All-cause mortality

**Results:**
- All-cause mortality was significantly reduced by NP-guided treatment [HR: 0.62 (0.45–0.86); p=0.004]

- HF hospitalizations were reduced in the NP-guided group, compared with clinically guided pts [HR: 0.80 (0.67–0.94); p=0.009] as were CV admissions [HR: 0.82 (0.67–0.99); p=0.048]

- Each of the included RCTs was relatively small and 2 trials did not
### De Vecchis et al. 2014 (7) 24522083

**Aim:** To assess the effects of NP-guided treatment of chronic HF on outcomes

**Study type:** Meta-analysis

**Size:** 6 studies, 1,775 pts

**Inclusion criteria:**
- RCT to a strategy of titrating drug therapy based on the level of a circulating NP (BNP or NT-proBNP) compared to clinical conventional criteria, and they reported all-cause mortality. Should have included >60 pts and its follow-up should have been longer than 90 d.

**Intervention:**
- BNP or NT-proBNP-guided therapy

**Comparator:** Clinically guided therapy

**1st endpoint:**
- Combined endpoint of all-cause mortality and HF hospitalization

**Results:** NP-guided therapy for outpatients with HF was shown to be associated with a decreased risk of death and HF hospitalizations (OR: 0.64; 95% CI: 0.43–0.95; p=0.026)

### Balion et al. 2014 (8) 25074674

**Aim:** To assess the effects of NP-guided treatment of chronic HF on outcomes

**Study type:** SR

**Size:** 9 RCTs; 2,104 pts

**Meta-analysis was not done due to study heterogeneity.**

**Intervention:**
- BNP or NT-proBNP-guided therapy (1,503)

**Comparator:** Clinically guided therapy (1,501)

**1st Outcome:**
- Review: Overall, there was a wide variation in study design and how parameters were reported including pt selection, BL characteristics, therapy goals, BNP/NT-proBNP cutpoint, and outcome types.
- The strength of evidence for the outcome of mortality, reported in 7 studies, was found to be low due to inconsistency and

| Size: 11 studies, 2,000 pts | report mortality (11 studies, 9 with individual pt data) | Significant interaction between age and treatment efficacy (p=0.028), with a survival benefit for BNP-guided vs. clinical treatment in pts <75 y [HR: 0.62 (0.45–0.85); p=0.004] but not in pts ≥75 y [HR: 0.98 (0.75–1.3); p=ns] | provide individual pt data.

| De Vecchis et al. 2014 (7) 24522083 | Aim: To assess the effects of NP-guided treatment of chronic HF on outcomes | study heterogeneity. | Limitations: Each of the included RCTs was relatively small Benefit was not seen in some of the studies

| Balion et al. 2014 (8) 25074674 | Aim: To assess the effects of NP-guided treatment of chronic HF on outcomes | study heterogeneity. | N/A

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
### Savarese et al. 2013 (9) 23472172

**Aim:** To determine whether NP-guided (BNP or NT-proBNP) therapy, compared to clinically guided therapy, improves outcomes.

**Study type:** Meta-analysis

**Size:**
- 12 trials enrolling 2,686 participants (730 in BNP, 1,956 in NT-proBNP related trials)

**Inclusion criteria:**
- All randomized trials reporting clinical endpoints (all-cause mortality and/or HF related hospitalization and/or all-cause hospitalization) with comparison of BNP or NT-proBNP guided therapy vs. a control group in chronic HF pts

**Intervention:**
- BNP-guided therapy: BNP-guided: 373
- NT-proBNP guided: 872

**Comparator:**
- Clinically guided therapy
- BNP group control 357
- NT-proBNP group control 1,084

**1° endpoints**
- All-cause mortality, all-cause hospitalization, HF hospitalization

**Results:**
- NP-guided therapy (either BNP or NT-proBNP) significantly reduced all-cause mortality (OR: 0.738; 95% CI: 0.596–0.913; p=0.005) and HF related hospitalization (OR: 0.554; 95% CI: 0.399–0.769; p=0.000), but not all-cause hospitalization (OR: 0.803; 95% CI: 0.629–1.024; p=0.077)
- When separately assessed, NT-proBNP-guided therapy reduced all-cause mortality (OR: 0.717; 95% CI:0.563–0.914; p=0.007) and HF hospitalization (OR: 0.531; 95% CI: 0.347–0.811; p=0.003), but not all-cause hospitalization (OR: 0.779; CI:0.414–1.465; p=0.438), whereas BNP-guided therapy did not significantly reduce all-cause mortality (OR: 0.814; CI:0.518–1.279; p=0.371), HF related hospitalization (OR: 0.599; 95% CI: 0.303–1.187; p=0.14) or all-cause hospitalization (OR: 0.726; 95% CI:0.509 – 1.035; p=0.077)
- Analysis from 3 trials showed the composite outcome of all-cause mortality and HF hospitalization was significantly reduced by NP-guided therapy in younger pts (<75 y) (OR: 0.449; 95% CI: 0.207–0.973; p=0.043), but not in older pts (>75 y) (OR: 0.800; 95% CI: 0.423–1.513; p=0.5)

### Li et al. 2013 (10) 23602555

**Aim:** To assess the effects of NP-guided treatment of chronic HF on all-cause mortality and HF hospitalization.

**Inclusion criteria**
- Studies with >40 pts and involved comparison of BNP-guided vs. guideline-guided drug therapy of the pts with chronic HF in the outpatient

**Intervention:**
- BNP-guided therapy

**Comparator:**
- Clinically guided therapy

**1° endpoint**
- Combined end point of all-cause mortality and HF hospitalization

**Results:**
- Significantly decreased risk of all-cause mortality (RR: 0.83; 95% CI: 0.69–0.99; p=0.035; and HF hospitalization
- In the subgroup analysis, HF rehospitalization was significantly decreased in the pts <70 y (RR: 0.45; 95% CI: 0.33–0.61; p=0.000; or with BL higher BNP (≥2114 pg/mL) (RR: 0.53; 95% CI: 0.39–0.72; p=0.000)
### RCTs of NP Guided Therapy in HF

<table>
<thead>
<tr>
<th>Study type: Meta-analysis</th>
<th>Size: 11 studies, 2,414 pts</th>
<th>Setting</th>
<th>rehospitalization (RR: 0.75; 95% CI: 0.62–0.91; p=0.004; in the BNP-guided therapy group.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Felker et al. 2009</strong> 19699866</td>
<td><strong>Aim:</strong> To determine whether titration of therapy based on NP measurements improves mortality in chronic HF</td>
<td><strong>Inclusion criteria:</strong> Prospective RCTs of pts with chronic HF randomized pts to a strategy of titrating medical therapy based on the level of a circulating biomarker compared to a parallel control group, reporting all-cause mortality</td>
<td><strong>Intervention:</strong> BNP-guided therapy</td>
</tr>
<tr>
<td></td>
<td><strong>Study type:</strong> Meta-analysis</td>
<td><strong>Comparator:</strong> Clinically guided therapy</td>
<td><strong>Results:</strong> Significant mortality advantage for biomarker-guided therapy (HR: 0.69, 95% CI: 0.55–0.86) compared to control</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type: Meta-analysis</th>
<th>Size: 6 studies; 1,627 pts</th>
<th>Inclusion criteria: Eligible RCTs were those that enrolled &gt;20 pts and involved comparison of BNP-guided drug therapy vs. usual clinical care of the pt with chronic HF in an outpatient setting</th>
<th>Intervention: BNP-guided therapy</th>
<th>Comparator: Clinically guided therapy</th>
<th>1° endpoint: All-cause mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Porapakkham et al. 2010</strong> 20308637</td>
<td><strong>Aim:</strong> To determine whether BNP guided therapy improves CV outcomes in chronic HF</td>
<td><strong>Results:</strong> Significantly lower risk of all-cause mortality (RR: 0.76; 95% CI: 0.63–0.91; p=0.003) in the BNP-guided therapy group compared with the control group</td>
<td><strong>Intervention:</strong> BNP-guided therapy</td>
<td><strong>Comparator:</strong> Clinically guided therapy</td>
<td><strong>1° endpoint:</strong> All-cause mortality</td>
</tr>
<tr>
<td></td>
<td><strong>Study type:</strong> Meta-analysis</td>
<td><strong>Results:</strong></td>
<td><strong>Comparator:</strong> Clinically guided therapy</td>
<td><strong>Results:</strong></td>
<td><strong>1° endpoint:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Size:</strong> 8 studies; 1,726 pts</td>
<td><strong>In pts &lt;75 y, all-cause mortality was significantly lower in the BNP-guided group (RR: 0.52; 95% CI: 0.33–0.82; p=0.005).</strong></td>
<td><strong>In pts ≥75 y (RR: 0.94; 95% CI: 0.71–1.25; p=0.70).</strong></td>
<td><strong>In pts &lt;75 y, all-cause mortality was significantly lower in the BNP-guided group (RR: 0.52; 95% CI: 0.33–0.82; p=0.005).</strong></td>
<td><strong>No reduction in mortality with BNP-guided therapy in pts ≥75 y (RR: 0.94; 95% CI: 0.71–1.25; p=0.70).</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>All-cause hospitalization and survival free of any hospitalization was not significantly different between groups (RR: 0.82; 95% CI: 0.64–1.05; p=0.12 and RR: 1.07; 95% CI: 0.85–1.34; p=0.58, respectively).</strong></td>
<td><strong>Additional % pts achieving target doses of ACE-inhibitors and beta blockers 21% and 22% in the BNP group and 11.7% and 12.5% in the control group, respectively.</strong></td>
<td><strong>Additional % pts achieving target doses of ACE-inhibitors and beta blockers 21% and 22% in the BNP group and 11.7% and 12.5% in the control group, respectively.</strong></td>
<td><strong>Additional % pts achieving target doses of ACE-inhibitors and beta blockers 21% and 22% in the BNP group and 11.7% and 12.5% in the control group, respectively.</strong></td>
</tr>
<tr>
<td>Study</td>
<td>Aim</td>
<td>Inclusion criteria</td>
<td>Intervention</td>
<td>1st endpoints</td>
<td>Results</td>
</tr>
<tr>
<td>-------</td>
<td>-----</td>
<td>------------------</td>
<td>--------------</td>
<td>---------------</td>
<td>---------</td>
</tr>
<tr>
<td>Troughton et al. 2000 (13) 10791374</td>
<td>To assess the effects of NT-proBNP-guided treatment of chronic HF on outcomes</td>
<td>Ambulatory pts with LVEF &lt;40% and symptomatic HF (NYHA II-IV)</td>
<td>(NT-pro)BNP-guided therapy with a target of NT-proBNP level &lt;200 pmol</td>
<td>Death, CV hospitalization and outpatient HF event</td>
<td>Fewer CV events (death, hospitals, or HF decompensation) in the NT-proBNP group than in the clinical group (19 vs. 54; p=0.02) At 6 mo, 27% of pts in the BNP group and 53% in the clinical group had experienced a first CV event (p=0.034).</td>
</tr>
<tr>
<td>STARS-BNP Jourdain et al. 2007 (14) 17448376</td>
<td>To evaluate the prognostic impact of a therapeutic strategy using plasma BNP</td>
<td>Ambulatory NYHA class II to III pts considered optimally treated</td>
<td>BNP-guided therapy Target : BNP &lt;100 pg/mL</td>
<td>HF-related death or hospital stay for HF</td>
<td>Mean dosages of ACE inhibitors and beta blockers significantly higher in the BNP group (p&lt;0.05), BNP-guided strategy reduced the risk of HF related death or hospital stay for HF (24% vs. 52%, p&lt;0.001), mainly obtained through an increase in ACE inhibitor and beta blocker dosages.</td>
</tr>
<tr>
<td>TIME-CHF Pfisterer et al. 2009 (15) 19176440</td>
<td>To compare 18-mo outcomes of N-terminal BNP-guided vs. symptom guided HF therapy</td>
<td>Ambulatory HF pts 60 y with systolic HF (LVEF ≤45%), NYHA class of II or greater, prior HF hospitalization within</td>
<td>Uptitration of guideline-based treatments to BNP level of ≤2 times of UL (BNP-guided therapy)</td>
<td>18 mo survival free of all-cause hospitalizations</td>
<td>Survival free of hospitalization for HF was higher among those in the N-terminal BNP-guided group (72% vs. 62%, respectively; HR: 0.68 [95% CI: 0.50–0.92]; p=0.01).</td>
</tr>
</tbody>
</table>
### BATTLESCARRED

**Laichubury et al. 2009**  
[(16) 20117364](https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.109.874409?journalCode=cir)

**Aim:** to compare the effects of NT-proBNP-guided therapy with those of intensive clinical management and with usual care  

**Study Type:** RCT (Australia hospitals)  

**Size:** 364 pts

<table>
<thead>
<tr>
<th>Inclusion criteria:</th>
<th>Pts admitted to a single hospital with HF, NT-proBNP &gt;50 pmoL or 400 pg/mL (included HFpEF)</th>
</tr>
</thead>
</table>
| **Intervention:**   | Outpatient post d/c therapy guided by NT-proBNP levels  
| Target: NT-proBNP <150 pmoL (1,270 pg/mL) |
| **Comparators:**    | Therapy guided by intensive clinical management, or according to usual care |

**1° endpoints:**  
Mortality  

**Results:**  
- 1-y mortality was less in both the hormone (9.1%) and clinically-guided (9.1%) groups compared with usual care (18.9%; p=0.03)  
- 3 y mortality was selectively reduced in pts ≤75 y receiving hormone guided treatment (15.5%) compared with either clinically managed treatment (30.9%; p=0.048) or usual care (31.3%; p=0.021).  
- NP guidance changed therapy  
- NT-ProBNP levels were not different between groups

### Berger et al. 2010  
[(17) 20170790](https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.110.987447?journalCode=cir)

**Aim:** To investigate whether the addition of NT-proBNP-guided, intensive pt management to multidisciplinary care improves outcome in pts following hospitalization due to HF  

**Study Type:** RCT (Australia hospitals)  

**Size:** 264 pts

<table>
<thead>
<tr>
<th>Inclusion criteria:</th>
<th>Pts admitted to a hospital with HF, NYHA III or IV on admission, Cardiothoracic Index&gt;0.5 or LVEF &lt;40%</th>
</tr>
</thead>
</table>
| **Intervention:**   | Outpatient post discharge discontinue  
| BM: NT-proBNP-guided, intensive up-titration of medication by HF specialists in high-risk pts.  
| Target: NT-proBNP (<2,200 pg/mL) |
| **Comparators:**    | Multidisciplinary care: 2 consultations from an HF |

**1° endpoints:**  
Hospitalization  

**Results:**  
- Pt management reduced HF hospitalization (488 D) compared with the multidisciplinary care (1254 D) and usual care (1,588 d) groups (p<0.0001)  
- Combined end point of death or HF rehospitalization was lower  
- NT-ProBNP levels were not different between groups: Pt management group had the highest proportion of RAAS inhibition triple-therapy  
- Death rate was similar between the pt management (22%) and multidisciplinary care groups (22%), but was lower compared with the usual care group (39%; vs. pt management: p<0.02; vs. multidisciplinary care: p<0.02)
### PRIMA

**Eurlings et al. 2010** (18) 21144969

**Aim:** To assess whether management by an individualized NT-proBNP target would lead to improved outcome compared with HF management guided by clinical assessment alone.

| Study Type: | RCT (8 Viennese hospitals) |
| Size:       | 278 pts                    |
| **Inclusion criteria:** | Specialist-therapeutic recommendations and home care by a HF nurse |
|             | • Usual care               |
|             | • NT-ProBNP levels lowered in guided pt management arm |

**Intervention:** After discharge discontinue outpatient management guided by an individually set NT-proBNP (n=174) defined by the lowest level at discharge or 2 wk thereafter.

**Comparators:** Clinically-guided outpatient management (n=171)

**1st endpoints:** Number of d alive outside the hospital after index

**Results:** Management guided by NT-proBNP target did not significantly improve the 1st endpoint (p=0.49)

- In the NT-proBNP-guided group mortality was lower, as 46 pts died (26.5%) vs. 57 (33.3%) in the clinically guided group, but this was not statistically significant (p=0.21)
- Individualized NT-proBNP target increased the use of HF medication (p=0.006)

### SIGNAL HF Trial

**Persson et al. 2010** (19) 20876734

**Aim:** To investigate if NT-proBNP-guided therapy in HF pts in 1st care would improve clinical outcomes over and above treatment according to guidelines.

| Study Type: | RCT (Sweden 1st care centers) |
| Size:       | 345 pts                      |
| **Inclusion criteria:** | Ambulatory HF pts NYHA class II-IV, LVEF <50% and NT-proBNP levels >800, females >1,000 ng/ |
|             | Target: At least a 50% reduction from BL NT-proBNP |
| **Intervention:** | Structured treatment of HF according to guidelines with or without NT-proBNP monitoring |
| **1st endpoints:** | Composite endpoint of d alive, d out of hospital and symptom score |

**Results:** There were no differences between the groups concerning either the 1st endpoint (p=0.28) or its components (CV death, p=0.93; CV hospitalization, p=0.88; or symptom score, p=0.28)

- Treatment doses of beta blockers and RAS blockers were markedly increased towards target doses in both groups
<table>
<thead>
<tr>
<th>Study Name</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>1° endpoints</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>STARBRITE Trial</td>
<td>Whether outpatient diuretic management guided by BNP and clinical assessment better compared with clinical assessment alone</td>
<td>Hospitalized HF pts with LEVF ≤35%</td>
<td>Outpatient post discharge BNP and clinical assessment guided therapy</td>
<td>Composite endpoint of d alive and d out of hospital,</td>
<td>No significant difference HR: 0.72; 95% CI: 0.41–1.27; p=0.25</td>
</tr>
<tr>
<td>(Shah et al. 2011) (20) 21807321</td>
<td></td>
<td>Serum creatinine &gt;3.5 mg/dL and ACS</td>
<td>Comparator: Clinical assessment alone.</td>
<td></td>
<td>• Change in serum creatinine, or change in SBP not different</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• BNP strategy pts received significantly more ACE inhibitors, beta blockers</td>
</tr>
<tr>
<td>PROTECT Study</td>
<td>Whether elders benefit from NP-guided HF care</td>
<td>Chronic HF pts with LV systolic dysfunction</td>
<td>Management guided by NT-proBNP with a goal to lower NT-proBNP ≤1000 pg/mL over 10 mo</td>
<td>Total CV events in 2 age categories 75 and ≥75 y</td>
<td>Pts ≥75 y with NT-proBNP management had lowest rate of CV events (1.76 events per pt with standard of care vs. 0.71 events per pt with NT-proBNP guide, p=0.03)</td>
</tr>
<tr>
<td>(Gaggin et al. 2012) (21) 22858078</td>
<td></td>
<td></td>
<td>Comparator: Standard of care</td>
<td></td>
<td>• Improvement in QoL, LVEF, and indices of LV volume with guided approach</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• NP guidance changed therapy: greater use of aldosterone antagonists and lesser use of loop diuretics in the guided therapy group (no difference in ACE inhibitors or beta blockers)</td>
</tr>
<tr>
<td>UPSTEP-study group</td>
<td>To determine whether BNP-guided HF treatment improves morbidity and/or mortality</td>
<td>Ambulatory HF NYHA II-IV, LVEF &lt;40% and elevated BNP levels</td>
<td>BNP-guided (BNP) with a goal &lt;150 or 300 ng/L for elderly</td>
<td>Combined death and worsening/hosp for HF</td>
<td>Pts &gt;30% decrease in BL BNP value vs. nonresponders.</td>
</tr>
<tr>
<td>(Karlstrom et al. 2011) (22) 21715446</td>
<td></td>
<td></td>
<td>Comparator: Conventional (CTR) HF treatment</td>
<td></td>
<td>• No differences for d out of hospital, and younger vs. elderly.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Subgroup analysis: improved survival (p&lt;0.0001 for the 1° outcome) among responders with &gt;30% decrease in BL BNP value vs. nonresponders.</td>
</tr>
</tbody>
</table>
### Maisel et al. 2002 (23) 12124404

**Aim:** To validate and characterize the use of BNP in the diagnosis of HF in pts with dyspnea.

**Study type:** Prospective, blinded, diagnostic accuracy study

**Size:** 279

**Inclusion criteria:** Pts who came to the emergency department with acute dyspnea

**Exclusion criteria:**
- Age <18 y
- Those whose dyspnea was clearly not secondary to HF (i.e., those with trauma or cardiac tamponade), acute myocardial infarction, unstable angina, or renal failure

**Intervention:** Comparisons of BNP values among diagnostic groups including HF and non HF pts

**Comparator:** Non-HF pts such as pulmonary disease, cor pulmonale

**1° endpoint:**
- Diagnostic accuracy of BNP at a cutoff of 100 pg/mL was 83.4%. The negative predictive value of BNP <50 pg/mL was 96%.

**Secondary endpoint:**
- In multiple logistic-regression analysis, measurements of BNP added significant independent predictive power to other clinical variables in models predicting which pts had HF.

- Used in conjunction with other clinical information, rapid measurement of BNP is useful in establishing or excluding the diagnosis of acute HF failure in pts with acute dyspnea.

### van Kimmenade et al. 2006 (24) 16860029

**Aim:** To analyze the role of NT-pro-BNP in diagnosis of HF in pts presenting with dyspnea, the so-called natriuretic peptide gray zone. NT-pro-BNP concentrations, clinical characteristics, and 60-d mortality were studied in acutely dyspneic pts from an international

**Inclusion criteria:** Acutely dyspneic pts

**Exclusion criteria:**
- With trauma or cardiac tamponade, acute myocardial infarction, unstable angina, or renal failure

**Intervention:** Comparisons of NT-pro-BNP among diagnostic groups including HF and non-HF pts

**Comparator:** Non-HF pts such as pulmonary disease, cor pulmonale

**1° endpoint:**
- Subjects with HF and diagnostically elevated NT-pro-BNP concentrations had the highest mortality rates, subjects without HF and NT-pro-BNP concentrations < 300 ng/L had the lowest mortality rates, and subjects with gray-zone NT-pro-BNP had intermediate outcomes, irrespective of their final diagnoses.

- Adding specific clinical information to NT-pro-BNP improves diagnostic accuracy in subjects with intermediate NT-pro-BNP concentrations. Mortality rates in subjects with intermediate NT-pro-BNP concentrations are lower than in those with NT-pro-BNP concentrations diagnostic for HF but are higher than in subjects with NT-pro-BNP concentrations less than the gray zone.
### Maisel et al. 2004

| **Aim:** | To examine the relationships among BNP levels and HF severity, clinical decision making, and outcomes |
| **Study type:** | Multicenter, prospective, blinded, diagnostic accuracy study |
| **Size:** | 464 |

| **Inclusion criteria:** | Pts over the age of 18 presenting to the ED with HF and who received treatment in the ED or hospital admission for HF were included. |
| **Exclusion criteria:** | Current MI or ACS with ST-segment deviation of ≥1 mm, renal failure requiring dialysis, or pts with a baseline BNP concentration of ≤100 pg/mL were excluded |

| **Intervention:** | Physicians were blinded to the actual BNP level and subsequent BNP measurements. |

**Comparator:**
Comparison between severity of HF determined by physicians or BNP and outcomes

**1st endpoint:**
ED doctor's intention to admit or discharge a pt had no influence on 90-d outcomes, while the BNP level was a strong predictor of 90-d outcome. The 90-d combined event rate (HF visits or admissions and mortality) in the group of pts admitted with BNP <200 pg/mL and >200 pg/mL was 9% and 29%, respectively (p=0.006).

- In pts presenting to the ED with HF, there is a disconnect between the perceived severity of HF by ED physicians and severity as determined by BNP levels. The BNP levels can predict future outcomes and thus may aid physicians in making triage decisions about whether to admit or discharge pts. Emerging clinical data will help further refine biomarker-guided outpatient therapeutic and monitoring strategies involving BNP.

### O'Connor et al. 2010

| **Aim:** | To identify high-risk HF pts at hospital discharge |
| **Study type:** | Predictive modeling using variables obtained during hospitalization in the ESCAPE trial |
| **Inclusion criteria:** | hospitalized with severe HF, LVEF ≤30%, SBP ≤125 mmHg. |
| **Exclusion criteria:** | creatinine >3.5 mg/dL, prior inotrope use |

| **Derivation cohort:** | ESCAPE trial, n=423 |
| **Validation cohort:** | FIRST trial, n=471 |

**1st endpoint:**
- 6-mo mortality and death or rehospitalization rates (64%)
- Multivariate discharge predictors of death included: BNP, per doubling (HR: 1.42), cardiac arrest or mechanical ventilation, yes/no (HR: 2.54), BUN, per 20 mg/dL increase (HR: 1.22) and sodium, per unit mEq/L increase (HR: 0.93)

- A simplified discharge score discriminated mortality risk from 5% (score=0) to 94% (score=8).
- Bootstrap validation demonstrated good internal validation for the model (c-index 0.78)
- Limitations: ESCAPE represented pts with severe LV dysfunction and advanced symptoms (not the general population of acute HF) managed at experienced centers; exclusion of pts with characteristics
known to be associated with worse outcomes (e.g., creatinine >3.5 mg/dL, requiring inotropes)

Search Terms and Date: natriuretic peptides, heart failure, human, last 5 years. Last search done on April 18, 2016.

Data Supplement B. Nonrandomized Trials/ Observational Studies/ Registries for Changes in or Discharge NP Levels in ADHF – Biomarkers (Section 6.3)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (P values, OR or RR &amp; 95% CI)</th>
<th>Summary / Conclusion / Comments</th>
</tr>
</thead>
</table>
| Bayés-Genís et al. 2005 (27) 15948093 | Aim: Percentage of NT-proBNP reduction during admission and its prognostic significance  
Study type: NR  
Size: 74 pts | Inclusion criteria: Pts diagnosed with acute HF in emergency department and who had follow-up evaluation for 6 & 12 mo after admission  
Follow up: 12 mo | 1° endpoints:  
- Percent reduction in NT-proBNP and its association with CV mortality  
Results:  
- The area under the ROC curve for % NT-proBNP reduction to predict CV death was 0.78 (95% CI: 0.66–0.90; p=0.002)  
- 30% NT-proBNP reduction percentage cutoff value had 75% accuracy for the identification of high-risk pts and was the only variable that was associated with CV death in multivariate analysis (OR: 4.4; 95% CI: 1.12–17.4; p=0.03).  
- Study relatively old and small | |
| Verdiani et al. 2008 (28) 18545069 | Aim: To evaluate the prognostic significance of NT-proBNP % reduction during ADHF  
Study type: Prospective cohort  
Size: 120 pts | Inclusion criteria: Pts consecutively admitted with ADHF  
Follow up: 6 mo | 1° endpoint  
- Percent reduction in NT-proBNP and its association with CV mortality  
Results:  
- In ROC, the mean AUC for NT-ProBNP % reduction was 0.63 (95% CI: 0.51–0.75; p=0.04) for the composite endpoint (death or readmission), and 0.81 (95% CI: 0.65–0.97, p=0.01) for CV mortality at risk of events.  
- NT-ProBNP reduction percentage <30% was the best cut off for the identification of pts  
- Study relatively old and small | |
<table>
<thead>
<tr>
<th>Study Reference</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>1° endpoints</th>
<th>Results</th>
<th>Study Type/Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bettencourt et al. 2004 (29) 15451800</td>
<td><strong>Aim:</strong> To compare 18 mo outcomes of NT-BNP-guided vs. symptom guided HF therapy</td>
<td>Consecutive ADHF pts defined by ESC or Framingham criteria</td>
<td>• Death or readmission</td>
<td>• Pts were classified into 3 groups: (1) decreasing NT-proBNP levels by at least 30% (n=82), (2) no significant modifications on NT-proBNP levels (n=49), and (3) increasing NT-proBNP levels by at least 30% (n=25). Among the 64 pts discharged without volume overload, a positive association between change in NT-proBNP and outcome was observed (HR: 2.66; 95% CI: 0.77–9.18 for change &lt;30%; HR: 16.04; 95% CI: 9.49–52.02 for increase ≥30% compared with those with decreasing NT-proBNP by at least 30%).</td>
<td>Prospective cohort single center study</td>
</tr>
<tr>
<td>Kociol et al. 2013 (30) 23250981</td>
<td><strong>Aim:</strong> Examine relationship between markers of decongestion and symptom relief and clinical outcomes</td>
<td>Pts enrolled in DOSE-AHF</td>
<td>• Time to death, first rehospitalization or emergency department visit</td>
<td>• Of the weight loss, fluid loss, and NT-proBNP reduction, only % reduction in NT-proBNP was significantly associated with symptom relief (r=0.13; p=0.04). Reduction in NT-proBNP Associated with better outcome (NT-proBNP HR: 0.95; 95% CI: 0.91–0.99 per 10% reduction).</td>
<td>Retrospective analysis of the RCT, DOSE-AHF</td>
</tr>
<tr>
<td>Kociol et al. 2011 (31) 21743005</td>
<td><strong>Aim:</strong> To examine if admission, discharge, or change from admission to discharge BNP measure is the most important predictor of long-term outcomes</td>
<td>Linked pts ≥65 y of age from hospitals in OPTIMIZE-HF to Medicare claims</td>
<td>• The discharge BNP had the best performance and was the most important characteristic for predicting 1 y mortality (HR for log transformation: 1.34; 95% CI: 1.28–1.40) and 1 y death or rehospitalization (HR: 1.15; 95% CI: 1.12–1.18).</td>
<td>• Compared with a clinical variables, discharge BNP model improved risk reclassification and discrimination in predicting each outcome (1 y mortality: NRI: 5.5%, p&lt;0.0001; IDI: 0.023, p&lt;0.0001; 1-y mortality or rehospitalization: NRI: 4.2%, p&lt;0.0001; IDI: 0.010, p&lt;0.0001)</td>
<td>Linked pts ≥65 y of age from hospitals in OPTIMIZE-HF to Medicare claims</td>
</tr>
<tr>
<td>Study type:</td>
<td>Retrospective analysis – from OPTIMIZE HF Trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size:</td>
<td>7,039 pts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Flint KM et al. 2014 (32) 24922626

**Aim:** To examine if admission, discharge, or change from admission to discharge BNP measure is the most important predictor of outcomes

**Study type:** Retrospective analysis from VA database

**Size:** 109,875 pts

---

| Inclusion criteria: | All hospital discharges with a 1° diagnosis of HF in the Veterans Affairs Health Care System from 2006 to 2009. |
| 1° endpoints: | 30 d readmission rate for HF |

**Follow up:** 30 d

**Results:**
- 30 d HF readmission was associated with elevated admission BNP, elevated discharge BNP, and smaller percent change in BNP from admission to discharge.
- Pts with a discharge BNP ≥1,000 ng/L had an unadjusted 30 d HF readmission rate over 3 times as high as pts whose discharge BNP was ≤200 ng/L (15% vs. 4.1%).
- Discharge BNP had the greatest effect (C-statistic, 0.639–0.664 [p<0.0001]; NRI, 9% [p<0.0001]).
- Large sample size

---

| ELAN-HF Score Salah et al. 2014 (33) 24179162 |
| Study type: | Individual pt data meta-analyses of prospective cohort studies |
| Size: | 1,301 pts |

---

| Inclusion criteria: | Pts from 7 prospective cohorts with pts admitted because of clinically validated ADHF, discharged alive, and NT-proBNP measurements available at admission and at discharge |
| 1° endpoints: | All-cause mortality and a composite of all-cause mortality and/or first readmission for CV reason within 180 d after discharge |

**Follow up:** 180 d

**Results:**
- NT-proBNP levels at discharge and the changes in NT-proBNP during hospitalization yielded the best C-statistic (AUC: 0.78; 95% CI: 0.74–0.82).
- In pts hospitalized for ADHF, the addition of the discharge NT-proBNP values as well as the change in NT-proBNP to known risk markers, generates a relatively simple yet robust discharge risk score that importantly improves the prediction of adverse events
<table>
<thead>
<tr>
<th>Reference</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Study type</th>
<th>Size</th>
<th>1st endpoints</th>
<th>Results</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohen-Solal et al. 2009 (34) 19539144</td>
<td>Examine whether decreases in BNP levels during the first few d of hospitalization were associated with greater survival in pts with ADHF</td>
<td>Of 1,327 SURVIVE pts, this analysis included 1,038 who had BNP samples at both BL and d 5</td>
<td>Retrospective analysis of SURVIVE</td>
<td>1,327 pts</td>
<td>All-cause mortality and a composite of all-cause mortality and/or first readmission for CV reason within 180 d after discharge</td>
<td>A pt was classified as a &quot;responder&quot; if the follow-up BNP level was ≥30% lower than BL BNP. Short-term 30 d mortality risk reduction was 67% in d 5 BNP responders compared with nonresponders, whereas long-term (180-d) all-cause mortality risk reduction was 47%.</td>
<td>pts with lowered BNP on treatment for ADHF had reduced mortality risks (31- and 180-d) compared to those with little or no BNP decrease</td>
</tr>
<tr>
<td>Logeart et al. 2004 (35) 14975475</td>
<td>To determine the value of BNP predicting post-discharge outcome of pts admitted for ADHF</td>
<td>Serial BNP measurements were performed from admission to discharge in 2 samples of consecutive pts</td>
<td>Prospective cohort</td>
<td>105 pts</td>
<td>Combined death or first re-admission for HF</td>
<td>The predischarge BNP assay had the best discriminative power (AUC for ROC=0.80) and remained the lone significant variable in multivariate analysis (HR: 1.14; 95% CI: 1.02–1.28; p=0.027). High predischarge BNP assay is a strong, independent marker of death or readmission after decompensated HF, more relevant than common clinical or echocardiographic parameters and more relevant than changes in BNP levels during acute cares.</td>
<td>Study relatively old and small</td>
</tr>
<tr>
<td>O’Brien et al. 2003 (36) 12921811</td>
<td>To determine the value of BNP predicting post-discharge outcome of pts admitted for ADHF</td>
<td>NT-proBNP was measured at admission in 96 pts hospitalized with acute LVF</td>
<td>Prospective cohort</td>
<td>96 pts</td>
<td>Combined death or HF</td>
<td>Only pre-discharge plasma NT-proBNP (OR: 15.30; 95% CI: 1.4–168.9], p=0.026) was independently predictive of the composite endpoint. The AUC ROC curve for pre-discharge NT-proBNP was superior to that for admission NT-proBNP for prediction of death or HF (AUC ROC 0.87 cf 0.70), for death (0.79 cf 0.66), LVF hospitalization (0.78 cf 0.70) or HF as an outpatient (0.71.</td>
<td>Plasma NT-proBNP measured pre-discharge provides useful prognostic information following hospitalization with acute LVF. Study relatively old and small</td>
</tr>
<tr>
<td>Study Type</td>
<td>Inclusion Criteria</td>
<td>1st Endpoint</td>
<td>Results</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------------</td>
<td>--------------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richards et al. 2001 (37)</td>
<td>Ischemic CM, EF&lt;45%, chronic stable CHF, NYHA II-III or prior II–IV</td>
<td>Association of plasma N-BNP and adrenomedullin with mortality and HF events at 18 mo</td>
<td>• Above median proBNP increased risk of mortality (HR: 4.7; CI 2–10.9) and HF admission (HR: 4.7, CI: 2–10) • Above median adrenomedullin increased risk of mortality (HR 3.9, CI 1.8-8.7) and HF admission (HR 2.4, CI 1.3-4.5) • Associations persist in multivariable modeling</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tang et al. 2003 (38)</td>
<td>Chronic systolic HF &gt;3 mo duration, stable medical therapy, LVEF&lt;50%, NYHA class I-III, followed in outpatient HF clinic at a single center who had BNP obtained at clinic visit</td>
<td>Prevalence, clinical characteristics, and characteristics of a BNP&lt;100 pg/mL in a HF clinic population</td>
<td>• 21% of symptomatic HF pts had BNP &lt;100 pg/mL • Characteristics associated with this phenotype include younger age, female gender, nonischemic etiology, better preserved cardiac and renal function, less have atrial fibrillation • A sizeable minority (21%) of ambulatory pts with chronic HF have a BNP &lt;100 pg/mL • This phenotype (HF with non-diagnostic BNP) is associated with identifiable clinical characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Januzzi et al. 2008 (39)</td>
<td>Studies using NT-proBNP assays used commercially</td>
<td>NT-proBNP had comparable sensitivity/specificty to BNP for diagnosis of acute HF in dyspneic pts NT-proBNP testing may be superior to</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
### Santaguida et al. 2014 (40) 25052418

**Study type:** Systematic review  
**Size:** 7 publications included  
**Inclusion criteria:** Study assessing incremental value of BNP or NT-proBNP for predicting morbidity and mortality in acute decompensated HF  
**Exclusion criteria:** Studies of stable HF; natriuretic peptide could not be included in base model to allow assessment of incremental value  
**1° endpoint:** BNP or NT-proBNP improved prognostic model performance for mortality as assessed by discrimination and or likelihood statistics  
**Results:**  
- 5 BNP publications consistently predicted all-cause mortality in short (3–6 mo) and long (9,12 mo) beyond base model but not all statistically significant  
- Two NT-proBNP publications both showed incremental value at 22 mo and 6.8 y with 1 being statistically significant  
**Clinical heterogeneity precluded formal meta-analysis**

### Hill et al. 2014 (41) 24957908

**Study type:** Systematic review  
**Size:** 76 publications included (37 BNP alone, 25 NT-proBNP alone, 14 both)  
**Inclusion criteria:**  
- Age >18 y presenting to ED or urgent care center with signs/symptoms suggestive acute HF  
- English language articles from 1989-2012  
- FDA-approved assays  
**Exclusion criteria:**  
- Studies with pts who had conditions that may impact NP levels (transplant, HCM, valvular)  
**1° endpoint:** Test performance characteristics  
**Results:**  
- BNP pooled sensitivity=95%, 95% CI: 93–97%), specificity 67% (58–75%)  
- NT-proBNP pooled sensitivity 91% (95% CI: 88–93), specificity 67% (50–80%)  
- Both BNP and NT-proBNP had high sensitivity but low specificity  
- Overall strength of evidence for sensitivity and all decision cutpoints for both peptides was high; strength of evidence for specificity rated as moderate.  
- Both BNP and NT-proBNP performed well to rule out, but less well to rule in, for the diagnosis of heart failure among patients presenting to the ED or urgent care centers.

### Zaphiriou et al. 2005 (42) 15921792

**Study type:** Diagnostic accuracy study (observational)  
**Size:** 306 pts  
**Inclusion criteria:** Pts with new symptoms suggestive of HF referred by GP to rapid access HF clinics at 5 centers in UK between 201 and 2003  
**1° endpoint:** Sensitivity, specificity, PPV, NPV, LR, AUC for diagnosis of HF  
**Results:**  
- 104 (34%) of pts had HF  
- 2 of 5 sites withdrew after recruiting 18 and 14 pts  
- Both BNP and NT-proBNP are useful for ruling out HF in pts presenting to PCP with possible HF symptoms

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
<table>
<thead>
<tr>
<th>Study type: Study type: Study type: Study type:</th>
<th>Exclusion criteria: Exclusion criteria: Exclusion criteria: Exclusion criteria:</th>
<th>Inclusion criteria: Inclusion criteria: Inclusion criteria: Inclusion criteria:</th>
<th>1° endpoint: 1° endpoint: 1° endpoint: 1° endpoint:</th>
<th>Results: Results: Results: Results:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observational, decision making model using rough set and decision tree approaches</td>
<td>None listed</td>
<td>ED presentation for dyspnea (HF vs. Noncardiac control) Complete medical records</td>
<td>HF diagnosis</td>
<td>NT-proBNP identified as a critical variable for decision making of HF in pts with dyspnea presenting to ED</td>
</tr>
<tr>
<td>Size: 159 subjects (71 HF, 88 control)</td>
<td>NT-proBNP was one of 6 variables identified in decision-tree rough set and one of 4 variables in logistic regression model</td>
<td>NT-proBNP had utility beyond the history and physical for diagnosing HF among primary care outpatients presenting with signs/symptoms of HF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Son et al. 2012 (43) 22564550</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type: Study type: Study type: Study type:</th>
<th>Exclusion criteria: Exclusion criteria: Exclusion criteria: Exclusion criteria:</th>
<th>Inclusion criteria: Inclusion criteria: Inclusion criteria: Inclusion criteria:</th>
<th>1° endpoint: 1° endpoint: 1° endpoint: 1° endpoint:</th>
<th>Results: Results: Results: Results:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross-sectional, diagnostic accuracy (observational)</td>
<td>None listed</td>
<td>Pts presenting with signs/symptoms of HF who were referred to 1 of 8 rapid access clinics in the Netherlands</td>
<td>Diagnosis of HF</td>
<td>NT-proBNP had utility beyond the history and physical for diagnosing HF among primary care outpatients presenting with signs/symptoms of HF</td>
</tr>
<tr>
<td>Size: 721 subjects</td>
<td>HF excluded if other diagnosis made</td>
<td>Known, established HF Acute HF requiring immediate therapeutic intervention</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kelder et al. 2011 (44) 22104551</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study type: Study type: Study type: Study type:</th>
<th>Exclusion criteria: Exclusion criteria: Exclusion criteria: Exclusion criteria:</th>
<th>Inclusion criteria: Inclusion criteria: Inclusion criteria: Inclusion criteria:</th>
<th>1° endpoint: 1° endpoint: 1° endpoint: 1° endpoint:</th>
<th>Results: Results: Results: Results:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic review</td>
<td>None listed</td>
<td>Pts presenting with signs or symptoms of HF or were at risk of HF a time of presentation Primary care setting</td>
<td>Diagnostic accuracy of BNP or NT-proBNP</td>
<td>Both BNP and NT-proBNP have good diagnostic utility for diagnosing HF in the primary care setting in those with signs/symptoms of HF or at risk of developing HF</td>
</tr>
<tr>
<td>Size: 12 BNP publications; 20 NT-proBNP publications</td>
<td>Studies with subjects with: Age &lt;18 y Acute HF Known exacerbation of chronic stable HF</td>
<td>Studies with subjects with: Age &lt;18 y Acute HF Known exacerbation of chronic stable HF</td>
<td></td>
<td>Tests have better sensitivity than specificity</td>
</tr>
<tr>
<td>Booth et al. 2014 (45) 24969534</td>
<td></td>
<td></td>
<td></td>
<td>Authors felt that it was unlikely that further studies will change these conclusions</td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
<table>
<thead>
<tr>
<th>Study Type</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
<th>1° Endpoint</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dao et al. 2001</strong> (46)</td>
<td><strong>Study type:</strong> Observational, convenience sample at 1 VA urgent care center</td>
<td><strong>Inclusion criteria:</strong> SOB as prominent complaint</td>
<td><strong>1° endpoint:</strong> Diagnostic utility of point-of-care BNP for diagnosis of HF</td>
<td>• Conditions that may interfere with NP levels (heart transplant, obesity, HCM, valvular lesion)</td>
</tr>
<tr>
<td><strong>Davis et al. 1994</strong> (47)</td>
<td><strong>Aim:</strong> Assessed value of ANP and BNP in pts presenting with dyspnea</td>
<td><strong>Inclusion criteria:</strong> Suspected HF among elderly pts presenting with acute dyspnea requiring admission</td>
<td><strong>1° endpoint:</strong> Strong negative correlations between LVEF and log BNP (r=-0.7; p&lt;0.001) and log ANP (r=-0.59; p&lt;0.001).</td>
<td>• One of the original studies that showed that plasma BNP was raised in dyspneic pts with HF • But not in acutely breathless pts with lung disease • Rapid BNP assays may assist in the diagnosis of pts with acute dyspnea</td>
</tr>
<tr>
<td><strong>Cheng et al. 2001</strong> (48)</td>
<td><strong>Aim:</strong> To determine if BNP levels predict outcomes of pts admitted with decompensated HF</td>
<td><strong>Inclusion criteria:</strong> Pts admitted with decompensated NYHA class III to IV HF, measuring daily BNP levels</td>
<td><strong>1° endpoint:</strong> Association between initial BNP and the predischARGE or premoribund BNP measurement and subsequent death and 30-d readmission</td>
<td>• In pts admitted with decompensated HF, changes in BNP levels during treatment are strong predictors for mortality and early readmission. • BNP levels might be used successfully to guide treatment of pts admitted for decompensated HF</td>
</tr>
<tr>
<td><strong>Fonarow et al. 2008</strong> (49)</td>
<td><strong>Aim:</strong> To determine additive prognostic value of</td>
<td><strong>Inclusion criteria:</strong> Hospitalizations for HF from April 2003 to December</td>
<td><strong>1° endpoint:</strong> BNP above the median and increased Tn were associated with significantly increased</td>
<td>• Admission BNP and cardiac Tn levels are significant, independent predictors of in-hospital mortality in</td>
</tr>
<tr>
<td>Study</td>
<td>Aim</td>
<td>Inclusion criteria</td>
<td>Exclusion criteria</td>
<td>1st endpoint</td>
</tr>
<tr>
<td>-------</td>
<td>-----</td>
<td>-------------------</td>
<td>-------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Zairis et al. 2010 (50) 19157603</td>
<td>To investigate the combined prognostic value of admission serum levels of BNP, cTnI and hs-CRP, in pts hospitalized because of acutely decompensated severe (NYHA class III/IV) low-output chronic HF.</td>
<td>Consecutive hospitalized acute decompensated HF pts with NYHA class III/IV recruited in the 5 participating centers</td>
<td>Competing diagnoses of renal failure, MI</td>
<td>Cardiac mortality by 31 d</td>
</tr>
</tbody>
</table>

In pts hospitalized for acute decompensated HF, BNP, cTnI and hs-CRP upon admission offers enhanced early risk stratification.

| Peacock et al. 2008 (51) 18480204 | Describe the association between elevated cardiac troponin levels and adverse events in hospitalized pts with acute decompensated HF. | Hospitalizations for acute decompensated HF between 2001 and 2004 in ADHERE. Entry criteria included a troponin level that was obtained at the time of hospitalization | Pts with a serum creatinine level ≥ 2.0 mg per deciliter | Overall, 4,240 pts (6.2%) were positive for troponin. | Pts who were positive for troponin had lower SBP on admission, a lower EF, and higher in-hospital mortality (8.0% vs. 2.7%, p<0.001) than those who were negative for troponin. The adjusted odds ratio for death in the group of pts with a positive troponin test was 2.55 (95% CI: 2.24–2.89; p<0.001) |

In pts with acute decompensated HF, a positive cardiac troponin test is associated with higher in-hospital mortality, independently of other predictive variables.

admission BNP and Tn levels in acutely decompensated HF

Study type: Registry analysis

Size: 48,629

2004 entered into ADHERE were analyzed. BNP assessment on admission was performed in 48,629 (63%) of 77,467 hospitalization episodes

Exclusion criteria: Absence of BNP levels

risk of in-hospital mortality (OR: 2.09 and 2.41 respectively, each p<0.0001). acutely decompensated HF.
<table>
<thead>
<tr>
<th>Study Source</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>1° endpoint</th>
<th>Results</th>
<th>Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee et al. 2012</td>
<td>To derive and validate a model for acute HF mortality applicable in the ED.</td>
<td>Population-based random sample of 12,591 pts presenting to the ED from 2004 to 2007</td>
<td>Death within 7 d of presentation</td>
<td>Mortality risk increased with higher triage heart rate (OR: 1.15; [95% CI: 1.03–1.30] per 10 beats/min) and creatinine concentration (OR: 1.35; [CI: 1.14–1.60] per 1 mg/dL [88.4 micro mol/L]), and lower triage SBP (OR: 1.52 [CI: 1.31–1.77] per 20 mm Hg) and initial oxygen saturation (OR, 1.16 [CI: 1.01–1.33] per 5%).</td>
<td>A multivariate index comprising routinely collected variables stratified mortality risk with high discrimination in a broad group of pts with acute HF presenting to the ED.</td>
</tr>
<tr>
<td>Dhaliwal et al. 2009</td>
<td>Compare the relationship between absolute and relative changes in BNP with future clinical events, and whether serial BNP measurements add prognostic information in pts treated for decompensated HF</td>
<td>Pts hospitalized for acute decompensated HF by Framingham criteria</td>
<td>For the combined end point of total mortality or readmission for HF</td>
<td>Increasing tertiles of BNP levels after treatment had a hazard ratio of 1.4 (1.1–1.7, p&lt;0.01) and increasing tertiles of percent reduction in BNP, had a HR:0.7 (0.6–0.9; p=0.005), respectively, for the combined end point of total mortality or readmission for HF. Follow-up BNP performed better than did baseline BNP or percent reduction in BNP. More BNP measurements other than the follow-up BNP did not improve the fit of the model further.</td>
<td>Both lower absolute BNP levels and greater percentage reduction in BNP with treatment of decompensated HF are associated with better event-free survival. Advocating a threshold BNP to which pts should be treated may not be possible given that high BNP levels tend not to decrease to levels associated with better outcomes during the short period of treatment. More BNP measurements do not add prognostic information beyond that provided by a single BNP level after treatment.</td>
</tr>
<tr>
<td>Alonso-Martinez et al. 2002</td>
<td>To determine usefulness of CRP in predicting need for readmission in HF</td>
<td>Intervention group: admission with HF; control group: admission with syncope</td>
<td>18-mo HF readmission</td>
<td>CRP levels were higher in pts with HF compared to syncope (3.94 vs. 0.84, p&lt;0.0007)</td>
<td>Multivariate predictors of readmission were CRP levels, NYHA class and plasma K on discharge. Limitation: small, single-center</td>
</tr>
<tr>
<td>Study type:</td>
<td>Observational</td>
<td>Exclusion criteria:</td>
<td>• Higher CRP levels were associated with higher NYHA class, increased risk of HF readmission, shorter time to readmission, and increased mortality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Size:</td>
<td>76</td>
<td>Safety endpoint:</td>
<td>NYHA class on discharge and death</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dieplinger et al. 2010 (55)</td>
<td>To evaluate the prognostic value of established and novel biomarkers in pts with acute dyspnea</td>
<td>Inclusion criteria:</td>
<td>Pts presenting to ED with acute dyspnea</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exclusion criteria:</td>
<td>STEMI, NSTEMI or ACS troponin pos.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Biomarkers:</td>
<td>BNP, MR-proANP, MR-proADM, copeptin, C-terminal pro-ET-1, soluble ST2, chromogranin A (CgA), adiponectin, proguanylin, prouroguanylin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1° endpoint:</td>
<td>All-cause mortality at 1 y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 25% died within 1 y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• At baseline, decedents (n=62) had higher median plasma concentrations of all 10 biomarkers than survivors (n=189)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• In multivariate model, only MR-proANP (RR: 1.6), ST2 (RR: 1.7) and CgA (RR: 1.5) were independent predictors of death</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Low systolic BP and advanced age were also independent predictors of 1-y mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Limitations: post-hoc analysis; subgroup (87 of 251) had dyspnea due to acute HF alone; single-center, majority men (94%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ilva et al. 2008 (56)</td>
<td>To evaluate prevalence and prognostic significance of elevated cTnI and cTnT in acute HF</td>
<td>Inclusion criteria:</td>
<td>Hospitalized with acute HF</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exclusion criteria:</td>
<td>ACS pts; missing sample for cardiac TnI/TnT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biomarkers on admission and 48 hours:</td>
<td>cTnT, cTnI, cystatin C, NT-proBNP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1° endpoint:</td>
<td>6-mo mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 51% of pts had +cTnI and 30% had +cTnT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• 6-mo all-cause mortality was 18.7%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Both cTnI (OR: 2.0; 95% CI: 1.2–3.5) and cTnT (OR: 2.6; 95% CI: 1.5–4.4) were associated with adverse outcome in pts with previous, but no de novo HF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• On multivariable analysis, cystatin C (OR: 6.3; 95% CI: 3.2–13), logNT-proBNP (OR: 1.4; 95% CI: 1.0–1.8) and SBP on admission (10 mm Hg increase; OR: 0.9; 95% CI: 0.8–0.9) were independent risk predictors, whereas troponins were not</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mortality was proportional to troponin release</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Limitations: exclusion of pts with ACS was based on clinician judgment; cut-off values for troponins was based on 2000 ESC/ACC guidelines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Januzzi et al. 2007 (57)</td>
<td>To examine the value of measuring ST2 in pts</td>
<td>Inclusion criteria:</td>
<td>Pts presenting to ED with acute dyspnea</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1° endpoint:</td>
<td>• death at 1 y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• ST2 levels were significantly higher in pts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| | • ST2 levels were higher in pts with HF/EF (0.67 ng/ml; IQR 0.31–1.50) vs. HFpEF (0.42 ng/ml; IQR 0.22–
### Manzano-Fernandez et al. 2011

**Aim:** To determine whether risk of mortality associated with ST2 differs in pts with acute HFpEF vs. HFrEF

**Study type:** Observational study combining 3 databases (Boston, MA; Linz, Austria; Murcia, Spain)

**Size:** 447

**Inclusion criteria:** Acute HF

**Exclusion criteria:** N/A

**Biomarkers:** ST2, troponin T, NT-proBNP, CRP

**1° endpoint:**
- 1 y vital status
- During 1-y follow-up, 117 pts (26%) died
- ST2 levels were higher among deceased than survivors (median 0.80 ng/ml vs.0.38 ng/ml; p<0.001); and this pattern was true for HFrEF and HFpEF

- On multivariate analysis, elevated ST2 levels were associated with greater risk of 1-y mortality for HFpEF (HR: 1.41; 95% CI: 1.14–1.76) than HFrEF (HR: 1.20; 95% CI: 1.10–1.32)

- PtS with HFpEF had higher ST2 levels than HFrEF (median 0.55 ng/ml vs. 0.38 ng/ml; p<0.001)

- Addition of ST2 to NT-proBNP improved C statistic and both net reclassification improvement and integrated discrimination improvement, regardless of LVEF

- Limitations: pooled multinational analysis that lacked predefined endpoints and complete echocardiographic measures; no pre-discharge ST2 levels

### Rehman et al. 2008

**Aim:** To examine patient-specific characteristic of ST2 in pts with acute HF

**Study type:** Observational study combining 2 databases (Boston, MA; Linz, Austria)

**Size:** 346

**Inclusion criteria:** Acute HF

**Exclusion criteria:** N/A

**Biomarkers:** ST2, BNP, NT-proBNP, CRP

**1° endpoint:**
- ROC curves and multivariable Cox proportional hazards analyses
- ST2 levels correlated with severity of HF (p<0.001), LVEF and creatinine clearance
- ST2 levels correlated with BNP, NT-proBNP and CRP
- In a multivariable model, ST2 remained a predictor of mortality (HR: 2.04; 95% CI: 1.30–3.24)

- Pts with HFpEF had lower ST2 levels compared to HFrEF

- 1-y mortality was 42% among 116 pts with elevation in both ST2 and BNP/NT-proBNP

- In the presence of a low ST2 level, BNP/NT-proBNP did not predict mortality

- Limitations: lack of serial measures of ST2; biologic role of ST2 in acute HF poorly understood

### Exclusion criteria:
- Not reported
**Shah et al. 2010 (60)**

**Aim:** To determine the relationship between galectin-3 and cardiac structure and function in pts with acute dyspnea

**Study type:** Observational

**Size:** 115

**Inclusion criteria:** PT presenting to ED with acute dyspnea, detailed echo exams during admission

**Exclusion criteria:** N/A

**Biomarkers:** galectin-3, NT-proBNP

**1° endpoint:**
- Association between galectin-3 and echo and clinical indices
- Higher levels of galectin-3 associated with older age, poorer renal function, and higher NT-proBNP
- Significant relationship between galectin-3 and poorer RV function, higher RV systolic pressure and more severe MR and TR
- Galectin-3 levels higher in pts who died at 1 and 4 y
- In multivariate analysis, galectin-3 remained a significant predictor of 4-y mortality independent to echocardiographic markers of risk
- Limitations: delay between collection of biomarkers and echocardiograms; small, single-center cohort

__Search Terms and Date:__ natriuretic peptides, heart failure, human, last 5 years. Last search done on April 18, 2016.

### Data Supplement 1. RCTs Comparing ARNI (Section 7.3.2.10)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| PARAMOUNT Solomon et al. 2012 (61)   | To address safety and efficacy of LCZ696 (ARNI) in pts with HF ≠ EF | Pts ≥40 y of age, LVEF ≥45%, NYHA class II-III HF, NT-pro BNP >400 pg/mL. | Intervention: LCZ696 (149) target dose 200 mg BID achieved in 81% Comparator: Valsartan (152) target dose 160 mg BID achieved in 78% | 1° endpoint: Change from BL at 12 wk for NT-proBNP
- Results: Reduction in LCZ696 group vs. valsartan (ratio of change from BL: 0.77, 95% CI: 0.64–0.92; p=0.005) 1° Safety endpoint:
- LCZ-696 well tolerated.
- Serious adverse events: 15% in LCZ696 vs. 20% in valsartan group | No difference in change in NT-proBNP from BL at 36 wk
BP reduced in the LCZ696 group vs. valsartan at 12 wk (p=0.001 for SBP and p=0.09 for DBP)
Change in BP correlated poorly with the change in pro-BNP
No difference in improvement in NYHA class at 12 wk (p=0.11) and 36 wk (p=0.05).
No difference in KCCQ scores
Trial not powered to ascertain clinical outcomes. Further studies needed to assess safety and efficacy in HFpEF pts. |
| PARADIGM-HF McMurray et al. 2014     | To compare survival rates with the use of | ≥18 y of age, NYHA class II, III, IV; EF ≤35%, BNP of at least 150 | Intervention: LCZ696 (4,187) target dose 200 mg BID (mean | 1° endpoint: Composite of death (CV causes) or a first | Less CV death in LCZ696 arm (558 vs. 693) HR: 0.8 (95% CI: 0.71–0.89; p<0.001) |

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
<table>
<thead>
<tr>
<th><strong>Study type:</strong></th>
<th>RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Size:</strong></td>
<td>8,442</td>
</tr>
</tbody>
</table>

**Study:** LCZ696 with enalapril in HF

**Comparator:** Enalapril (4,212) target 10 mg BID (mean 18.9±3.4 mg daily)

**Comparator:** LCZ696 (4,212) target 375±71 mg daily

**Exclusion criteria:**
- Symptomatic hypotension, SBP <95 mm Hg, eGFR <30 mL/min/1.73m² of body surface area, serum K level >5.2 mmol/L, angioedema history, unacceptable side effects of ACE inhibitors or ARBs
- Prior to randomization pts were required to complete 2 wk each of enalapril 10 mg BID and LCZ 100 BID.

**Results:** Composite less in LCZ696 group vs. enalapril, 914 (21.8%) vs. 1,117, (26.5%) HR: 0.80 (95% CI: 0.73–0.87; p<0.001)

- Less HF hospitalizations in LCZ696 arm (537 vs. 658) HR: 0.79 (95% CI: 0.71–0.89; p<0.001)
- Less death from any cause in LCZ696 arm (711 vs. 835), HR: 0.84 (95% CI: 0.76–0.93; p<0.001)
- The change from baseline to 8 mo in the score on the KCCQ in LCZ696 arm (2.99 points reduction vs. 4.63 points), HR: 1.64 (95% CI: 0.63–2.65; p=0.001)
- No difference in new onset of AF (84 vs. 83; p=0.84)
- No difference in protocol defined decline in renal function, HR: 0.86 (95% CI: 0.65–1.13; p=0.28).
- More symptomatic hypotension (14% vs. 9.2%; p<0.001)
- No difference in angioedema, 19 vs. 10 (p=0.13)

**Search Terms and Date:** 3 trials identified by chairs in December 2015.
### Data Supplement 2. RCTs Comparing RAAS Inhibition (Section 7.3.2.3)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2nd Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ONTARGET</strong> ONTARGET Investigators et al. 2008 (63) 18378520</td>
<td><strong>Aim:</strong> Compare ACE (ramipril), ARB (telmisartan), and combination ACE/ARB in pts with CVD or high-risk DM</td>
<td><strong>Inclusion Criteria:</strong> Pts &gt;55 y of age, CAD, PVD, previous stroke, or high-risk DM with end-organ damage</td>
<td><strong>Exclusion Criteria:</strong> HF at trial entry, ACE or ARB intolerance, revascularization planned or &lt;3 mo</td>
<td><strong>1st endpoint:</strong> • Composite of CV death, MI, stroke, or HF hospitalization at 5 y</td>
<td>• Compared to the ramipril arm: Telmisartan had more hypotensive symptoms (p&lt;0.001); less cough (p&lt;0.001) and angioedema (p=0.01); same syncope. • Combination arm had more hypotensive symptoms (p&lt;0.001); syncope (p=0.03); and renal dysfunction (p&lt;0.001) • BP fell by 6.4/7.4/9.8 mm Hg • Less angioedema with telmisartan</td>
</tr>
<tr>
<td><strong>TRANSCEND</strong> Yusuf et al. 2008 (64) 18757085</td>
<td><strong>Aim:</strong> To assess the effectiveness of ARB in ACE-intolerant pts with CVD or high-risk DM</td>
<td><strong>Inclusion Criteria:</strong> ACE-intolerant pts with CAD, PVD, previous stroke, or high-risk DM with end-organ damage</td>
<td><strong>Exclusion Criteria:</strong> HF at trial entry, ACE or ARB intolerance, revascularization planned or &lt;3 mo</td>
<td><strong>1st endpoint:</strong> • Composite of CV death, MI, stroke, or HF hospitalization at 5 y</td>
<td>• No difference in 2nd outcomes; ARB was safe in this pt population - no angioedema</td>
</tr>
<tr>
<td><strong>SUPPORT</strong> Sakata et al. 2015 (65) 25637937</td>
<td><strong>Aim:</strong> Discover whether addition of ARB to ACE and beta blockers in pts with chronic HF will</td>
<td><strong>Inclusion Criteria:</strong> Pts 20–79 y of age with hypertension, NYHA class II-IV, stable on ACE ± beta blockers</td>
<td><strong>Intervention:</strong> Randomization to olmesartan (578) titrated up to 40 mg as tolerated (578) (mean dose achieved at 5 y, 17.9</td>
<td><strong>1st endpoint:</strong> • Composite of all-cause death, MI, stroke, or HF hospitalization at 4.4 y</td>
<td>• Pts on triple therapy with ACE/ARB/Beta blocker had more of 1st composite outcome, 38.1 vs. 28.2%, HR: 1.47 (95% CI: 1.11–1.95; p=0.006); all-cause death, 19.4 vs. 13.5%, HR: 1.50 (95% CI:</td>
</tr>
</tbody>
</table>
### 2017 Heart Failure Focused Update Data Supplement

<table>
<thead>
<tr>
<th>Study Type:</th>
<th>Inclusion Criteria:</th>
<th>Intervention:</th>
<th>1° endpoint:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open label blinded endpoint</td>
<td>Creatinine &gt;3.0, MI or, revascularization within 6 mo</td>
<td>Titration to control BP without use of an ARB (568)</td>
<td>1.01–2.23; p=0.046; and renal dysfunction (21.1 vs. 12.5%, HR: 1.85 (95% CI: 1.24–2.76; p=0.003).</td>
</tr>
<tr>
<td>Study Type:</td>
<td>Exclusion Criteria:</td>
<td>Comparator:</td>
<td></td>
</tr>
<tr>
<td>Open label blinded endpoint</td>
<td>Creatinine &gt;3.0, MI or, revascularization within 6 mo</td>
<td>Titratin to control BP without use of an ARB (568)</td>
<td></td>
</tr>
<tr>
<td>Size:</td>
<td>Comparator:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,147</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Mineralocorticoids Antagonist Trials

#### EMPHASIS subgroup analysis

**Aim:** Investigate the safety and efficacy of eplerenone in pts at high risk for hyperkalemia

**Study Type:** Prespecified subgroup analysis of RCT

**Size:** 2,737

**Inclusion Criteria:** Pts enrolled in EMPHASIS at high risk for hyperkalemia of worsening renal function (>75 y, DM, eGFR <60, or SBP <123)

**Exclusion Criteria:** eGFR<30

**Intervention:** Randomization to eplerenone

**Comparator:** Placebo

**1° endpoint:**
- Efficacy: Hospitalization for HF or worsening renal failure. **Safety:** K >5.5, >6.0, <3.5, hospitalization for significant hyperkalemia, hospitalization for worsening renal function

**Results:**
- Efficacy: reduced composite endpoint. Safety: increased risk of K+ >5.5 mmol/L, hospitalization for hyperkalemia or discontinuation of study medication due to adverse events. No differences from the main trial results in the high-risk subgroups. K >5.5 was increased in the whole cohort and the subgroups, but K >6.0, clinically significant hyperkalemia, and change in eGFR were not substantially higher.

- The beneficial effects of eplerenone were maintained in the high-risk subgroups.

#### RALES

**Aim:** To investigate the effect of spironolactone on mortality and morbidity in pts with severe HF.

**Study Type:**

**Inclusion Criteria:** NYHA class III, IV; HF≤6 mo, Left EF≤35%, On ACE inhibitors, loop diuretic. Digitalis and vasodilators allowed.

**Exclusion Criteria:** 1° operable VHD (other than

**Intervention:** Spironolactone 25 mg daily (822)

**Comparator:** Placebo (841)

**1° endpoint:**
- Death from all causes

**Results:**
- Placebo vs. Spironolactone group (46% vs. 35%; RR: 0.70; 95% CI: 0.60–0.82; p<0.001)
- Trial stopped early due to favorable results at 24 mo.

- Reduction in death from cardiac causes and Hospitalization for cardiac causes (p<0.001)
- Improvement in NYHA class (p<0.001)
- No clinically important safety concerns for electrolytes. Gynecomastia/breast pain more frequent in the spironolactone
The ARB evidence table from the 2013 Heart Failure Guideline is included at the end of this document. The ACE inhibitor evidence table from the 2013 Heart Failure Guideline is also included at the end of this document. The Beta Blocker evidence table from the 2013 Heart Failure Guideline is included at the end of this document.

### Data Supplement 3. RCTs Comparing Pharmacological Treatment for of ARNI With ACE (Section 7.3.2.10)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint; Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| IMPRESS Rouleau et al. 2000 (68) 10968433 | Aim: Determine if inhibition of neutral endopeptidase and ACE with the vasopeptidase inhibitor omapatrilat is better than ACE inhibition alone with lisinopril | Inclusion criteria:  
- Informed consent  
- Age ≥18  
- Stable (>3 mo) symptomatic HF (NYHA class II–IV HF)  
- Decreased LVEF <40  
- ≥4 wk dose of ACE inhibitors  
- Seated SBP ≥90 mm Hg  

Exclusion criteria:  
- Uncontrolled hypertension  
- Acute coronary events within 3 mo  
- Revascularization within 3 mo  
- Serum potassium <3.5 or >5.3 mmol/L  
- Creatinine >221 mmol/L  
- Transaminases >2 upper limit of normal  
- Leucocytes <3.0x10^9/L, neutrophils <1.5x10^9/L, or platelets <120x10^9/L | Intervention: Omapatrilat (289) target dose 40 mg daily  
Comparator: Lisinopril (284) target dose 20 mg daily | 1° endpoint: Change in exercise duration from baseline to wk 12  
Results: Similar exercise duration at 12 wk (p=0.45) | 2° endpoint:  
- No difference in combined endpoint of death and admission for worsening HF (p=0.52)  
- Combined endpoint of death and comorbidity for worsening HF was better for omapatrilat HR: 0.52 (95% CI: 0.28–0.96; p=0.035)  
- Angioedema occurred in no pts taking omapatrilat vs. 1 taking enalapril | Comments: Vasopeptidase inhibitor omapatrilat did not improve exercise tolerance compared with ACE inhibitor lisinopril |
## OVERTURE

**Packer et al. 2002 (69) 12186794**

**Aim:**
Determine dual ACE and NEP inhibitors provides greater benefit in pts with HF than ACE inhibitors alone

**Study type:**
Double blind RCT

**Size:**
5,770 pts

**Inclusion criteria:**
- NYHA class II–IV HF due to non/ischemic cardiomyopathy for ≥2 mo, or
- LVEF ≤30% and hospitalized for HF within 12 mo

**Exclusion criteria:**
- Surgically correctable or reversible cause of HF
- Likely to receive cardiac transplant or left ventricular assist device
- Severe 1° pulmonary, renal, or hepatic disease
- Hx of intolerance to ACE inhibitors
- ACS within 1 mo
- Coronary revascularization or an acute cerebral ischemic event within 3 mo
- Hx of ventricular tachycardia, ventricular fibrillation, or sudden death who did not have an ICD placed and had not fired within 2 mo
- Hx or hospitalization or intravenous therapy for HF within 48 h
- IV positive inotropic agent within 2 wk
- SBP >180 or <90 mm Hg
- Heart rate >130 bpm
- Serum creatinine >2.5 mg/dL
- Serum potassium <3.5 or >5.2 mmol/L

**Intervention:**
Omapatrilat (2,886), target dose 40 mg daily achieved 82.5%

**Comparator:**
Enalapril (2,884) target dose 10 mg BID achieved 86.4%

**1° endpoint:** Combined risk of death or hospitalization for HF requiring IV treatment

**Results:**
- No significant difference HR: 0.94 (95% CI: 0.86–1.03; p=0.187)
- Omapatrilat reduced risk of death and hospitalization for chronic HF HR: 0.89 (95% CI: 0.82–0.98; p=0.012). For this analysis, pts were treated with intensification of oral medications.

**Comments:**
- More frequent angioedema with omapatrilat (0.8% vs. 0.5%)

## OCTAVE

**Kostis et al. 2004 (70) 14751650**

**Aim:**
Compare safety and efficacy of dual ACE and NEP inhibitors to ACE inhibitors alone

**Study type:**
Double blind RCT

**Inclusion criteria:**
- Age ≥18
- 3 separate BP criteria for 3 groups: Group 1 untreated hypertension (SBP ≥140 mm Hg or DBP ≥90 mm Hg); Group 2 hypertension and persistent mild hypertension (trough SBP 140–159 mm Hg and DBP <100 mm Hg, or trough DBP 90–99 mm Hg and SBP <160 mm Hg);

**Intervention:**
Omapatrilat target dose 80 mg daily

**Comparator:**
Enalapril target dose 40 mg daily

**1° endpoints:**
- Reduction in SBP at wk 8
- Need for new adjunctive antihypertensive therapy by wk 24

**2° endpoints:**
- Reduction in DBP at wk 8
- Reduction in SBP and DBP at wk 24
- BP control (SBP <140 mm Hg and DBP <90 mm Hg) at wk 8 and 24

**Comments:**
- Omapatrilat reduced risk of death and hospitalization for chronic HF HR: 0.89 (95% CI: 0.82–0.98; p=0.012). For this analysis, pts were treated with intensification of oral medications.

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
Group 3 hypertension with persistent moderate to severe hypertension (trough SBP 160–179 mm Hg and DBP <110 mm Hg, or trough DBP 100–109 mm Hg and SBP <180 mm Hg)

**Exclusion criteria:**
- Contraindication to therapy with ACE inhibitors or angiotensin II receptor antagonists
- Hx of angioedema, anaphylaxis, drug-induced or chronic urticarial, or multiple drug sensitivities
- Recent hospitalization for MI, unstable angina, stroke, TIA or COPD
- Recent treatment for malignancy, chronic renal disease 2° to autoimmune disease, or end-stage renal disease of any etiology
- Hypertensive pts treated with ACE inhibitors whose BP placed them in study group 3

Greater reductions in BP in omapatrilat within each study (p<0.001)
- Overall mean reduction in SBP ≥3.6 mm Hg
- Larger reductions in BP in black pts with omapatrilat than with enalapril. But overall reduction smaller with both drugs than in other subgroups.
- Adverse events, serious adverse events, and deaths were the same for omapatrilat and enalapril
- More angioedema with omapatrilat (2.17% vs. 0.68%)
- More angioedema in blacks with omapatrilat (5.54% vs. 1.62%) and current smokers (3.93% vs. 0.81%)

Search Terms and Date: March 2016, angioedema, nepriysin inhibitors, omapatrilat.

**Data Supplement 4. RCTs Comparing Pharmacological Treatment for Stage C HFrEF (Section 7.3.2.11)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHIFT HF Böhm et al. 2015 (71) 26508709</td>
<td>Aim: To assess influence of comorbidities on outcomes and ivabradine treatment effect of heart rate reduction in stable HF. <strong>Study type:</strong> Post hoc analysis of RCT</td>
<td>Inclusion criteria: Pts ≥18 y of age in sinus rhythm, heart rate at rest ≥70 bpm, MTD for HF meds <strong>Exclusion criteria:</strong> N/A</td>
<td>Intervention: Ivabradine Comparator: Placebo</td>
<td>1° endpoint: CV death or HF hospitalization rate increased with the comorbidity load (p&lt;0.0001) with most events in pts with &gt;3 comorbidities for both drug and placebo. • Hospitalization rate lower for comorbidity loads of ivabradine</td>
<td>• Number of comorbidities was related to outcomes • Heart rate reduction with Ivabradine is conserved at all comorbidity loads</td>
</tr>
</tbody>
</table>
### SHIFT

**Aim:**
To assess the effect of heart rate reduction by the selective sinus-node inhibitor ivabradine on outcomes in HF

**Study type:** randomized, double-blind placebo-controlled trial.

677 centers 37 countries

**Inclusion criteria:**
- Over 18 y of age, in sinus rhythm, resting heart rate of ≥70 bpm, stable symptomatic chronic HF (NYHA class II-IV) for ≥4 wk, previous admission to the hospital for HF within 12 mo, LVEF ≤35%

**Exclusion criteria:**
- HF due to congenital heart disease or 1° severe valvular disease.
- MI within 2 mo, ventricular or AV pacing for ≥40% of the d, AF or flutter, symptomatic hypotension
- The following treatments not allowed during study:  
  - diltiazem and verapamil (nondihydropyridine CCB)  
  - class I antiarrhythmics  
  - strong inhibitors of CYP450 3A4

**Intervention:**
- Ivabradine

**Comparator:**
- Placebo

**1° endpoint:**
- Composite of CV death or hospital admission for worsening HF  
  - Primary endpoint: ivabradine better. Event rate 24% vs. 29%, HR 0.82 (0.75–0.90); p<0.0001  
  - Hospitalization for worsening HF: ivabradine better. 16% vs 21%, HR: 0.74 (95% CI: 0.66–0.83; p<0.001)  
  - Death from HF: ivabradine better. 3% vs. 5%; HF: 0.74 (0.58–0.94); p=0.014
  
  **Composite of CV death or hospital admission for worsening HF among those receiving at least 50% of target beta blocker dose at time of randomization. All cause death; any CV death; HF hospitalization; all-cause hospitalization; any CV hospitalization; death from HF, composite of CV death HF hospitalization, nonfatal MI.**

- No difference in all-cause mortality or CV mortality
- Ivabradine better for all-cause hospitalization, HF hospitalization, CV hospitalization, and composite 2° endpoint
  
  **Adverse Effects:**
  - 1% withdrew due to bradycardia (p<0.001)  
  - Phosphenes 3% (p<0.001)  
  - AF - ivabradine 9% vs. placebo 8% (p=0.012)  
  - Comparable across age groups  
  - AF - ivabradine 9% vs. placebo 8% (p=0.012)

### SIGNIFY

**Aim:**
Assess the mortality-morbidity

**Inclusion criteria:**
- Stable CAD without clinical HF and heart rate of ≥70

**Intervention:**
- Ivabradine (n=9,550)

**1° endpoint:**
- Composite of CV death and nonfatal MI

- Composite of CV death or hospital admission for worsening HF among those receiving at least 50% of target beta blocker dose at time of randomization. All cause death; any CV death; HF hospitalization; all-cause hospitalization; any CV hospitalization; death from HF, composite of CV death HF hospitalization, nonfatal MI.

- No difference in all-cause mortality or CV mortality
- Ivabradine better for all-cause hospitalization, HF hospitalization, CV hospitalization, and composite 2° endpoint

**Adverse Effects:**
- 1% withdrew due to bradycardia (p<0.001)  
- Phosphenes 3% (p<0.001)  
- AF - ivabradine 9% vs. placebo 8% (p=0.012)  
- Comparable across age groups  
- AF - ivabradine 9% vs. placebo 8% (p=0.012)
### Study 1

**Aim:** Assess the mortality-morbidity benefits of Ivabradine in pts with CAD and LV systolic dysfunction

**Study type:** Randomized, double-blind, placebo-controlled

**Size:** 10,917

5,479 ivabradine
5438 placebo

**Inclusion criteria:**
- Pts ≥55 y of age with stable CAD defined as: previous MI, previous revascularization (PCI or surgery), or angiographic evidence of ≥1 stenosis of ≤50% AND LVEF ≤40% and end diastolic internal dimension of >56 mm. Sinus rhythm with resting heart rate of ≥60 bpm.
- Angina and HF symptoms stable for 3 mo
- Appropriate conventional CV medication for 1 mo.

**Exclusion criteria:** MI or coronary revascularization within the previous 6 mo; stroke or TIA within 3 mo, PPM or ICD, valvular disease likely to

**Intervention:** Ivabradine n=5,479

**Comparator:** Placebo in addition to appropriate CV medication n=5,438

**1° endpoint:**
- Composite of CV death, admission for MI and admission for HF

**Comparator:** Placebo in addition to appropriate CV medication

**Results:** No difference in composite 1° endpoint (22.5% vs. 22.8%; HR: 1.00; 0.91–1.1; p=0.94)

**2° endpoints:**
1) All-cause mortality
2) Cardiac death (death from MI or HF or related to a cardiac procedure)
3) CV death (death from a vascular procedure, presumed arrhythmic death, stroke death, other vascular death or sudden death of unknown cause) or admission for HF,
4) Composite of admission for fatal and nonfatal MI or UA
5) Coronary revascularization
6) CV death
7) Admission for HF
8) Admission for MI

No differences in 2° endpoints in overall population.

In subgroup with heart rate of ≥70, ivabradine reduced
1) admission for AMI (fatal and nonfatal) (HR 0.64; 0.49–0.84; p=0.001)
2) composite of admission for AMI or UA (HR 0.78; 0.62–0.97; p=0.023)

**Safety endpoint:**
- Incidence of bradycardia higher in Ivabradine group (p=0.001)
- Significant interaction between ivabradine and presence of angina in a subgroup analysis (p=0.02).
### 2017 Heart Failure Focused Update Data Supplement

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
</table>
| **HYVET** Beckett et al. 2008 (75) 18378519 | **Aim:** To determine whether treatment of HTN is beneficial in the elderly.  
**Study type:** RCT  
**Size:** 3,845 | **Inclusion criteria:**  
Age >80, persistent HTN (SBP >160)  
**Exclusion criteria:**  
Known HF, creatinine >150 μmol/L (1.7 mg/dL), CVA <6 mo | **Intervention:** Indapamide + perindopril if needed for BP control. Target 150/80 mm Hg (1,933)  
**Comparator:** Placebo (1,912) | **1° endpoint:**  
- Fatal or nonfatal stroke.  
- Trend for improved outcome with active treatment 51 strokes (12.4/1,000 pt-y) vs. placebo 69 (17.7/1,000 pt-y), HR: 0.70; 95% CI: 0.49–1.01; p=0.06) and significantly reduced fatal stroke 27 (6.5/1000 pt-y) vs. placebo 42 (10.7/1000 pt-y), HR: 0.61; 95% CI: 0.38–0.99; p=0.046)  
- Significantly reduced all-cause death HR: 0.79 (95% CI: 0.65–0.95; p=0.02) and HF incidence HR: 0.36 (95% CI: 0.22–0.58; p=0.001) with active treatment  
- Trend for decreased CV and HF death (p=0.06 for both) |  

| **ALLHAT Long-term Follow-up** Piller et al. 2011 (76) 21969009 | **Aim:** To compare diuretic-based to ACE-inhibitor or CCB-based treatment of HTN  
**Study type:** RCT | **Inclusion criteria:**  
Age >55, HTN (SBP ≥140, DBP≥90), at least 1 CV risk factor (MI, stroke, LVH, diabetes, low HDL, PVD)  
**Exclusion criteria:** | **Intervention:** Amlodipine (8,898) 572 with in-trial HF, Lisinopril (8,904); 469 with in-trial HF  
**Comparator:** Chlorthalidone (15,002); 720 with in-trial HF | **1° endpoint:**  
- Adjusted mortality risk  
- Increased mortality with in-trial incident HF, both HFrEF: HR: 2.42 (95% CI: 2.08–2.81; p=0.001) and HFrEF: HR: 3.06; 95% CI: 2.67–3.51; p=0.001)  
- Increased HF mortality with incident HF, both HFrEF: HR: 3.81 (95% CI: 2.18–6.67, p=0.001) and HFrEF: HR: 6.80; 95% CI: 4.36–10.62; p<0.001)  
- No difference in mortality in pts with incident HF by drug treatment |  

Search Terms and Date: studies identified by chairs in December 2015, one study added by Jan 2016.
### SHEP HF Results

**Kostis et al. 1997**

**Aim:** To assess the effect of antihypertensive treatment in isolated systolic HTN

**Study type:** RCT

**Size:** 4,736

**Inclusion criteria:** Age > 60, SBP 160–219, DBP<90

**Exclusion criteria:** Recent MI or CABG, pts with DM, stroke, AF

**Intervention:** Antihypertensive therapy: step 1, chlorthalidone, step 2, atenolol (2,365)

**Comparator:** Placebo (2,371)

**1° endpoint:**
- Incident HF
- Active treatment decreased BP from mean of 170/77 to mean of and decreased HF events from 105 (4.4%) with placebo to 55 (2.3%) RR: 0.51 (95% CI: 0.37–0.71, p<0.001) at 4.5 y

- LV function was not measured

**2° endpoint:**
- No differences for covariate adjusted risk of HF admission HR: 0.84 (95% CI: 0.70–1.00; p=0.047).
- CV death 11.2 vs. 11.3% HR: 0.99 (95% CI: 0.80–1.22; p=0.918).
- Adverse effects requiring discontinuation: hypotension (2.4 vs. 1.1%; p=0.009; increased creatinine, 4.8 vs. 2.4%; p=0.005; hyperkalemia 1.5 vs. 0.6%; p=0.029)

**Limitations:** Some pts may have had previous EF <40%.

### CHARM-Preserved

**Yusuf et al. 2003**

**Aim:** To ascertain efficacy of candesartan in pts with HFpEF.

**Study type:** RCT

**Size:** 3,023

**Inclusion criteria:** HF pts in NYHA class II-IV with EF >40%

**Exclusion criteria:** Creatinine >265 μmol/L (3.0 mg/dL), potassium >5.5 mmol/L, MI, stroke, or open-heart surgery in the previous 4 wk

**Intervention:** Candesartan (1,514)

**Comparator:** Placebo (1,509)

**1° endpoint:**
- CV death or admission for HF.
- No difference for candesartan 333 (22%) vs. placebo 366 (24%) at 3.5 y, HR: 0.92; 95% CI: 0.70–1.21; p=0.5.
- HF hospitalization lower at 1 y with perindopril: 34 events (8.0%) vs. placebo 53 (12.4%), HR: 0.63; 95% CI: 0.41–0.97; p=0.033.
- Limitations: Many pts withdrew (40% by 18 mo), often to take open-label ACE inhibitors (36% by study end).

**2° endpoint:** None

### PEP-CHF

**Cleland et al. 2003**

**Aim:** To ascertain efficacy of perindopril in pts with HFpEF.

**Study type:** RCT

**Size:**

**Inclusion criteria:** Age ≥70, Rx with diuretics for clinical diagnosis of HF, echo criteria for diastolic dysfunction

**Exclusion criteria:**

**Intervention:** Perindopril (424)

**Comparator:** Placebo (426)

**1° endpoint:**
- All-cause mortality or admission for HF.
- No difference for perindopril 107 (25.1%) vs. placebo 131 (23.6%) at 3 y, HR: 0.92; 95% CI: 0.70–1.21; p=0.5.
- LF function was not measured
<table>
<thead>
<tr>
<th>Study</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>1º endpoint</th>
<th>Limitations</th>
</tr>
</thead>
</table>
| **I-PRESERVE**<br>Massie et al. 2008<br>(80) **19001508**<br><br>Aim: To ascertain efficacy of irbesartan on in pts with HFpEF.<br>Study type: RCT<br>Size: 4,128<br><br>**Inclusion criteria:** Age > 60, HF pts in NYHA class II-IV with EF >45%<br><br>**Exclusion criteria:** Previous EF <40%, creatinine >222 μmol/L (2.5 mg/dL), ACS, stroke, or revascularization in the previous 3 mo | **Intervention:** Irbesartan (2,067)<br><br>**Comparator:** Placebo (2,061) | • CV death or hospitalization for CV cause.<br>• No difference for irbesartan vs. placebo (742 (36%) vs. 763 (37%); HR: 0.95; 95% CI: 0.86 – 1.05; p=0.35)<br>• No differences for mortality or any other 2º endpoints<br>• Minnesota living with HF scale improved in both, groups to the same<br>• No difference in BNP levels<br>• No difference in adverse effects requiring discontinuation: doubling of creatinine, 6% vs. 4%; p<0.001; K >6.0 3% vs. 2%; p=0.01)<br>• Limitations: Study drug discontinuation in 34% of pts by end of study. High rate of concomitant ACE-I (40%) |<br>
| **NEAT-HFpEF**<br>Redfield et al. 2015<br>(81) **26549714**<br><br>Aim: To ascertain efficacy of isosorbide mononitrate on daily activity in pts with HFpEF.<br>Study type: Double-blind crossover<br>Size: 110<br><br>**Inclusion criteria:** Age ≥50 y on stable HF therapy, EF ≥50%, activity limited by dyspnea, fatigue, or chest pain<br><br>**Exclusion criteria:** SBP <110mm Hg and >180 mm Hg, current nitrates or PDE-5 inhibitors | **Intervention:** Isosorbide mononitrate (110)<br><br>**Comparator:** Placebo (110) | • Average daily activity assessed by accelerometer units during 120 mg phase.<br>• Nonsignificant trend for lower daily activity in the treatment group. (-381 accelerometer units; 95% CI: -780–17; p=0.06) and significant decrease in h of activity/d (-0.30 h; 95% CI: -0.55– 0.05; p=0.02)<br>• No differences for any of the 3 doses on QoL scores, 6MWT and levels of NT-proBNP (trend unfavorable for nitrates)<br>• Limitations: Rapid dose escalation of study drug. |<br>
| **RELAX**<br>Redfield et al. 2013<br>(82) **23478662**<br><br>Aim: To ascertain effects of sildenafil on exercise capacity in pts with HFpEF.<br>Study type: | **Intervention:** Sildenafil (113)<br><br>**Comparator:** Placebo (103) | • Change in peak VO2 from BL at 24 wk<br>• No difference between sildenafil (-0.20, IQR -1.7–1.11) and placebo (-0.20, |<br>

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
### TOPCAT

**Pitt et al. 2014 (83)**

- **New England Research Institutes**
- **Post-hoc analysis that captures differences in outcomes by geography - for reference list only**

<table>
<thead>
<tr>
<th>Aim: To assess the effects of spironolactone in pts with HFpEF.</th>
<th>Inclusion criteria: Symptomatic HF, Age ≥50y, LVEF ≥45% stratified according to - HF Hospitalization within past y - Elevated NPs</th>
<th>Intervention: Spironolactone (1,722)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study type: RCT</td>
<td>Exclusion criteria: Renal disease (eGFR &lt;30 or creatinine &gt;22 μmol/L (2.5 mg/dL), systemic illness with life expectancy &lt;3 y. Specific co-existing conditions, meds, and acute events</td>
<td>Comparator: Placebo (1,723)</td>
</tr>
</tbody>
</table>
| Size: 3,445 | | 1° endpoint and results: • Composite of CV mortality, HF hospitalization, or aborted cardiac arrest. • No difference with spironolactone vs. placebo 320 (18.6%) vs. 351 (20.4%), HR: 0.89; 95% CI: 0.77–1.04; p=0.138 | |}
### TOPCAT Regional Analysis

**Pfeffer et al. 2015 (84) 25406305**

Post-hoc analysis that captures differences in outcomes by geography

<table>
<thead>
<tr>
<th>Aim:</th>
<th>To assess regional differences in the effects of spironolactone in pts with HFpEF.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study type:</strong></td>
<td>RCT</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>3,445</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong></td>
<td>Symptomatic HF, Age ≥50y, LVEF ≥45% stratified according to • HF Hospitalization within past y • Elevated NPs</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong></td>
<td>Renal disease (eGFR &lt;30 or creatinine &gt;22 μmol/L (2.5 mg/dL), systemic illness with life expectancy &lt;3 y. Specific co-existing conditions, meds, and acute events</td>
</tr>
<tr>
<td><strong>Intervention:</strong></td>
<td>Spironolactone (1,722)</td>
</tr>
<tr>
<td><strong>Comparator:</strong></td>
<td>Placebo (1,723)</td>
</tr>
</tbody>
</table>

**1° endpoint and results:**

- Composite of CV mortality, HF hospitalization, or aborted cardiac arrest across regions.
- 1° outcome events in 522 (29.5%) pts in the Americas and 149 (8.9%) in Russia/Georgia. 1° outcome event rates with spironolactone and placebo 10.4/100 pt y and 12.6/100 pt y in the Americas and 2.5/100 pt y and 2.3/100 pt y in Russia/Georgia. HR spironolactone vs. placebo 0.82; 95% CI: 0.69–0.98; p=0.026) in the Americas and 1.10 95% CI: 0.79–1.51; p=0.12) in Russia/Georgia.

- Spironolactone had markedly greater effects on BP (4.2 mm Hg drop vs. 0.6 mm Hg; p<0.001, potassium change relative to placebo (0.26 mmol/L vs. 0.08 mmol/L), and increase in creatinine (0.10 vs. 0.02 mg/dL; p<0.001)

**Limitations:** post-hoc analysis

---

### Chen et al. 2015 (85) 25598008

<table>
<thead>
<tr>
<th>Aim:</th>
<th>To assess effects of MRAs in pts with HFpEF.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study type:</strong></td>
<td>Meta-analysis</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>14 RCTs with 6,428 pts</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong></td>
<td>Prospective, RCTs that enrolled adult pts with LVEF ≥40% (including post-MI and those with symptomatic or asymptomatic HF) with a study duration of ≥24 mo that assessed at least 1 clinical outcome of interest.</td>
</tr>
<tr>
<td><strong>Intervention:</strong></td>
<td>MRAs (3,249)</td>
</tr>
<tr>
<td><strong>Comparator:</strong></td>
<td>Placebo (2,861) Or standard therapy (301) Or active comparator (31)</td>
</tr>
</tbody>
</table>

**1° endpoint and results:**

- All-cause mortality and HF hospitalization
- No difference in all-cause mortality (RR: MRAs vs. placebo 0.90; 95% CI: 0.78–1.04; p=0.17)
- Reduced risk of HF hospitalization (RR: MRA vs. placebo 0.83; 95% CI: 0.70–0.98; p=0.03)

**1° Safety endpoint :**

- More hyperkalemia with MRAs (12.2% vs. 6.2%, p<0.001)

- MRAs improved QOL (weighted mean difference −5.2; 95% CI: −8.0–−2.3).
- MRA’s improved echo indices of LV function: E/e’, E/A ratio, deceleration time, interventricular relaxation time
- Renal failure in 1.19% of pts with MRAs vs. 0.39%
- Gynecomastia in 2.81%R vs. 0.3%

**Limitations:** discrepancies in definitions of HFpEF in different trials; heterogeneity of trial outcomes and their assessment, including follow-up duration; 1° outcome results driven by
### 2017 Heart Failure Focused Update Data Supplement

**Aim:** To address safety and efficacy of LCZ696 in pts with HFpEF.

**Study type:** RCT

**Size:** 308

**Inclusion criteria:**
- Pts ≥40 y of age,
- LVEF ≥45%,
- NYHA class II-III HF, NT-pro BNP >400 pg/mL

**Exclusion criteria:**
- Previous EF <45%,
- isolated right HF,
- noncardiac dyspnea, CAD or CVD needed revascularization <3 mo
- Right HF due to pulmonary disease, dyspnea due to noncardiac causes, valvular/myocardial disease, CAD or CVD needing revascularization within 3 mo of screening.

**Intervention:** LCZ696 (149)

**Comparator:** Valsartan (152)

**1° endpoint:**
- Change in BNP at 12 wk
- Greater reduction with LCZ696 (ratio of change compared to valsartan 0.77; 95% CI: 0.64–0.92; p=0.001)

**1° Safety endpoint:**
- Serious adverse events 15% in LCZ676 group and 20% in valsartan group (p=NS)

- Effect persisted after adjustment for more lowering of BP in LCZ676 group
- Improvement in NYHA class at 36 wk in LCZ676 group compared to valsartan.
- Reduction of LA size at 36 wk in LCZ676 group compared to valsartan.
- BNP levels higher than in other HFpEF trials, perhaps because this was an entry criterion.

---

**Data Supplement D. RCTs Comparing Anemia (Section 9.2)**

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2° Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARAMOUNT Solomon et al. 2012 (61) 22932717</td>
<td>Aim: To address safety and efficacy of LCZ696 in pts with HFpEF.</td>
<td>Inclusion criteria: Pts ≥40 y of age, LVEF ≥45%, NYHA class II-III HF, NT-pro BNP &gt;400 pg/mL Exclusion criteria: Previous EF &lt;45%, isolated right HF, noncardiac dyspnea, CAD or CVD needed revascularization &lt;3 mo Right HF due to pulmonary disease, dyspnea due to noncardiac causes, valvular/myocardial disease, CAD or CVD needing revascularization within 3 mo of screening.</td>
<td>Intervention: LCZ696 (149) Comparator: Valsartan (152)</td>
<td>1° endpoint: Change in BNP at 12 wk Greater reduction with LCZ696 (ratio of change compared to valsartan 0.77; 95% CI: 0.64–0.92; p=0.001) 1° Safety endpoint: Serious adverse events 15% in LCZ676 group and 20% in valsartan group (p=NS)</td>
<td>Effect persisted after adjustment for more lowering of BP in LCZ676 group Improvement in NYHA class at 36 wk in LCZ676 group compared to valsartan. Reduction of LA size at 36 wk in LCZ676 group compared to valsartan. BNP levels higher than in other HFpEF trials, perhaps because this was an entry criterion.</td>
</tr>
</tbody>
</table>

---

**Date:** Some studies added by chairs in December 2015, others added by the writing committee.
<table>
<thead>
<tr>
<th>CONFIRM-HF</th>
<th>Aim: To assess benefits and safety of long term FCM in iron-deficient pts with HF</th>
<th>Inclusion criteria: Pts at least 18 y, NYHA class II or III, LVEF≤45%, elevated NPs, ID defined as ferritin &lt;100 ng/mL, or ferritin 100–300 ng/mL if TSAT &lt;20%, Hb &lt;15 mg/dL</th>
<th>Intervention: FCM (152)</th>
<th>1st endpoint: • Change in 6MWT distance from BL to wk 24</th>
<th>2nd Endpoints: • Changes in NYHA class • PGA • 6MWT distance • Fatigue score • KCCQ • EQ-5D • Assessed at wk 6, 12, 24, 36, 52 • Rate of any hospitalization, rate of hospitalization for any CV reason, and rate of hospitalization due to worsening HF; • Time to first hospitalization for any reason, time to first hospitalization for any CV reason and time to first hospitalization due to worsening HF; • Time to death for any reason, time to death for any CV reason, and time to death due to worsening HF.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study type: RCT (1:1)</td>
<td>Exclusion criteria: Pts in need of transfusion, if not able to complete 6MWT, uncontrolled HTN, infection, malignancy, impaired liver or renal function</td>
<td>Comparator: Placebo (152)</td>
<td>Results: Change in 6MWT distance FCM vs. placebo of 33±11 m (p=0.002)</td>
<td>Results: • Significant improvements in NYHA class, PGA, QoL and Fatigue scores, 6 MWD up to 52 wk • Significant reduction in the risk of hospitalizations for deteriorating HF, HR: 0.39 (95% CI: 0.19–0.82) (p=0.009) • Preserved treatment effect across subgroups • No differences in adverse events when compared to placebo • Study was not designed to test morbidity and mortality outcomes of the ID therapy with FCM</td>
</tr>
<tr>
<td></td>
<td>Size: 304</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
| FAIR-HF | Aim: To evaluate the effects of intravenous iron (FCM) on HF symptoms in pts with systolic HF and ID, with and without anemia. | Inclusion criteria: | Intervention: Ferric carboymaltose 200 mg weekly until hemoglobin was corrected (n=304) | 1° endpoint: PGA at 24 wk | Comparator: Placebo (n=155) | 1° endpoint: PGA and NYHA at wk 4 and 12 (p<0.001) | Mean improvement in 6MWT of 35±8m at 24 wk (p<0.001); also significant improvements at 4 and 12 wk | Improvement in the FCM group in PGA and NYHA at wk 4 and 12 (p<0.001) | Amgen |
|-----|----------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------------------------------------------------------------------------------------|--------------------------|-----------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Study type: RCT (2:1) | Studies type | Inclusion criteria: | Intervention: Ferric carboymaltose 200 mg weekly until hemoglobin was corrected (n=304) | Comparator: Placebo (n=155) | 1° outcome: Composite of death from any cause or hospitalization for worsening HF | Results: 1° outcome occurred in 576 pts in the darbepoetin alfa group vs. 562 in the placebo group (HR: 1.01; 95% CI: 0.90–1.13; p=0.87) | Increased thromboembolic adverse events in the treatment group (p=0.01); Limitation: pts with severe anemia were excluded |
| Size: 459 | Inclusion criteria: | Intervention: Ferric carboymaltose 200 mg weekly until hemoglobin was corrected (n=304) | Comparator: Placebo (n=155) | 1° endpoint: PGA at 24 wk | Results: improvement in the FCM group compared to placebo | 50% much or moderately improved vs. 28% (OR for being in a better rank, 2.51; 95% CI: 1.75–3.61; p<0.001) | NYHA class at 24 wk | Improvement in the FCM group in PGA and NYHA at wk 4 and 12 (p<0.001) | 2017 Heart Failure Focused Update Data Supplement

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
### Data Supplement E. RCTs Comparing HTN (Section 9.5)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2º Endpoint (if any); Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xie et al. 2016 (89) 26559744</td>
<td>Aim: To assess the efficacy and safety of intensive BP lowering strategies. Study Type: SR and meta-analysis Size: 19 trials with 44,989 pts; 3.8 y of follow-up.</td>
<td>Inclusion Criteria: RCTs with different BP targets or different BP changes between more vs. less intense therapy with at least 6 mo follow-up. Exclusion Criteria: Trials that did not assess a different target or relevant outcome.</td>
<td>5 RCTs (6,960 pts) enrolled only pts with DM and 6 trials (2,809 pts) specifically recruited pts with CKD.</td>
<td>1º Outcomes: Major CV events, defined as MI, stroke, HF or CV death, separately and combined; nonvascular and all-cause mortality; ESRD; and adverse events; new onset microalbuminuria/macroalbuminuria or change from micro- to macroalbuminuria and retinopathy in pts with DM. Results: Pts in the more intensive BP-lowering treatment group had mean BP 133/76 mm Hg compared with 140/81 mm Hg in the less intensive group. Intensive BP-lowering treatment achieved RR reductions for major CV events: 14% (95% CI: 4, 22), MI: 13% (95% CI: 0, 24), stroke: 22% (95% CI: 10, 32), albuminuria: 10% (95% CI: 3, 16), and retinopathy progression: 19% (95% CI: 0–34). However, more</td>
<td>Study Limitations: Only 6,960 pts with DM were included in the total study size of 44,989 pts. Conclusions: The absolute CV benefits were greatest in trials in which all enrolled pts had vascular disease, renal disease or DM. However, only 6,960 of the 44,989 pts had DM and no subanalysis for DM was provided; however, the outcome benefits were qualitatively most striking for pts with DM, CKD and/or vascular disease.</td>
</tr>
</tbody>
</table>
### SPRINT
Wright et al. 2015 (90) 26551272

**Aim:** To test the effectiveness of a goal SBP <120 mm Hg vs. a goal SBP <140 mm Hg for the prevention of CVD in pts with SBP ≥130 mm Hg at BL.

<table>
<thead>
<tr>
<th>Study type:</th>
<th>Inclusion criteria: SBP ≥130 mm Hg, with upper limit varying as number of pre-trial BP-lowering meds increased. Age ≥50 y Presence of at least 1: • Clinical or subclinical CVD</th>
<th>Intervention: Intensive BP lowering treatment to goal SBP &lt;120 mm Hg (4,678)</th>
<th>1st Endpoint: • Composite of MI, non-MI ACS, stroke, ADHF, CV death; HR: 0.75 (95% CI: 0.64, 0.89)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Lower BP target reduced composite outcome 243 pts (1.65%/y) vs. higher target 319 (2.19%/y); HR: 0.75; 95% CI: 0.64–0.89; p&lt;.001 and death: lower target 155 vs. 201, HR: 0.73; 95% CI: 0.60–0.90;</td>
</tr>
<tr>
<td><strong>Summary:</strong></td>
<td></td>
<td></td>
<td>• More intensive SBP lowering to a goal of &lt;120 mm Hg with achieved mean of ~121 mm Hg resulted in less CVD and lower total mortality over 3.26 y in comparison with a goal SBP &lt;140 mm Hg and achieved SBP of ~135 mm Hg.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• There were small increases in some expected SAEs. Perhaps unexpected, a sizable increase</td>
</tr>
</tbody>
</table>

Intensive treatment had no clear effects on HF: RR: 15% (95% CI: -11, 34), CV death: 9% (-11, 26), total mortality: 9% (95% CI: -3, 19), or ESRD: 10% (95% CI: -6, 23). The reduction in major CV events was consistent across pt groups, and additional BP lowering had a clear benefit even in pts with SBP <140 mm Hg. The absolute benefits were greatest in trials in which all enrolled pts had vascular disease, renal disease, or DM. Serious adverse events associated with BP lowering were only reported by 6 trials and had an event rate of 1.2% per y in intensive BP lowering group pts, compared with 0.9% in the less intensive treatment group (RR: 1.35 (95% CI: 0.93, 1.97)). Severe hypotension was more frequent in the more intensive treatment regimen (RR: 2.68 (95% CI: 1.21, 5.89), p=0.015), but the absolute excess was small (0.3% vs. 0.1% per pt-y for the duration of follow-up).
| RCT | Size: 9361 pts followed median of 3.26 y. | CKD stage 3 or greater  
Age ≥75  
Framingham General CVD risk ≥15% in 10 y  
Exclusion criteria:  
DM, history of stroke, ESRD  
(eGFR <20 mL/min), anticipated survival <3 y  
| average  
During the trial, mean SBP was 121.5 vs. 134.6.  
p=0.003)  
Other endpoints:  
Total deaths HR: 0.73 (95% CI: 0.60–0.90)  
1° or death HR: 0.78 (95% CI: 0.67–0.90)  
Components of 1° composite mostly consistent in direction other than ACS – no difference.  
CKD outcomes:  
1° in CKD pts: reduction in GFR of ≥50% or ESRD HR: 0.89 (95% CI: 0.42, 1.87)  
Incident albuminuria HR: 0.72 (95% 0.48, 1.07)  
In pts without CKD: reduction in GFR ≥30% and to <60  
HR: 3.49 (95% CI: 2.44–5.10)  
Incident albuminuria HR: 0.81 (95% CI: 0.63–1.04)  
Adverse events:  
SAEs: 1.04, p=0.25  
Significant absolute increases seen in intensive group for hypotension (1%), syncope (0.6%), electrolyte abnormality (0.8%), AKI/ARF (1.6%) over the study period.  
1.7% fewer pts had orthostatic hypotension in intensive group, p=0.01.  
in reduced eGFR in the non-CKD group and AKI/ARF overall was observed in the intensive group. While of uncertain etiology and significance, there is speculation this could be an acute hemodynamic effect, especially given the findings regarding albuminuria.  
Low target significantly reduced HF: HR: 0.62 (95% CI: 0.45–0.84; p=0.002)  
No difference in composite or individual renal outcomes with lowering of BP  
Limitations:  
Few pts were untreated at BL ~9%, so SPRINT provides little if any insight at present regarding BP lowering medication initiation for untreated people with SBP 130–139. |
### SPRINT: Senior Williamson et al. 2016

**Aim:** Intensive SBP goal (<120 mmHg) vs standard (SBP goal <140 mmHg)

**Study Type:** RCT

**Size:** 2,636

30% met criteria for being classified as ambulatory frail

**Mean follow-up:** 3.1 y

**Inclusion:** Men and women age 75+; mean age 79.8 y; 38% women; 17% black, 74% Caucasian; Exclusions: Nursing home residents; diabetes, Stroke, symptomatic HF in past 6 mo or EF <35%, dx or treatment of dementia, unintentional wt loss >10% in past 5 mo. SBP<110 after standing 1 min, expected survival <3y

**Intervention:** Medications and dietary advice to achieve SBP of <120 mm Hg

**Comparator:** Medications and dietary advice to achieve SBP of <140 mm Hg

**Achieved SBP:**
- **Intensive:** 123.4 mm Hg
- **Standard:** 134.8 mm Hg

**1 endpoint:** Composite CVD outcome (AMI, non-MI ACS, Stroke, HF, CVD death).

**Results:**
- 102 events in the intensive treatment group vs 148 events in the standard treatment group; HR: 0.66; 95% CI: 0.51–0.85 and all-cause mortality (73 deaths vs. 107 deaths, respectively; HR: 0.67; 95% CI: 0.49–0.91. No significant difference in falls, orthostatic hypotension, or overall SAEs. NNT for primary outcome=27 and NNT for all-cause mortality=41

**Limitations:** Does not apply to nursing home patients or those with dementia

**Conclusions:** Intensive SBP is safe and effective for lowering CVD events and total mortality in persons age 75 and older

---

### TOPCAT Regional Analysis

**Pfeffer et al. 2015**

**Post-hoc analysis that captures differences in outcomes by geography**

**Aim:** To assess regional differences in the effects of spironolactone in pts with HFpEF.

**Study Type:** RCT

**Size:** 3,445

**Inclusion criteria:** Symptomatic HF, Age ≥50 y, LVEF ≥45% stratified according to
- HF Hospitalization within past y
- Elevated NPs

**Exclusion criteria:** Renal disease (eGFR <30 or creatinine >22 μmol/L/ (2.5 mg/dL), systemic illness with life expectancy <3 y, Specific co-existing

**Intervention:** Spironolactone (1,722)

**Comparator:** Placebo (1,723)

**1° endpoint and results:**
- Composite of CV mortality, HF hospitalization, or aborted cardiac arrest across regions.
- 1° outcome events in 522 (29.5%) pts in the Americas and 149 (8.9%) in Russia/Georgia. 1° outcome event rates with spironolactone and placebo 10.4/100 pt y and 12.6/100 pt y in the Americas and 2.5/100 pt y and 2.3/100 pt y in Russia/Georgia. HR spironolactone vs. placebo 0.82; 95% CI: 0.69–0.98; p=0.026) in the Americas and 1.10 95% CI: 0.79–1.51; p=0.12) in Russia/Georgia.

- Spironolactone had markedly greater effects on BP (4.2 mm Hg drop vs. 0.6 mm Hg; p<0.001, potassium change relative to placebo (0.26 mmol/L vs. 0.08 mmol/L), and increase in creatinine (0.10 vs. 0.02 mg/dL; p<0.001)

**Limitations:** post-hoc analysis
| Law et al., 2009 (92) 19454737 | **Study type:** Meta-analysis of use of BP lowering drugs in prevention of CVD from 147 randomized trials  
**Size:** Of 147 randomized trials of 464,000 pts, 37 trials of beta blockers in CAD included 38,892 pts, and 37 trials of other antihypertensive drugs in CAD included 85,395 pts  
**Inclusion criteria:** The database search used Medline (1966-Dec. 2007 in any language) to identify randomized trials of BP lowering drugs in which CAD events or strokes were recorded. The search also included the Cochrane Collaboration and Web of Science databases and the citations in trials and previous meta-analyses and review articles.  
**Exclusion criteria:** Trials were excluded if there were <5 CAD events and strokes or if treatment duration was <6 mo.  
**endpoint:** CAD events; stroke | **Results:** In 37 trials of pts with a history of CAD, beta blockers reduced CAD events 29% (95% CI: 22%–34%). In 27 trials in which beta blockers were used after acute MI, beta blockers reduced CAD events 31% (95% CI: 24%–38%), and in 11 trials in which beta blockers were used after long term CAD, beta blockers insignificantly reduced CAD events 13%. In 7 trials, beta blockers reduced stroke 17% (95% CI: 1%–30%). CAD events were reduced 14% (95% CI: 2%–25%) in 11 trials of thiazide diuretics, 17% (95% CI: 11%–22%) in 21 trials of ACE inhibitors, insignificantly 14% in 4 trials of angiotensin receptor blockers, and 15% (95% CI: 8%–22%) in 22 trials of CCBs. Stroke was reduced 38% (95% CI: 28%–47%) in 10 | • With the exception of the extra protective effect of beta blockers given shortly after a MI and the minor additional effect of CCBs in preventing stroke, all the classes of BP lowering drugs have a similar effect in reducing CAD events and stroke for a given reduction in BP.
Aim: To determine effect of propranolol vs. no propranolol on mortality plus nonfatal MI in pts with prior MI and HFpEF

**Inclusion criteria:**
- Pts ≥62 y with MI and LVEF ≥40% and HF NYHA class II or III treated with diuretics and ACE inhibitors for 2 mo

**Intervention:**
- 79 pts were randomized to treatment with propranolol

**Comparator:**
- 79 pts were randomized to no propranolol. All pts continued diuretic and ACE inhibitor therapy.

1° endpoint:
- At 32-mo mean follow-up, multivariate Cox regression analysis showed that compared with no propranolol, propranolol reduced mortality 35% (p=0.03) and mortality plus nonfatal MI 37% (p=0.018)

Relevant 2° Endpoint:
- HR for reduction of all-cause mortality by nebivolol: 0.84 (95% CI: 0.66–1.08) for HFrEF and 0.91 (95% CI: 0.62–1.33) for HFpEF

**Van Veldhuisen et al. 2009 (94)**

<table>
<thead>
<tr>
<th>Aim:</th>
<th>To determine the effect of nebivolol vs. placebo in pts with HFrEF and HFpEF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria:</strong></td>
<td>Pts ≥70 y history of HF and HFrEF or HFpEF</td>
</tr>
<tr>
<td><strong>Intervention/Comparator:</strong></td>
<td>1,359 pts with a history of HFrEF and 752 pts with a history of HFpEF were randomized to nebivolol or to placebo</td>
</tr>
</tbody>
</table>

1° endpoint:
- At 21-mo follow-up, the primary endpoint of all-cause mortality or CV hospitalization was reduced by nebivolol 14% (95% CI: 0.72–1.04) in pts with HFrEF and 19% (95% CI: 0.63, 1.04) in pts with HFpEF

Relevant 2° Endpoint:
- HR for reduction of all-cause mortality by nebivolol: 0.84 (95% CI: 0.66–1.08) for HFrEF and 0.91 (95% CI: 0.62–1.33) for HFpEF

**Yusuf et al. 2003 (78)**

<table>
<thead>
<tr>
<th>Aim:</th>
<th>To determine the effects of candesartan vs. placebo in pts with HFpEF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria:</strong></td>
<td>3,023 pts, mean age 67 y, with HFpEF and NYHA class II-IV HF</td>
</tr>
<tr>
<td><strong>Intervention/Comparator:</strong></td>
<td>3,023 pts were randomized to candesartan or placebo</td>
</tr>
</tbody>
</table>

1° endpoint:
- At 36.6 m follow-up, the primary outcome of CV death or hospitalization for HF was reduced 11% (p=0.118) by candesartan

Relevant 2° Endpoint:
- Hospitalization was reduced 16% (p=0.047) by candesartan

**Massie et al. 2008 (80)**

<table>
<thead>
<tr>
<th>Aim:</th>
<th>To determine the effect of irbesartan vs. placebo on all-cause mortality or hospitalization for a CV cause in pts with HFpEF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inclusion criteria:</strong></td>
<td>Pts 60 y and older with HFpEF and NYHA class II, III, or IV HF</td>
</tr>
<tr>
<td><strong>Intervention/Comparator:</strong></td>
<td>4,128 pts were randomized to irbesartan or placebo</td>
</tr>
</tbody>
</table>

1° endpoint:
- At 49.5-mo follow-up, the primary outcome of all-cause mortality or hospitalization for CV cause was reduced 5% by irbesartan (p=0.35)

Relevant 2° Endpoint:
- Irbesartan did not significantly reduce the secondary outcomes of death from HF or hospitalization for HF, death from any cause and from CV causes, and quality of life
### Data Supplement F. Nonrandomized Trials for Hypertension (Section 9.5)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Primary Endpoint and Results (P values, OR or RR &amp; 95 % CI)</th>
<th>Summary / Conclusion / Comments</th>
</tr>
</thead>
</table>
| Thomopoulos et al. 2016 (96) 26848994 | Meta-analysis of RCT’s of more versus less intense BP control | 16 trials (52,235 pts) compared more vs. less intense treatment 34 (138,127 pts) active vs. placebo | More intense BP  
- Stroke RR: 0.71; 95% CI: 0.60–0.84  
- Coronary heart disease RR: 0.80; 95% CI: 0.68–0.95  
- Major CV events RR: 0.75; 95% CI: 0.68–0.85  
- CV mortality RR: 0.79; 95% CI: 0.63–0.97 |  
- Intensive BP reduction improves CV outcomes compared to less intense  
- Achieved BP of <130/80 mm Hg may be associated with CV benefit.  
Stratification of SBP cutoffs (150, 140 and 130)
mmHg) showed that a SBP/DBP difference of \(-10/\_5\) mmHg across each cutoff reduced risk of all outcomes.

Date: Chairs selected trials in October 2016.

## Data Supplement G. RCTs Comparing Treatment of Sleep Disorders (CPAP makers) (Section 9.6)

<table>
<thead>
<tr>
<th>Study Acronym; Author; Year Published</th>
<th>Aim of Study; Study Type; Study Size (N)</th>
<th>Patient Population</th>
<th>Study Intervention (# patients) / Study Comparator (# patients)</th>
<th>Endpoint Results (Absolute Event Rates, P values; OR or RR; &amp; 95% CI)</th>
<th>Relevant 2nd Endpoint; Study Limitations; Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVE McEvoy et al. 2016 (97) 27571048</td>
<td>Aim: To whether treatment with CPAP prevents major CV events.</td>
<td>Inclusion criteria: • Adults 45 - 75 y of age • Moderate-to-severe OSA • Coronary or cerebrovascular disease</td>
<td>Intervention: CPAP treatment plus usual care (CPAP group) Comparator: Usual care alone (usual-care group)</td>
<td>1st endpoint: Composite of death from CVD, MI, stroke, or hospitalization for UA, HF, or TIA Results: • Duration of CPAP=3.3 h/night; AHI events/h decreased from baseline to end of follow up at 3.7 y, 29.0–3.7 events/h • Primary endpoint – no significant difference in CPAP vs usual-care group (n=229, 17.0% vs. n=207; 15.4%; HR: 1.10 with CPAP; 95% CI: 0.91–1.32; p=0.34). • No significant difference in any individual or other composite CV end point. • CPAP significantly reduced snoring and daytime sleepiness and improved health-related quality of life and mood.</td>
<td>Secondary end points: • Other CV outcomes • Health-related quality of life • Snoring symptoms • Daytime sleepiness • Mood Study Limitations: • Primarily men with moderate-to-severe OSA and minimal sleepiness Adverse Events:</td>
</tr>
<tr>
<td>ORBIT-AF Holmqvist et al. 2015 (98) 25965712</td>
<td>Aim: 1) Define frequency of diagnosed</td>
<td>Inclusion criteria: • (\geq 18) years of age • Electrocardiographic evidence of AF</td>
<td>Intervention: N/A Comparator: N/A</td>
<td>1st endpoint: • All-cause mortality; • First all-cause hospitalization; • Composite of first event of CV</td>
<td>Secondary end points: N/A Study Limitations:</td>
</tr>
<tr>
<td>Study type:</td>
<td>Exclusion criteria:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Prospective descriptive, correlational / comparative, time-series design</td>
<td>• Life expectancy of &lt;6 months or AF secondary to reversible conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Data collection at enrollment &amp; 6-month intervals for minimum of 2 years</td>
<td>2) Determine whether OSA is associated w/: a) Worse outcomes; b) Arrhythmic AF progression; &amp;</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Multicenter, ambulatory-based registry</td>
<td>3) Determine whether CPAP treatment is associated w/ outcomes in patients w/ AF &amp; OSA.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Size:** Nationally representative

**Results:**

- Frequency of diagnosed OSA among nationwide AF population
  - 18% (n = 1,841)

- OSA associations w/ outcomes
  - Higher risk of:
    - Hospitalization (43 vs 35 events/100 patient-years among patients without OSA [adjusted hazard ratio (HR), 1.12; 95% confidence interval (CI), 1.03-1.22; p = .0078])
  - No higher risk of:
    - Death (HR, 0.94; 95% CI, 0.77-1.15; p = .54);
    - Composite of CV death, stroke/non–central nervous system embolism, TIA, or MI (HR, 1.07; 95% CI, 0.85-1.34; p = .57);
    - First major bleeding (HR, 1.18; 95% CI, 0.96-1.46; p = .11)

- OSA associations w/ AF progression
  - Not associated w/ higher risk of AF progression (HR, 1.06; 95% CI, 0.89-1.28; p = .51)

- CPAP treatment association w/ outcomes in patients w/ AF & OSA
  - Less likely to progress to more permanent forms of AF versus patients w/out CPAP (HR, 0.66; 95% CI, 0.46-0.94; p = .021).

**Exclusion criteria:**

- Life expectancy of <6 months or AF secondary to reversible conditions
- First major bleed within 2 years of baseline enrollment in registry

**Adverse Events:**

N/A

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
### 2017 Heart Failure Focused Update Data Supplement

<table>
<thead>
<tr>
<th>Sample enrolled consecutively</th>
</tr>
</thead>
<tbody>
<tr>
<td>- n=10,132 w/ AF</td>
</tr>
<tr>
<td>- n=1,841 w/ AF &amp; OSA</td>
</tr>
<tr>
<td>- n=1,837 patients w/ OSA &amp; complete CPAP data</td>
</tr>
<tr>
<td>- n =1,763 patients w/ OSA &amp; 2-year outcomes data</td>
</tr>
<tr>
<td>- n =937 patients w/ AF, OSA, &amp; CPAP treatment</td>
</tr>
</tbody>
</table>

**Sites**: 176 national sites that w/ provider & geographic heterogeneity

**Aim**: Effects of adaptive servo-ventilation in HF pts with reduced EF and CSA

**Study type**: RCT

**Size**:

<table>
<thead>
<tr>
<th>Inclusion criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Chronic HF (defined as ≥12 wk since diagnosis) according to current ESC guidelines</td>
</tr>
<tr>
<td>- LVEF ≤45%</td>
</tr>
<tr>
<td>- Hypopnea index of ≥10/h</td>
</tr>
<tr>
<td>- Stable, GDMT</td>
</tr>
<tr>
<td>- NYHA class III or IV, or NYHA class II with ≥1 hospitalization for HF in the last 24 mo</td>
</tr>
<tr>
<td>- No hospitalization for HF in 4 wk prior to enrolment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intervention:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adaptive servo-ventilation use ≥5h/night, 7d/wk. (n=666)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparator:</th>
</tr>
</thead>
<tbody>
<tr>
<td>GDMT (n=659)</td>
</tr>
</tbody>
</table>

**1° endpoint:**
- Death from any cause
- Lifesaving CV intervention (cardiac transplantation, implantation of a ventricular assist device, resuscitation after sudden cardiac arrest, or appropriate lifesaving shock) or
- Unplanned hospitalization for HF

**Significant Results**
- All-cause mortality was higher with the intervention (34.8%) than

**2° Endpoint**
- CV death
- Unplanned hospitalization from any cause
- Time to death from CV causes
- Change in NYHA class
- Change in 6-MWT (both at follow-up visits).
- General QoL (EuroQOL)
- HF-specific QoL (MLWHF)
- Daytime sleepiness

---

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
| 1,325 |
| --- | --- |
| **Optimized GDMT**  | **control (29.3%; HR: 1.28; 95% CI: 1.06–1.55; p=0.01).** |
| **No new class of disease-modifying drug for prior ≥4 wk**  | **CV mortality was higher with the intervention (29.9%) than control (24.0%; HR: 1.34; 95% CI: 1.09–1.65; p=0.006).** |
| **AHI >15/h with ≥50% central events and a central AHI ≥10/h**  | **6MWT decreased over time and were significantly lower with the intervention than with the control (p=0.02).** |
| **Exclusion criteria:**  | **Daytime sleepiness decreased over time and was significantly lower with the intervention than with the control (p<0.001).** |
|  | **Non-Significant Results** |
|  | **Unplanned hospitalization for HF was not significantly higher with** |
|  | **the intervention (43.1%) than control (41.3%; HR: 1.13; 95% CI: 0.95–1.33; p=0.16)** |
|  | **Of the lifesaving CV interventions, none were significantly higher with** |
|  | **the intervention than control (p=0.08–0.61)** |
|  | **Unplanned hospitalization for any cause was not significantly lower** |
|  | **with the intervention (67.9%) than control (68.0%; HR: 1.05; 95% CI: 0.92–1.20; p=0.47)** |
|  | **The NYHA class change was not significantly different with the** |
|  | **intervention than with the control (p=0.46)** |
|  | **General QoL trends were not significantly higher with the** |
|  | **intervention than with the control (p=0.09).** |
|  | **HF-specific QoL trends were not significantly higher with the** |
|  | **Exclusion criteria:** |
|  |  | **Significant COPD with a forced expiratory volume in 1 s in 4 wk before randomization** |
|  |  | **Current receiving PAP therapy** |
|  |  | **Cardiac surgery, PCI, MI or UA within the previous 6 mo** |
|  |  | **Cardiac resynchronization therapy implantation scheduled or performed within 6 mo prior to randomization** |
|  |  | **TIA or stroke within the previous 3 mo** |
|  |  | **1° hemodynamically-significant uncorrected VHD (obstructive or regurgitant) or any valvular disease expected to require surgery during the trial:** |
|  |  | **Acute myocarditis/pericarditis within the previous 6 mo** |
|  |  | **Untreated or therapy-refractory restless legs syndrome** |
|  |  | **Contraindication to the use of AutoSet CS2 because of symptomatic hypotension or significant intravascular volume depletion or pneumothorax or pneumomediastinum** |
|  |  | **Pregnancy** |
|  | Limitations: |
|  |  | **Unblinded study - more likely to favor treatment group, particularly for QOL, but no QOL improvement seen** |
|  |  | **HF pts with reduced EF only** |
|  |  | **HF pts with predominantly CSA not obstructive sleep apnea.** |
|  |  | **Sample had very limited # of women but reflects epidemiology of CSA with HF/EF** |

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
### CANPAP
Arzt et al. 2007 (100) 17562959

| **Aim:** Investigate whether suppression of CSA below threshold by CPAP would LVEF & ht tx–free survival. |
| **Study type:** Post hoc analysis of RCT |
| **Size:** 100 |

**Inclusion criteria:**
- Age 18 to 79 y
- NYHA II-IV
- HF due to ischemic, hypertensive, or idiopathic DCM
- Stabilized w/ optimal medical therapy for ≥1 mo
- LVEF <40%
- CSA

**Exclusion criteria:**
- Pregnancy
- MI
- Unstable angina
- Cardiac surgery w/in 3 mo of enrollment
- OSA

**Intervention:**
- CPAP=CSA suppressed, n=57
- CPAP=CSA suppressed, n=43

**Comparator:**
Control, n=110:

**1° endpoint:**
- Transplant free survival - Combined rate of all-cause mortality & ht tx

**Significant Results**

1° endpoint:
- Significantly different between 3 groups (p=0.016)
- Significantly higher in CPAP-suppressed vs. control group (p<0.043)
- No difference between CPAP-unsuppressed vs. control group (p<0.26)

2° endpoint:
- AHl
  - AH! significantly > reduction in both CPAP-suppressed (p<0.001) and CPAP-unsuppressed (p<0.001) groups
  - AHl significantly > reduction in CPAP-suppressed (p<0.001) and CPAP-unsuppressed (p<0.002) than control groups

**Mean nocturnal SaO2**
- Mean nocturnal SaO2 significantly > increased in CPAP-suppressed vs. control group (p<0.001)
- No significant difference between CPAP-unsuppressed and control group

**Limitations:**
- Post hoc analysis
- Stratification of CPAP-treated pts based on polysomnogram performed 3 mo after randomization.
- Because suppressed and unsuppressed status could not be ascertained until completion of PSG, events that occurred during the first 3 mo could not be included
- The CPAP-CSA–suppressed group was younger, had a lower AH!, and had a slightly lower proportion of central events than the CPAP CSA–unsuppressed group
### CPAP for CSA & HF (CANPAP)

**Aim:** Test long-term treatment of CSA w/ CPAP in HF pts receiving optimal medical therapy on combined rates of death & ht tx.

**Study type:** 11 center RCT

**Size:** 258

<table>
<thead>
<tr>
<th>Inclusion criteria:</th>
<th>Intervention:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 18-79 y</td>
<td>CPAP n=128</td>
</tr>
<tr>
<td>• NYHA II-IV</td>
<td>Comparator:</td>
</tr>
<tr>
<td>• HF due to ischemia</td>
<td>No CPAP n=130</td>
</tr>
<tr>
<td>• HTN, Idiopathic DCM</td>
<td>1° endpoint:</td>
</tr>
<tr>
<td>• Stable condition</td>
<td>Transplant free survival</td>
</tr>
<tr>
<td>• Optimal medical therapy for 1+ mon</td>
<td>No significant difference in transplant free survival between CPAP and control groups (p=0.54)</td>
</tr>
<tr>
<td>• LVEF &lt;40%</td>
<td>2° endpoints:</td>
</tr>
<tr>
<td>• CSA w/ ≥15 AHI &gt;50% of AHI had to be central.</td>
<td>• Hospitalizations</td>
</tr>
<tr>
<td>• Cardiac surgery within prior 3 mon, OSA</td>
<td>• EF</td>
</tr>
<tr>
<td></td>
<td>• Frequency of apnea and hypopnea episodes</td>
</tr>
<tr>
<td></td>
<td>• Mean nocturnal SaO2</td>
</tr>
<tr>
<td></td>
<td>• Neurohormones – norepinephrine and atrial NP</td>
</tr>
</tbody>
</table>

**Exclusion criteria:**

| • Pregnancy | Limitations: |
| • MI | • Underpowered because trial stopped early for low enrollment |
| • UA | |

**1° endpoints:**

- Transplant free survival
- No significant difference in transplant free survival between CPAP and control groups (p=0.54)

**2° endpoints:**

- Hospitalizations: No significant difference between CPAP and control groups (p=0.45)
- EF: Significant increase in EF between CPAP vs. control groups (p=0.02)
- Frequency of apnea and hypopnea episodes
- Significant reduction between CPAP vs. control groups (p=0.001)
- Mean Nocturnal SaO2
- Significant increase between CPAP vs. control groups (p≤0.001)
- 6MWT: Significant increase in 6MWT between CPAP vs. control groups (p=0.016)
- QoL: No significant difference between CPAP and control groups

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
<table>
<thead>
<tr>
<th>Study</th>
<th>Aim</th>
<th>Inclusion criteria</th>
<th>Intervention</th>
<th>1st endpoint</th>
<th>2nd endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rutta</td>
<td>To determine whether attenuation of CSA by CPAP in pts w/ HF reduces the frequency of arousals from sleep or improves sleep structure.</td>
<td>Age 18 - 79 y of age; NYHA II -IV; HF due to ischemic, hypertensive, or idiopathic DCM, stabilized on optimal medical therapy ≥1 mo; LVEF &lt;40% by radionuclide angiography; CSA defined as an AHI ≥15, w/ &gt;50% central apneas &amp; hypopneas</td>
<td>CPAP n=97, Comparator: Control n=108</td>
<td>AHI (central and obstructive); Mean and lowest SaO2</td>
<td>Arousals from sleep; Sleep structure (time in bed, sleep period time, total sleep time, sleep efficiency, sleep onset latency, percentage in each sleep stage, periodic leg movement index)</td>
</tr>
<tr>
<td>Kaneko</td>
<td>To determine the effect of CPAP on LVEF when awake and daytime BP in pts w/ HF and OSA</td>
<td>HF due to ischemic or nonischemic dilated CM for &gt;6 mo; LVEF &lt;45% by radionuclide angiography; NYHA class II–IV; Absence, in last 3 mo, of HF exacerbations while receiving optimal pharmacologic therapy at highest tolerated doses;</td>
<td>CPAP n=12, Comparator: Control n=12</td>
<td>LVEF when awake; LVEDD; LVESD; Heart rate; Daytime BP</td>
<td>BMI; Episodes of apnea and hypopnea; Total; Obstructive; Central; Desaturation index (# hr of sleep); Lowest oxyhemoglobin saturation (%)</td>
</tr>
</tbody>
</table>
Size: 24

**OSA defined as ≥20 episodes of apnea and hypopnea /h of sleep of which >50% were obstructive**

**Exclusion criteria:**
- 1° valvular heart disease;
- Presence of implanted cardiac pacemaker;
- UA;
- MI;
- Cardiac surgery within 3 mo of enrollment

- Significant increase in CPAP (p<0.001) but not control group and difference between groups was significant (p=0.009)

**LVEF**
- No significant difference for either group or between groups

**LVESD**
- Significant reduction in CPAP (p=0.009) but not control group and difference between groups was significant (p=0.02)

**Heart Rate**
- Significant decrease in CPAP (p=0.007) but not control group and difference between groups was significant (p=0.02)

**Daytime BP**
- Significant decrease in systolic BP in CPAP (p=0.02) but not control group and difference between groups was significant (p=0.008)
- No significant difference in diastolic BP for either group or between groups

2° endpoint:
- BMI
  - No significant difference for either group or between groups

**Episodes of apnea and hypopnea**
- Total sleep time
- Stage I and II sleep (% of total sleep time)
- Stage III and IV sleep (% of total sleep time)
- REM sleep (% of total sleep time)
- Arousals/hr of sleep

**Limitations:**
- No placebo
- Small sample size
- Pts unblinded to group
<table>
<thead>
<tr>
<th>Obstructive</th>
<th>Central</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Significant reduction in CPAP (p&lt;0.001) but not control group and difference between groups was significant (p&lt;0.001)</td>
<td>• No significant difference for CPAP group or between groups</td>
</tr>
<tr>
<td>Desaturation index (# hr of sleep)</td>
<td></td>
</tr>
<tr>
<td>• Significant reduction in CPAP (p&lt;0.001) but not control group and difference between groups was significant (p=0.008)</td>
<td></td>
</tr>
<tr>
<td>Lowest oxyhemoglobin saturation (%)</td>
<td></td>
</tr>
<tr>
<td>• Significant increase in CPAP (p=0.004) but not control group and difference between groups was significant (p=0.01)</td>
<td></td>
</tr>
<tr>
<td>Total sleep time</td>
<td></td>
</tr>
<tr>
<td>• No significant difference for CPAP group or between groups</td>
<td></td>
</tr>
<tr>
<td>Stage I and II sleep (% of total sleep time)</td>
<td></td>
</tr>
<tr>
<td>• No significant difference for CPAP group or between groups</td>
<td></td>
</tr>
<tr>
<td>Stage III and IV sleep sleep (% of total sleep time)</td>
<td></td>
</tr>
<tr>
<td>• No significant difference for CPAP group or between groups</td>
<td></td>
</tr>
<tr>
<td>REM sleep (% of total sleep time)</td>
<td></td>
</tr>
</tbody>
</table>
| Mansfield et al. 2004 (104) 14597482 | **Aim:** To assess long-term effect of OSA treatment with nocturnal CPAP on systolic heart function, sympathetic activity, BP, and QoL in pts with HF | **Inclusion criteria:**
- HF due to ischemic or nonischemic dilated CM for >6 mo;
- LVEF <45% by radionuclide angiography
- NYHA class II–IV;
- Absence, in last 3 mo, of HF exacerbations while receiving optimal pharmacologic therapy at highest tolerated doses;
- OSA defined as ≥20 episodes of apnea and hypopnea /h of sleep of which >50% were obstructive | **Intervention:** CPAP X 3 mo n=19 | **1° endpoint:**
- LVEF
- Overnight urinary norepinephrine excretion
- BP
- QoL | **Comparator:** Control n=21 | **Significant Results 1° endpoint:**
- Significant improvement in CPAP group (p<0.001) and vs. control group (p=0.04) | **2° endpoint:**
- Peak Vo₂
- NYHA class
- Epworth sleepiness scale
- BMI
- AHÍ events per h
- Minimum SpO₂ saturation | **Exclusion criteria:**
- 1° valvular heart disease;
- Presence of implanted cardiac pacemaker;
- UA;
- MI;
- Cardiac surgery within 3 mo of enrollment | **Significant Results 2° endpoint:**
- Significant improvement in CPAP group (p<0.001) and vs. control group (p=0.04) | **Limitations:**
- No placebo
- Significant difference between groups in peak Vo₂ and mean BP at BL
- Dropout rate = 27%
- Higher than expected death rate
- Higher than expected rate of interventions initiated that may have effected end points
- Small sample size with only 3 females | **Studies Type:** RCT | **Size:** 44 |
<table>
<thead>
<tr>
<th>Chronic HF questionnaire</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Significant improvements between groups in 3/4 domains</td>
</tr>
<tr>
<td>o Fatigue (p=0.01)</td>
</tr>
<tr>
<td>o Emotional well-being (p=0.02)</td>
</tr>
<tr>
<td>o Disease mastery (p=0.02)</td>
</tr>
</tbody>
</table>

2º endpoint:
Peak VO₂
• No significant difference in CPAP group or between groups

NYHA class
No significant difference CPAP group or between groups

Epworth sleepiness scale
• Significant reduction in CPAP vs. control group (p=0.01)

BMI
No significant difference CPAP group or between groups

AHI events per h
• Significant reduction in CPAP group (p<0.001) and vs. control group (p<0.001)

Minimum SpO₂ saturation
• Significant improvement in CPAP group (p<0.001) and vs. control group (p=0.001)

Date: Study selected by the chairs in December 2015 and some trials added by the writing committee.
### 2013 HF Guideline Data Supplement 18. ACE Inhibitors (Section 7.3.2.2)

<table>
<thead>
<tr>
<th>Study Name, Author, Year</th>
<th>Aim of Study</th>
<th>Study Type</th>
<th>Background Therapy</th>
<th>Study Size</th>
<th>Etiology</th>
<th>Patient Population</th>
<th>Endpoints</th>
<th>Mortality</th>
<th>Trial Duration (Years)</th>
<th>Absolute Benefit</th>
<th>P Values &amp; 95% CI:</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONSENSUS 1987 283575</td>
<td>To Evaluate influence of enalapril on prognosis of NYHA class IV HF</td>
<td>RCT</td>
<td>Diuretics (spironolactone 53%, mean dose 80mg), digitalis (93%), other vasodilators, except ACEI (ie, nitrates 40%)</td>
<td>253; 127;126</td>
<td>Ischemic/Nonischemic</td>
<td>Severe HF/symptoms at rest/NYHA class IV; Increased heart size &gt;600 mL; BP: 120/75; HR: 80; AF 50%</td>
<td>APE; hemodynamically import aortic/MV stenosis; MI w/in prior 2 mo Unstable angina; planned cardiac surgery; right HF b/c of pulm disease; Cr &gt;300 mmol/L</td>
<td>Mortality</td>
<td>Change in NYHA-FC, LV size, Cr level</td>
<td>52% placebo group and 36% enalapril group (6 mo mortality: 26% in enalpril group and 44% in placebo group)</td>
<td>0.51 y</td>
</tr>
<tr>
<td>10 y FU of CONSENSUS 1999 1009910</td>
<td>Report on the survival at the 10-y follow up of the pts randomized in CONSENSUS. (1st study to show prognostic improvement by an ACEI. Pts in NYHA class IV HF treated with enalapril or placebo. After study completion all pts were offered open-label enalapril therapy).</td>
<td>RCT</td>
<td>All pts were offered open-label enalapril therapy</td>
<td>315; 77; 58</td>
<td>Ischemic heart disease 72% LVEF &lt;35%; Mild to severe (11% class II&lt;2% class IV); LVEF 25%; BP: 125/77; HR: 80; AF: 8-12%</td>
<td>Age &gt;80 y; Unstable angina; MI w/in past mo; Cr&gt;2.0 mg/dL</td>
<td>Mortality</td>
<td>10 y</td>
<td>5 pts, all in the enalapril group, were long-term survivors (p=0.004). Averaged over the trial (double-blind plus open-label extension) risk reduction was 30% (p=0.008), 95% CI: 11% - 46%. At end of double-blind study period, mortality considerably higher among pts not receiving open ACEI therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOLVD 1991 2057034</td>
<td>Study the effect of enalapril on mortality and hospitalization in pts with chronic HF and EF &lt;35%</td>
<td>RCT</td>
<td>Diuretics + Digoxin</td>
<td>2569; 1285; 1284</td>
<td>Ischemic heart disease 72%</td>
<td>Age &gt;80 y;</td>
<td>Mortality</td>
<td>15.70%</td>
<td>Treating 1000 SOLVD+ pts with enalapril for ~3 y would save ~50 premature deaths and 350 hospitalizations. Reduced mortality by 18%; (95% CI, 5-26%; p=0.0036)</td>
<td>3.45 y</td>
<td>N/A</td>
</tr>
</tbody>
</table>
### SOLVD 1992

<table>
<thead>
<tr>
<th>Study effect of ACEIs on total mortality and mortality from CV causes, the development of HF, and hospitalization for HF in pts with EF ≤35%</th>
<th>RCT</th>
<th>No drug treatment for HF</th>
<th>4228; 2111; 2117</th>
<th>History of ischemic heart disease 85%</th>
<th>EF &lt;35%; Asymptomatic; NYHA class I (67%) + II, EF: 28%, BP: 126/78, HR: 75, AF: 4%</th>
<th>As per SOLVD+</th>
<th>Mortality; Combined mortality and the incidence of HF and rate of hospitalization for HF</th>
<th>Incidence of HF and rate of hospitalization for HF</th>
<th>3.12 y</th>
<th>Reduced mortality: p=0.30; 95% CI: -9.21%</th>
</tr>
</thead>
</table>

### SOLVD F/U 2003

| 12-y FU of SOLVD to establish if the mortality reduction with enalapril among pts with HF was sustained, and whether a subsequent reduction in mortality would emerge among those with asymptomatic ventricular dysfunction. | 12 y FU of RCTs [SOLVD+ and SOLVD-] | N/A | 6784; 3391; 3393 | N/A | Participation in SOLVD+ and SOLVD-; Asymptomatic to severe; NYHA l-V | N/A | Mortality | N/A | N/A | N/A | Enalapril extended median survival by 9.4 mo in the combined trials (95% CI: 2.8–16.5, p=0.004). In the prevention trial, 50.9% of the enalapril group had died c/w 56.4% of the placebo group (p=0.001). In the treatment trial, 79.8% of the enalapril group had died c/w 80.8% of the placebo group (p=0.01). Combined prevention and treatment trials: HR for death was 0.90 for the enalapril group c/w placebo group (95% CI: 0.84–0.95, p=0.0003). |

### ATLAS 1999

| To compare the efficacy and safety of low and high doses of ACEI on the risk of death and hospitalization in chronic HF. than the large doses that have been shown to reduce morbidity and mortality in pts with HF. AIM: Investigate if low doses and high doses of ACEI have similar benefits. | RCT | N/A | 3164; 1596 to the low-dose strategy and 1568 to the high-dose strategy. | CAD 65% | LVEF <=30%; NYHA class II, III, or IV, despite treatment with diuretics for ≤2 mo (Treatment for HF in ED or hospital within 6 mo required for pts in class II); Prior use of digitals, ACEIs, or vasoconstrictors allowed but not mandated; NYHA II-IV (mainly class II); LVEF 23%; SBP 128 mmHg; HR 80; NYHA class: II (few II and IV) | Acute coronary ischemic event or revascularization procedure within 2 mo; History of sustained or symptomatic ventricular tachycardia; Intolerant of ACEIs; SCr >2.5 mg/dL | Mortality from all causes | Combined risk of all-cause mortality and hospitalization for any reason; CV mortality, CV hospitalizations; All-cause mortality combined with CV hospitalizations; CV mortality combined with CV hospitalizations; Combined risk of fatal and nonfatal MI plus hospitalization for unstable angina | 5 y | High-dose group had 8% lower risk of all-cause mortality (p=0.129) and 10% lower risk of CV mortality (p=0.073) than low-dose group. Death or hospitalization for any reason, high-dose group had 12% lower risk than low-dose group, p=0.002. Total number of hospitalizations: high-dose group 13% fewer hospitalizations for any reason (p=0.021), 16% fewer hospitalizations for CV reason (p=0.05), and 24% fewer hospitalizations for HF (p=0.002). |

---

**Post-MI ACEI Use**
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Year</th>
<th>Number</th>
<th>Population</th>
<th>Intervention</th>
<th>Randomization</th>
<th>Follow-up</th>
<th>Outcomes</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVE, 1992</td>
<td>RCT</td>
<td>1992</td>
<td>1386652</td>
<td>(111)</td>
<td>To test the hypothesis that the long-term administration of captopril to survivors of acute MI who had baseline LV dysfunction but did not have overt HF requiring vasodilator therapy would reduce mortality, lessen deterioration in cardiac performance, and improve clinical outcome.</td>
<td>Beta-blockers 36%; Digitals 26%; Nitrates 51%</td>
<td>LVEF &lt;40%; &gt;21 y of age; Killip class I—III; EF 31%; BP 113/70; HR 78;</td>
<td>3.5 y</td>
<td>Mortality from all causes: RR: 19% (95% CI, 3-32%; p=0.019) for death from CV causes, 37% (95% CI, 20-50%; p=0.001) for the development of severe HF, 22% (95% CI, 4-37%; p=0.019) for CHF requiring hospitalization, and 25% (95% CI, 5-40%; p=0.015) for recurrent MI.</td>
</tr>
<tr>
<td>RCT</td>
<td>2006; 1014; 992</td>
<td>Aged ≥18 y, with a definite acute MI 3-10 d before randomization; Clinical evidence of HF at any time since acute MI</td>
<td>Use of an ACEI considered to be mandatory</td>
<td>1.3 y</td>
<td>Mortality from all causes: RR: 27% (95% CI: 11-40%; p=0.002). Prespecified secondary outcomes: risk reduction of 19% for the 1st validated outcome—namely, death, severe/resistant HF, MI, or stroke (95% CI: 5% - 31%; p=0.008).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIRE 1993</td>
<td>RCT</td>
<td>1993</td>
<td>8104270</td>
<td>(112)</td>
<td>Investigated the effect of therapy with ACEI ramipril, on survival in pts who had shown clinical evidence of HF at any time after an acute MI. Also, to compare the incidences of progression to severe or resistant HF, nonfatal reinfarction and stroke between the 2 groups.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TRACE 1995
**Study Name:** TRACE: Trial of Ranolazine in Ischemic Cardiomyopathy: Evaluation of Reducing Events<br>**Author:** Granger et al.<br>**Year:** 2002 (114)

**Aim of Study:** To determine whether pts who LV dysfunction soon after MI benefit from long-term oral ACE inhibition.

**RCT** | Beta blocker 16%, Calcium antagonist 28%, Diuretic 66%, Nitrates 53%, Digoxin 28%, Ischemic 100% | Consecutive pts >18 y hospitalized with MI; Criteria for MI: chest pain or electrocardiographi c changes, accompanied by >2X increase in ≥1 cardiac enzymes; LV dysfunction (EF <35%); NYHA class 1 - 41%; BP: 121/76; HR 81 | Contraindication to ACEI or a definite need for them; Severe, uncontrolled DM; Hyponatremia (<125 mmol/L); Elevated SCr level (2.3 mg/dL) | Death from any cause | Death from a CV cause, sudden death, Progression to severe HF (hospital admission for HF, death due to progressive HF, or HF necessitating open-label ACEI); Recurrent infarction (fatal or nonfatal); Change in the wall-motion index (EF) | The mortality from all causes at 1 year was 24%.

**Pro-trial standard treatment.** | N (Total) | n (Experimental) | n (Control) | Ischemic/Non-ischemic | Inclusion Criteria | Exclusion Criteria | Primary Endpoint | Secondary Endpoint | 1st Y Mortality | Mortality | Trial Duration (Y) | Statistical Results |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2028; 1013; 1015</td>
<td>Ischemic 67-70%</td>
<td>Symptomatic HF, EF &lt;40%, no ACEI (b/c of intolerance)</td>
<td>NYHA II-IV; mild to severe (&lt;4% class IV); EF: 30%; BP: 130/70; HR: 74-75; AF: 25-26%</td>
<td>Composite of CV death or hospital admission for CHF</td>
<td>CV death, hospital admission for CHF or nonfatal MI; CV death, CHF admission, nonfatal MI, nonfatal stroke, coronary revascularization; Death (any cause); New DM</td>
<td>2.8 y</td>
<td>Absolute reduction of 7 major events per 100 pts treated - NNT 14 pts to prevent 1 CV death or hospitalization. HR: 0.77 (95% CI: 0.67-0.89); p&lt;0.0004</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 2013 HF Guideline Data Supplement 19. ARBs (Section 7.3.2.3)

<table>
<thead>
<tr>
<th>Study Name, Author, Year</th>
<th>Aim of Study</th>
<th>Study Type</th>
<th>Background Therapy</th>
<th>Study Size</th>
<th>Etiology</th>
<th>Patient Population</th>
<th>Severity</th>
<th>Endpoints</th>
<th>Mortality</th>
<th>Trial Duration (Y)</th>
<th>Statistical Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHARM Alternativ e; Granger et al; (2003) 13678870 (114)</td>
<td>To investigate if ARB could improve outcome in pts not taking an ACEI (intolerant)</td>
<td>RCT</td>
<td>Diuretics, Beta-blockers (55%), spironolactone 24%, Digoxin 45-46%</td>
<td>2028; 1013; 1015</td>
<td>Ischemic 67-70%</td>
<td>Symptomatic HF, EF &lt;40%, no ACEI (b/c of intolerance)</td>
<td>NYHA II-IV; mild to severe (&lt;4% class IV); EF: 30%; BP: 130/70; HR: 74-75; AF: 25-26%</td>
<td>Composite of CV death or hospital admission for CHF</td>
<td>CV death, hospital admission for CHF or nonfatal MI; CV death, CHF admission, nonfatal MI, nonfatal stroke, coronary revascularization; Death (any cause); New DM</td>
<td>2.8 y</td>
<td>Absolute reduction of 7 major events per 100 pts treated - NNT 14 pts to prevent 1 CV death or hospitalization. HR: 0.77 (95% CI: 0.67-0.89); p&lt;0.0004</td>
</tr>
</tbody>
</table>

| CHARM-ADDDED; McMurray et al; (2003) 13678869 (115) | To investigate if ARB + ACEI in pts with chronic HF improve clinical outcomes | RCT | Beta blocker-55%; spironolactone 17%; Digoxin 58-59% | 2548; 1276; 1272 | Ischemic 62-63% | Symptomatic HF, EF <40%; Treatment with ACEI; Age ≥18 y | NYHA class II-IV; mild to severe (<3% class IV); EF 28%; BP 125/75; HR 74; AF 27% | Composite of CV death or hospital admission for CHF | CV death, hospital admission for CHF or nonfatal MI; CV death, CHF admission, nonfatal MI, nonfatal stroke, coronary revascularization; Death (any cause); New DM | 3.4 y | Absolute reduction of 4.4 pts with events per 100 pts treated- NNT of 23 to prevent 1 first event of CV death or CHF hospitalization. RR: 0.85 (95% CI: 0.75-0.96); p<0.011 |
Death from any cause
Prior intolerance or contra-indication to ACEI

12.5% VAL
13.2% CAP

Prior intolerance or contra-indication to ACEI/

Beta-blockers: ASA

2.1 y

Death or all-cause admission

Composite endpoint of death or all-cause admission, CV death, all-cause admission, CV death, all-cause admission, CV death, all-cause admission, CV death

For the combined endpoint: RR: 0.87; 97.5% CI, 0.77-0.97; p=0.009

NYHA class II–IV; LVEF <40%, with stable CV medical therapy for at least 2 wk; 3 distinct populations:

NYHA class II–IV for at least 4 wk; 3 distinct populations:

Patients with LVEF >40%

SCr > 265 mmol/L, serum creatinine >5.5 mmol/L

Bilateral renal artery stenosis; symptomatic hypertension

Women of childbearing potential not using adequate contraception; Critical aortic or mitral stenosis; MI, stroke, or open-heart surgery in the previous 4 wk; Use of an ARB in the previous 2 wk

The annual CV death rate among the placebo group who had reduced LVEF was around 9% and was only 4% in the placebo group of CHARMM-Preserved.

The primary outcome of the overall program: all-cause mortality; For all the component trials: CV death or hospital admission for CHF

The primary aim of the study was to find out whether the use of an ARB could reduce mortality and morbidity.

The annual CV death or hospital admission for CHF.

The annual CV death rate among the placebo group who had reduced LVEF was around 9% and was only 4% in the placebo group of CHARMM-Preserved.

The primary outcome of the overall program: all-cause mortality; For all the component trials: CV death or hospital admission for CHF

The primary aim of the study was to find out whether the use of an ARB could reduce mortality and morbidity.
CIBIS II Investigators and Committee Members (1999) - 1032943 (1999) - 1236047

RCT: Multicenter double-blind randomized placebo controlled trial (Europe)

Diuretics + ACEI; [arniodarone allowed-14-16%]

NYHA class II or IV

EF: <35%  18-50 y old

Uncontrolled HTN;

MI-UA w/in previous 3 mo;

PTCA/CABG w/in previous 6 mo;

AV-block >1st degree w/o PPM;

Heart rate >60 bpm;

resting SBP <100mmHg;

renal failure;

Reversible obstruct lung disease;

Use of beta blocker

Moderate to severe;

Mean BP: 130/80;

Mean HR: 80;

Mean LVEDD: 6.7 cm;

AF: 20%  

All-cause mortality  

All-cause hospital admissions

Combi endpoints

Permanent treatment withdrawal

13.2% Placebo group

8.6% Treatmnt group

N/A 1.3 y

HR: 0.66 (95% CI: 0.54-0.81); p<0.0001

2017 Heart Failure Focused Update Data Supplement


RCT: Multicenter double-blind randomized placebo controlled trial [Europe + USA]

Diuretics + ACEI; [arniodarone NOT allowed]

NYHA IV;  

40-80 y old;

LVEF <40% (36-40 if 6-min walk <450m);

Heart rate >68 bpm

MRA w/in 28 d;

Contraindication or current use of beta blocker;

PTCA/CABG w/in 4 mo;

Heart block >1st degree w/o PPM;

Mean BP: 130/80; Mean HR: 80; Mean EF 28%; Mean LVEDD 6.7 cm; AF: 20%

All-cause mortality

All-cause hospital admissions

Combined endpoints

Permanent treatment withdrawal

11.0%; 0.81); p<0.0001  

Investigate whether the beta blocker Carvedilol is beneficial in severe HF

11.6% in placebo group

7.2% Treatment group

[24.0% in pts with recent or recurrent cardiac decompensations]

COPERNICUS


Assess effects of the beta blocker Nebivolol in pts >70 y regardless of EF.

RCT: Double blind

Diuretics (PO or IV) + ACEI (or ARB); [arniodarone allowed 17-18%]

NYHA class IV;

LVEF <25%; No positive inotropes or vasodilators w/in 4 d

Pl reporting hospitalized intensive care;

Use of positive inotropes or IV; vasodilators w/in 4 d;

Coronary revascularization/MICVA/ sign VT or VF w/in 2 mo;

SBP <85 mmHg;

Heart rate <68;

Cr >2.8 mg/dL

Serious

Mean BP: 133/76; Mean HR: 83; Mean EF 20%  

All-cause mortality  

Combinded risk of death or hospitalization-any reason;

Combinded risk of death or hospitalization-CV reason;

Combinded risk of death or hospitalization-HF reason;

Pf global assessment

18.5% in placebo group

12.4% in Carvedilol group

Treatin 1000 pt for 1 y led to savings of 70 premature deaths

p=0.0014


NYHA class II or IV;

LVEF <35% w/in the past 6 mo

Age >70 y old

CHF w/in 1 of the following:

hospitalization with CHF w/in a year or EF <35% w/in the past 6 mo

New HF Therapy w/ 6 wk

or change in drug therapy w/ 2 wk

Contranidication to beta blockers, current use of beta blockers

Significant renal dysfunction

CVA w/in 3 mo.

Moderate to severe

Mean BP: 139/81; Mean HR: 79; Mean EF 36% (13 with EF >35%)  

Composite of all-cause mortality or CV hospital admission

All-cause mortality

Composite of all-cause mortality or CV hospital admissions

CV hospital admissions

CV mortality

Composite of CV mortality or CV hospital admissions

NYHA class assessment; 6 MWT  

N/A  

N/A 1.75 y

Absolute risk reduction 4.2%; 24 pts would need to be treated for 21 mo to avoid one event

RR: 0.89; 95% CI: 0.74-0.99; p=0.039

A Trial of the Beta-Blocker Bucindolol In Pt with Advanced Chronic HF The Beta-Blocker Evaluation of Survival Trial Investigators - 11366264 (123)

Designed to determine whether bucindolol hydrochloride, a nonselective beta- 

adrenergic blocker and mild vasodilator, would reduce the rate of death from any cause among pt with advanced HF

RCT: ACEIs (if tolerated) [91% ACE; 7% ARB], for at least 1 mo. Before the publication of the results of the DIG trial, 12 digoxin therapies were started

NYHA class III or IV

LVEF <35% >18 y

Reversible cause of HF present

Candidates for heart transplantation

Cardiac revascularization procedure within the previous 60 d UA

Heart rate <50 bpm, SBP <80mmHg

Decompensated HF

NYHA III or IV (62% class III) EF 23%; HR 82; BP 117/71; AF 12%  

Death from any cause

Death from CV causes (death due to pump failure or an ischemic event or sudden death)

Hospitalization for any reason

Hospitalization because of HF

Composite of death or heart transplantation

LVEF at 3 and 12 mo

MI, QTL, and any change in

For pt in NYHA functional class III, the annual mortality rate was 16% in the placebo group; For pt with NYHA class IV, the annual mortality rate in the placebo group was 28%  

Overall: annual mortality of 17% in placebo group crw  

N/A 2 y

449 pt in placebo group (33%) died, 411 pt in the bucindolol group (30%); HR: 0.90; 95% CI: 0.78-1.02; unadjusted p=0.10; adjusted p=0.13
and to assess its effect in various subgroups defined by ethnic background and demographic criteria — specifically women and members of minority groups.

The need for concomitant therapy remains uncertain, but there is evidence that its use becomes discretionary [DIG 94%].

The COMET; Poole-Wilson et al; (2003) study compared the effects of carvedilol and metoprolol on clinical outcome in pts with HF and to assess its effect in various subgroups defined by ethnic background and demographic criteria — specifically women and members of minority groups.

The primary endpoint was time-to-the-first-event of combined all-cause mortality or all-cause hospitalization. Combined endpoint at the end of the monotherapy phase and the individual components of the primary endpoint, at study end and at the end of the monotherapy phase. CV death CV hospitalization


<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Patient Characteristics</th>
<th>Primary Endpoint</th>
<th>Mean Time to Event (y)</th>
<th>Mean Event Rate (y)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COMET</td>
<td>RCT</td>
<td>Diuretics, ACEIs</td>
<td>NYHA class II/IV</td>
<td>3026</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EF &lt;35%</td>
<td>N/A</td>
<td>Mild to severe</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Previous CV admission</td>
<td>N/A</td>
<td>All-cause mortality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Composite endpoint</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>of all-cause mortality, or all-cause admission</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.8 y</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All-cause mortality</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>34% carvedilol and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40% metoprolol (HR: 0.83; 95% CI 0.74-0.93; p=0.0017)</td>
</tr>
</tbody>
</table>

**CIBIS III**: 2005; 16143696 (125) Sufficient data do not currently exist to establish the optimum order of initiating chronic HF therapy (ACEI vs. beta blocker). This was the objective of the CIBIS III trial — it compared the effect on mortality and hospitalization of initial monotherapy with either bisoprolol or enalapril for 6 mo, followed by their combination for 6 to 24 mo.

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Patient Characteristics</th>
<th>Primary Endpoint</th>
<th>Mean Time to Event (y)</th>
<th>Mean Event Rate (y)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1010 Bisoprol 505; Enalapril 505</td>
<td>CAD 62%</td>
<td>&gt;65 y; NYHA class II or III; and LVEF &lt;35% (By echo within the 3 mo) Clinically stable HF (without clinically relevant fluid retention or diuretic adjustment within 7 d)</td>
<td>Treatment with an ACEI, an ARB, or a beta blocker for &gt;7 d during the 3 mo before randomization Heart rate at rest &lt;60 bpm without a functioning pacemaker Supine SBP &lt;100 mm Hg at rest SCr &lt;220 mmol/L AV block II/III without a functioning pacemaker Obstructive lung disease contraindicating bisoprolol treatment</td>
</tr>
</tbody>
</table>

**COPERNICUS**, carvedilol prospective randomized cumulative survival; **DIg**, Digitalis Investigation Group; **EF**, ejection fraction; **HF**, heart failure; **h/o**, history of; **HR**, hazard ratio; **ICD**, implantable cardioverter defibrillator; **ITT**, intent to treat; **MERIT-HF**, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure; **MI**, myocardial infarction; **MWT**, minute walk test; **NYHA**, New York Heart Association; **PPM**, permanent pacemaker; **PTCA**, percutaneous transluminal coronary angioplasty; **Pts**, patients; **QoL**, quality of life; **RCT**, randomized control trial; **RR**, relative risk; **SBP**, systolic blood pressure; **SCR**, serum creatinine; **UA**, unstable angina; **USA**, United States of America; **VF**, ventricular fibrillation; **VT**, ventricular tachycardia; and **w/o**, without.
References


2017 Heart Failure Focused Update Data Supplement

2017 Heart Failure Focused Update Data Supplement


© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.
2017 Heart Failure Focused Update Data Supplement

125. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005; 112:2426-35.

© 2017 American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America.